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 Abstract 
Watson L. Renal biomarkers in Juvenile-onset Systemic Lupus Erythematosus 
Background: Juvenile-onset Systemic Lupus Erythematosus (JSLE) is a rare, but severe, 
autoimmune condition with lupus nephritis (LN) occurring in up to 80% of patients and 
predisposing to an increased mortality.  
Aims/Objectives: As part of the UK JSLE Cohort Study this study aimed to identify whether 
standard and/or novel biomarkers are useful for monitoring LN and to assess whether novel 
urine biomarkers are released from the podocyte (kidney epithelial cell). 
Method/Results: A prospective translational study encompassing a clinical cross sectional 
biomarker analysis, a longitudinal observational biomarker study and scientific laboratory 
investigation. The study had full ethical approval. 
Cross sectional investigation identified whether (a) urine biomarkers (monocyte 
chemoattractant protein-1, MCP1; alpha-1-acid glycoprotein, AGP; interferon producing 
protein-10, IP10; neutrophil gelatinase associated lipocalin, NGAL) or (b) plasma biomarkers 
(interferon-gamma, IFN-γ; IP10; tumour necrosis factor alpha, TNF-α; interleukin 6, IL6; IL1β; 
MCP1; IL13; vascular endothelial growth factor, VEGF) are increased in JSLE patients with 
active renal disease. JSLE patients (n=60) and healthy controls (n=23) were recruited. Of 
JSLE patients, 45 were female (75%) and aged 14.7 (12.2-16.1) years.  All had ≥ 4 ACR SLE 
classification criteria (median 5, range 4-9). Urinary MCP1 concentration increased in patients 
with JSLE active renal disease compared to JSLE non-active renal disease (582 (251-2100) 
pg/mgCr; 207 (121-280) pg/mgCr; p=0.018) and healthy controls (117 (68-193) pg/mgCr; 
p=0.005), AGP concentration also increased (JSLE active renal disease: 1517 (753-2389) 
ng/mgCr; JSLE non-active renal disease: 485 (212-967) ng/mgCr; p=0.027; healthy controls 
313 (108-729) ng/mgCr; p=0.013). On cross sectional testing IP10 and NGAL showed no 
significant difference. Plasma analysis demonstrated increased IL-13 and a trend toward 
increased IFN-γ, TNF-α, IL-6 and VEGF in patients with JSLE active renal disease (n=12). For 
prospective longitudinal analysis, JSLE samples were collected at clinical reviews and 
standard/novel biomarkers assessed against disease activity. The longitudinal JSLE cohort 
(n=64), seen at 3 (IQR: 2-5) clinical reviews over 364 (182-532) days were aged 14.1 (11.8-
15.8) years and 80% female. Active renal episodes had increased concentration of; MCP-1, 
NGAL, ESR, anti-double stranded DNA, urine albumin:creatinine ratio (UACR), creatinine, and 
reduced complement 3 (C3), C4 and lymphocytes. On multivariate analysis, MCP-1 and C3 
were independent variables (p<0.001) of active renal disease. MCP-1 was an excellent 
predictor of improved renal disease (AUC: 0.81; p=0.013; specificity 71%, sensitivity 70%); 
NGAL was a good predictor of worsened activity (AUC 0.76; p=0.04; specificity 60%, 
sensitivity 61%).  
An in vitro model was developed using a human podocyte cell line. Podocytes were cultured in 
macrophage media (activated with IFN-γ or inactive), and subsequently TNF-α, and 
protein/gene biomarker, TNF-α receptor (TNFR) podocyte expression quantified. Podocyte 
MCP-1 gene expression increased when exposed to active macrophage media (8.87x10
-
3
+1.3x10
-3
) compared to inactive media (1.29x10
-3
+0.9x10
-3
; p<0.01), as did protein analysis. 
Podocyte NGAL expression was not directly related to macrophage exposure. The podocyte 
adopted a pro-inflammatory TNFR2 predominance when exposed to active macrophages. 
Conclusion Novel biomarkers perform well for monitoring and predicting JSLE associated 
renal disease. The podocyte up regulates MCP-1 and adopts a pro-inflammatory TNFR2 
pathway; the podocyte may be responsible for urinary MCP-1. Further studies are required to 
determine NGAL signalling.  
Impact: Increased local, national and international awareness of lupus nephritis. Advancing 
biomarkers from planning/discovery to prospective validation. Understanding biomarker 
regulation using in vitro techniques may explain their renal specificity. Biomarker 
commercialization would truly improve the renal management of JSLE patients.  
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1. Chapter 1: Introduction 
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1.1. Juvenile-onset Systemic Lupus Erythematosus 
Systemic lupus erythematous (SLE) is a rare autoimmune disorder. It involves 
many different parts of the body; indeed any organ system can be affected, 
and as such is the archetypal multi-systemic autoimmune disorder. It is 
characterised by the production of antibodies directed against auto-antigens, 
specifically nuclear auto-antigens, including antinuclear antibodies (ANA), anti-
extractable nuclear antibodies (ENA) and anti-double stranded 
deoxyribonucleic acid (DNA) antibodies (dsDNA). Disease occurring before the 
age of 17 years is referred to as Juvenile-onset SLE (JSLE). 
 
1.1.1. Epidemiology of JSLE 
SLE is rare in children although around 15-20% of all cases of SLE will have 
an onset before adulthood (1). The incidence of JSLE is reported to be 0.36 to 
0.9 per 100,000 children per year (2-7). JSLE is more prevalent in females and 
typically presents during adolescence. In a similar manner to adult-onset 
disease, the incidence varies significantly according to racial background, with 
a higher incidence in patients of Black African or Asian descent.  Ethnicity may 
also influence disease phenotype with an earlier disease onset and more 
nephritis seen in patients of Black African or Asian origin (8). 
 
1.1.2. Lupus-like disorders 
Lupus-like features can present secondary to either medications (termed drug-
induced lupus), or in neonates due to maternal disease (termed neonatal 
lupus).  
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1.1.2.1. Drug-induced lupus 
The medications with the highest risk of producing drug-induced lupus include 
the anti-hypertensive medication hydralazine, the anti-arrhythmic drug 
procainamide and biologic agents including anti-TNFα therapy (9).  Drug-
induced SLE is usually associated with transient autoantibodies and cutaneous 
manifestations.  
 
1.1.2.2. Neonatal lupus syndrome 
In neonatal lupus, passive antibody transfer occurs across the placenta during 
the fetal period and manifests as lupus-like cutaneous symptoms, auto-
antibodies and occasionally cardiac involvement such as congenital heart 
block (10). Neonatal lupus most frequently occurs in infants of mothers who 
are positive for anti-Ro and/or anti-La antibodies as these are contained within 
immunoglobulin (Ig) G, which can freely cross the placenta (11, 12).   
 
In drug-induced and neonatal lupus, symptoms and autoantibodies, typically 
resolve either with cessation of the offending medication or gradually over 
time, however cardiac involvement (mainly heart block) may persist in 
neonates requiring artificial cardiac pacing. 
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1.1.3. Aetiology of JSLE 
Hormonal, environmental and genetic factors play a contributory role in the 
development of JSLE.  
 
1.1.3.1. Hormonal influences 
An appreciation of hormonal influences, particularly oestrogen, in its 
contribution to disease aetiology is illustrated in patients taking oral 
contraceptive medication or during pregnancy, both of which can trigger a flare 
of the disease (13). In JSLE the male to female sex ratio is less striking (6:1) 
when compared to adult-onset disease, where it presents as 9 females to 
every male (14), supporting the influence of post-pubertal hormones.  
 
1.1.3.2. Environmental factors 
Environmental factors including certain medications, ultra-violet light exposure 
and infectious stimuli such as viruses including the Epstein Barr virus, can all 
play a precipitating role in the onset of lupus (15).  
 
1.1.3.3. Genetic susceptibility genes 
Individuals with SLE have a genetic susceptibility to developing the disease, as 
the risk of autoimmunity in a first-degree relative is significantly higher than that 
of the general population (16).  Genetic contribution in JSLE may be more 
significant than that seen in adult onset disease, as the sex distribution is less 
striking, the disease presents earlier and severe inherited conditions such as 
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Aicardi-Goutiers syndrome and C1q deficiency present with a lupus phenotype 
in childhood (17, 18).  
 
Like most autoimmune conditions it is more common in females suggesting an 
aetiological role for the X chromosome (19, 20), which is known to host the 
most immune-related genes (20).  In support of this observation is the finding 
that men with Kleinfelters syndrome (46XXY) have an increased risk of 
developing SLE (21, 22).  
 
Several genetic susceptibility genes in lupus have been identified using 
genome wide associated studies (GWAS) in large populations. These highlight 
the importance of the immune pathways mentioned in section 1.1.13 and 
include genes associated with the B cell signalling pathways (23), interferon 
(IFN) signalling (24), toll-like receptor (TLR) expression (25) and 
polymorphisms for cytokines or chemokines such as tumour necrosis factor 
alpha (TNF-α) (26) and monocyte chemo-attracant protein-1, MCP-1 (27) 
respectively. Genetic contribution may additionally explain the varying 
incidence and clinical manifestations seen in patients from different ethnic 
ancestries (28, 29). 
 
Although genetic contribution is clearly very important in JSLE, it cannot be the 
entire cause as the concordance rate between monozygotic twins is only 
around 25% (30). 
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1.1.4. Diagnosing JSLE  
A combination of clinical features and laboratory markers are used to diagnose 
SLE. Classification criteria developed by the American College of 
Rheumatology (ACR) are considered when forming the diagnosis (Table 1) 
with four out of the 11 stated criteria proposed to be highly suggestive of SLE 
(31-33).
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Table 1: The revised American College of Rheumatology SLE 
Classification criteria.  
Taken from reference (32). 
Criterion Definition
1. Malar Rash 
Fixed erythema, flat or raised, over the malar eminences, tending to spare the nasolabial 
folds 
2. Discoid rash 
Erythematous raised patches with adherent keratotic scaling and follicular plugging; atrophic 
scarring may occur in older lesions 
3. Photosensitivity 
Skin rash as a result of unusual reaction to sunlight, by patient history or physician 
observation 
4. Oral ulcers Oral or nasopharyngeal ulceration, usually painless, observed by physician 
5. Non-erosive Arthritis Involving 2 or more peripheral joints, characterized by tenderness, swelling, or effusion 
11. Positive Antinuclear Antibody
An abnormal titer of antinuclear antibody by immunofluorescence or an equivalent assay at 
any point in time and in the absence of drugs
6. Pleuritis or Pericarditis 
7. Renal Disorder 
8. Neurologic Disorder 
9. Hematologic Disorder 
10. Immunologic Disorder
1. Pleuritis-convincing history of pleuritic pain or rubbing heard by a physician or evidence of 
pleural effusion OR 2. Pericarditis-documented by electrocardigram or rub or evidence of 
pericardial effusion 
1. Persistent proteinuria > 0.5 grams per day or > than 3+ if quantitation not performed OR 2. 
Cellular casts-may be red cell, hemoglobin, granular, tubular, or mixed
1. Seizures-in the absence of offending drugs or known metabolic derangements; e.g.uremia, 
ketoacidosis, or electrolyte imbalance  OR 2. Psychosis-in the absence of offending drugs or 
known metabolic derangements, e.g.uremia, ketoacidosis, or electrolyte imbalance 
1. Hemolytic anemia-with reticulocytosis  OR 2. Leukopenia-< 4,000/mm3 on ≥ 2 occasions  
OR 3. Lyphopenia-< 1,500/ mm3 on ≥ 2 occasions  OR 4. Thrombocytopenia-<100,000/ mm3 
in the absence of offending drugs 
1. Anti-DNA: antibody to native DNA in abnormal titer OR 2. Anti-Sm: presence of antibody to 
Sm nuclear antigen OR 3. Positive finding of antiphospholipid antibodies on: (a) an abnormal 
serum level of IgG or IgM anticardiolipin antibodies, (b) a positive test result for lupus 
anticoagulant using a standard method, or (c) a false-positive test result for at least 6 months 
confirmed by Treponema pallidum immobilization or fluorescent treponemal antibody 
absorption test 
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1.1.5. Clinical presentation 
Typically patients with JSLE present with non-specific constitutional symptoms, 
such as fever, lymphadenopathy, lethargy and weight loss. These may or may 
not accompany end-organ disease. Musculoskeletal, cutaneous, 
haematological and renal system involvement are common features of JSLE at 
presentation, and can occur in varying severity. Less frequent but important 
manifestations are neurological symptoms and signs, which occur in up to 10% 
of JSLE patients and can present with headaches, altered consciousness, 
seizures and even psychosis. Liver, ophthalmic, and especially cardiac and 
pulmonary involvement are rare manifestations in the paediatric form of SLE 
(34, 35).  
 
The multi-systemic nature of the condition means that JSLE may present to a 
multitude of different specialists, including psychiatrists, haematologists or 
nephrologists. In addition, patients may have lupus or evolving lupus without 
meeting 4 or more of the ACR criteria, making a formal diagnosis difficult (36).  
 
Important general features to enquire about in history taking and examination 
are outlined in Table 2. Clinical signs of lupus can also be defined by 
system/organ involvement as shown in Table 3 and relevant investigations are 
described in Table 2.  
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Table 2: Symptoms and signs of JSLE 
A broad range of symptoms and signs can be the presenting feature of JSLE 
and should be enquired about during the clinical assessment (37). 
Constitutional symptoms 
 Pyrexia 
 Weight loss 
 Lymphadenopathy 
 Fatigue/lethargy 
 Anorexia 
   
 Mucocutaneous 
 Malar erythema 
 Discoid lesions 
 Mucosal ulceration 
 Alopecia 
 Photosensitive skin 
   
 Neurological 
 Headache 
 Cognitive dysfunction 
 Seizures 
 Hallucinations 
   
 Cardiovascular & Respiratory 
 Dyspnoea 
 Chest pain 
   
 Vasculitis 
 Thromboembolism 
 Cuteanous changes +/- 
ulceration 
 Raynauds 
   
 Renal 
 Oedema 
 Haematuria 
   
 Gastrointestinal 
 Coilitis 
 Pancreatitis 
 Cholecystitis 
   
 Ophthalmic 
 Proptosis 
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Table 3: JSLE clinical characteristics . 
General assessment 
 Weight, height centiles 
 Systolic and diastolic blood pressure and centiles 
 Lymphadenopathy 
 Hepatosplenomegaly 
 
  Mucocutaneous 
 Skin rashes (discoid lesions, malar erythema) 
 Alopecia 
 Peri-ungal erythema 
 Mucosal ulceration 
 
  Neurological 
 Altered consciousness 
 Acute delirium or psychosis 
 Meningitis 
 Demyelitis 
 Peripheral or cranial neuropathy 
 
  Cardiovascular & Respiratory 
 Cardiac failure 
 Pericardial or pleural effusion 
 
  Musculoskeletal 
 Myositis 
 Arthritis (poly or mono) 
 Tendonitis 
 
  Vasculitis 
 Cutaneous ulceration/phlebitis 
 Raynauds phenomenon 
 Livido reticularis 
 Thromboembolism 
 
  Renal 
 Odema (nephrotic syndrome) 
 
  Gastrointestinal 
 Ascities 
 Jaundice 
 Abdominal pain 
 
  Ophthalmic 
 Uveitis, keratitis, episcleritis 
 Optic neuritis 
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1.1.6. Differential diagnosis 
The main differential diagnoses of JSLE include: other systemic autoimmune 
conditions - including juvenile dermatomyositis, systemic juvenile-onset 
idiopathic arthritis (JIA), systemic vasculitis, periodic fever syndromes and 
Kawasaki’s disease -, infections (bacterial or viral), immunodeficiency 
syndromes, or malignancy (38).  
 
Multi-system organ involvement signifies that any organ-specific diseases may 
also need excluding and potentially included in the differential diagnosis. For 
example, children with JSLE manifesting predominantly as nephritis may 
present with signs indistinguishable from childhood nephrotic syndrome (39), 
or JSLE patients with neuropsychiatric lupus may be indistinguishable from 
encephalitis or primary psychiatric problems (40). Thorough evaluation and 
investigation by an experienced clinician is required to distinguish JSLE from a 
wide range of other diagnoses.  
 
1.1.7. Disease monitoring 
In view of the characteristic multi-system nature of SLE and the complexity of 
the clinical features of JSLE, a number of disease activity assessment tools 
have been developed for use in standardising disease monitoring. These 
endeavour to assess and summarise the overall disease activity, and are 
particularly useful at the time of disease flares - an episode of measurable 
increase in disease activity in one or more organ systems involving new or 
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worse clinical signs and symptoms and/or laboratory measurements and 
considered clinically significant and may require altered treatment (41). 
 
In JSLE two main disease activity tools are in use, the British Isles Lupus 
Assessment Group Index (BILAG) and the Systemic Lupus Erythematosus 
disease activity index (SLEDAI). Both of these were originally designed for 
adult-onset SLE and have been modified and validated (in part at least) for use 
in childhood disease (42, 43).  
 
1.1.7.1. The BILAG disease activity assessment tool 
The BILAG disease activity score (44) is commonly used in recent clinical trials 
of lupus, as it is able to separate disease activity into different organ systems 
and score accordingly, although it is not widely used in the everyday 
monitoring of JSLE. It takes into account the disease features experienced by 
a patient in the past four weeks compared to the four weeks prior and is 
designed to reflect a clinician’s intention to alter treatment at the time of 
assessment. The traditional BILAG2004 scoring system produces an 
alphabetical score (A-E) to classify the severity of disease activity in each of 
the organ domains (44). A numerical total (global) BILAG2004 score can be 
calculated using each of the organ domains (A=9, B=6, C=3, D=0, E=0; 
Appendix 1). More recently, further adaptation and validation of the BILAG 
scoring has taken place with a revised scoring system implicated (A = 12, B = 
8, C = 1 and D/E = 0) (45). Preliminary validation of the BILAG in JSLE has 
taken place in two studies. Using prospective observational studies, Brunner et 
al and Marks et al investigated its relationship with changing disease actvitiy 
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markers using laboratory markers and visual anologue scales; both groups 
concluded that the BILAG is sensitive for use in JSLE (42, 43).  
 
1.1.7.2. The SLEDAI scoring system 
The original SLEDAI scoring system (46), evaluates the presence of multiple 
features of SLE at the time of completion or in the previous ten days. It is a 
weighted, cumulative index, able to differentiate mild and moderate from 
severe lupus disease activity. It generates an overall disease activity score 
ranging from 0-105, with higher scores meaning increased disease activity. 
The SLEDAI is a valid and reliable measure (47) that is sensitive to changes in 
disease activity in children (48). The SLEDAI was modified in the Safety of 
Estrogens in Lupus Erythematosus National Assessment (SELENA) trial; due 
to the difficulties in its use in clinical trials, the latest version is known as the 
SELENA-SLEDAI (49, 50). 
 
1.1.8. Investigations in JSLE 
Investigations assist clinicians in forming a diagnosis, monitoring disease 
activity and assessing organ damage. Children with lupus often present with 
haematological involvement affecting any of the blood cell lines together with 
evidence of autoantibodies. Lymphopenia is almost universally seen, with 
neutropenia, thrombocytopenia and haemolytic anaemia common.  
 
Over 90% of patients will have ANAs, the precise levels of which are poor 
indicators of disease activity. ANAs may even occur as an isolated finding in 
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healthy individuals (51). Useful laboratory tests and the common findings in 
JSLE are shown in Table 4. 
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Table 4: Investigations and typical abnormalities seen in JSLE 
Investigation Features with pSLE 
Full blood count, blood film Anaemia, leucopenia (especially lymphopenia), 
thrombocytopenia 
Direct coombs test Haemolytic anaemia 
Urea & electrolytes Abnormal renal function 
Liver function tests, bone profile Hypoalbuminaemia (nephrotic syndrome)m 
elevated transaminases (hepatitis) 
Creatinine kinase May be elevated (myositis) 
Lactose dehydrogenase May be elevated (myositis) 
C reactive protein Often low or normal, unless concurrent 
infection 
Erythrocyte sedimentation rate (ESR) Usually elevated 
Complement (C3, C4) Often reduced, particularly in renal lupus 
Coagulation, INR, lupus anticoagulant May be deranged, lupus anticoagulant positive 
Ferritin Often elevated due to inflammation 
Immunoglobulins G,A,M May get hypogammaglobulinaemia 
Antinuclear antibodies (ANA) Positive 
Anti-double stranded DNA (dsDNA) Often positive, may reflect renal lupus 
Anti-extractable nuclear antibodies 
(anti ENA), includes anti-Sm, -RNP, -
Ro, -La May be present 
Anticardiolipin antibodies IgG, IgM May be present 
Complement C1q levels and anti-C1q 
antibodies 
May be C1q deficient or have C1q antibodies, 
especially seen in renal lupus 
Anti-neutrophil cytoplasmic antibody 
(ANCA) Often normal (useful for differential diagnosis) 
Thyroid function tests (TFTs) Autoimmune thyoiditis may accompany JSLE 
Urinalysis Protein, blood, casts 
Urine albumin:creatinine ratio Important in quantification of proteinuria 
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Appropriate investigations need to be tailored to the individual patient 
balancing the invasiveness of each procedure with the ability to establish a 
diagnosis and determine the extent of the disease process. Investigations may 
include: electrocardiograph, chest x-ray, echocardiography, bone marrow 
aspiration, lumbar puncture, magnetic resonance imaging, angiography, tissue 
histology (skin, lymph nodes) and renal biopsy (if significant proteinuria, 
haematuria, altered renal function or hypertension). Many procedures will 
require sedation and occasionally the use of general anaesthesia to protect the 
child from pain.  
 
1.1.9. JSLE disease management 
The management of JSLE requires comprehensive and holistic 
multidisciplinary team (MDT) input to achieve optimal disease control and a 
good quality of life. Key challenges include preventing disease progression, 
controlling symptoms, minimizing adverse consequences of treatment whilst 
supporting the patient and their families through the enormous impact a 
chronic disease may have upon them. The long term impact of the disease, its 
complications and those associated with the treatments used need to be 
minimised as much as possible in JSLE, as patients have potentially a life-long 
risk of associated morbidity and associated mortality. 
 
1.1.9.1. The Multi-disciplinary team 
Due to the complexity of the disease, the care of a patient with JSLE requires 
involvement of multiple specialists preferably coordinated by a paediatric 
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rheumatologist with experience of JSLE (52). Nurse specialists have an 
essential role in liaison with the patient/family and can be useful in educating 
the patient about the disease and medication and liaising with schools. 
Paediatric specialists such as dermatologists, nephrologists and 
haematologists may assist with the initial diagnosis, management of disease 
flares and long term disease monitoring.  Physiotherapists, occupational 
therapists and play specialists can assist the patient with adapting and coping 
with the disease and have a role in rehabilitation following disease activity 
flares.  
 
JSLE can have significant and debilitating neuropsychiatric manifestations, 
and psychosocial consequences can occur. The MDT should therefore include 
paediatric psychologists who can assist the patients through such difficulties. 
The family general practitioner should be kept informed about medication 
regimens and any monitoring required in the primary care setting including the 
special circumstances surrounding vaccination.  
 
1.1.9.2. Medical management of JSLE 
Clinical manifestations of JSLE are generally more severe and the disease 
appears more aggressive than the adult-onset form. Almost exclusively it 
requires higher doses of corticosteroid treatment as well as more intensive 
immunosuppressive treatment (53).  
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Optimum disease management requires repeated and regular review. The 
overall aim of treatment is to achieve symptomatic resolution, disease control 
and improved quality of life by reducing disease progression and preventing 
further tissue damage. Under-treatment can be associated with increased 
symptoms, worsening growth and poor educational abilities and hasten 
disease progression and tissue damage (54, 55). Alternatively, over treatment 
poses more drug toxicity and potentially more frequent, severe opportunistic 
infections and may be linked to chronic damage (54, 55).  
 
In JSLE, corticosteroids still have a crucial role in disease control. 
Immunosuppressive treatment regimens usually consist of a period of intensive 
induction of remission therapy over 6 to 12 months to achieve disease 
quiescence followed by a period of long-term maintenance therapy to control 
disease and prevent disease flares. Disease flares should be proactively 
screened for and aggressively treated.   
 
1.1.9.2.1. Induction therapies 
Induction treatment options include intravenous corticosteroids (e.g. 
intravenous methylprednisolone 30mg/kg/day for 3 days, up to maximum 
1gm/day) and long term high-dose oral corticosteroids (e.g. 1-2mg/kg/day, 
followed by gradual weaning regime) combined with a disease-modifying 
agent. Traditionally, intravenous cyclophosphamide has been used for major 
organ involvement in JSLE (56), with azathioprine (AZA) or methotrexate used 
for milder or moderate disease. More recently, mycophenolate mofetil (MMF) 
has offered an alternative therapeutic option for severe disease. For example, 
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in cases of severe renal involvement, lupus nephritis (LN), identified by the 
ISN/RPS (57) as class III (focal) and IV (diffuse), cyclophosphamide and MMF 
have been shown to be equally effective in adult-onset SLE (58) and may be 
more effective in those of Black African ethnicity (59). However in cases of 
other major organ involvement, or where there is concurrent severe systemic 
vasculitis, intravenous cyclophosphamide along with corticosteroids remains 
the preferred induction therapy. In circumstances of rapidly progressive life 
threatening disease (typically involving the neurological or renal systems) 
plasma exchange and intravenous immunoglobulin can be effective short-term 
treatment options whilst awaiting response to cytotoxic and corticosteroid 
treatment. 
 
1.1.9.2.2. Maintenance therapies 
All patients should receive hydroxychloroquine (HCQ), unless contraindicated 
as in cases of glucose-6-phospate dehydrogenase (G6PD) deficiency. Adult 
studies indicate HCQ (60, 61): has a disease-modifying role; reduces long-
term risk of flares; and has a steroid-sparing and lipid-lowering effect. It can be 
particularly useful for skin and joint disease; indeed occasionally some patients 
with mild disease can be managed with HCQ alone.  
 
Maintenance therapy of JSLE usually involves the use of either AZA or MMF 
as immunosuppressive therapy, with reports suggesting that MMF is equally 
efficacious, if not slightly superior to AZA (62, 63). These disease-modifying 
drugs are steroid sparing and usually initially administered in combination with 
oral prednisolone, which is gradually withdrawn as the disease permits.  
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Maintenance therapy should be continued for several years to achieve on 
going disease remission, particularly during critical stages of childhood 
development and educational milestones.  For disease manifesting 
predominantly in the musculoskeletal system, methotrexate can achieve a 
good clinical response.  
 
1.1.9.2.3. Second line treatments 
Second line therapies include “biologic” therapies including monoclonal B cell 
antibodies (Rituximab, Rituxan) and anti-BAFF treatment (Belimumab). Clinical 
trials have not yet proven the efficacy of monoclonal B cell antibody treatment 
in randomised controlled trials of adult-onset SLE (64, 65); however failure to 
demonstrate lack of a significant outcome may in part be due to a number of 
methodological problems related to trial design and conduct, as clinical 
experience and case series demonstrate its efficacy and tolerability (66-68), 
even in childhood disease (69, 70). Belimumab has proven efficacy in clinical 
trials (71-73) and paediatric trials are currently in the recruitment phase (74). 
 
Other therapies that can be used for recalcitrant, complex disease, not 
controlled by the above options, include cyclosporin and monoclonal 
antibodies against TNF-α or newer biologic therapies outlined below.  
Thalidomide has been used effectively in patients with severe unremitting skin 
involvement; however clinicians have a duty to counsel patients appropriately 
with respect to its teratogenic consequences and ensure adequate 
contraception in sexually active patients. A summary of the medications, along 
with commonly encountered side effects, is outlined in Table 5. 
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Table 5: Medications commonly used in JSLE.  
Medications commonly used in JSLE, their indications and the most commonly 
experienced side effects. 
Medication Indications  Common side effects 
Corticosteroids 
Induction and maintenance therapy.  All 
moderate to severe cases; may be required 
for mild unremitting disease 
Adrenal suppression 
Straie 
Obesity 
Mood alterations 
Growth failure 
Osteoporosis 
Cyclophosphamide 
Induction therapy, usually intravenous Infertility 
Moderate to severe disease with organ 
involvement 
Hair loss 
Increased risk of 
infection 
Nausea and vomiting 
Long-term increased risk 
of malignancy 
Mycophenolate mofetil 
Induction and maintenance therapy.  
Moderate to severe cases. 
Abdominal discomfort 
Diarrhoea 
Liver inflammation 
Increased risk of 
infection 
Teratogenic in pregnancy 
Azathioprine 
Maintenance treatment 
Increased risk of 
infection 
Mild, moderate or severe disease 
Bone marrow 
suppression 
Methotrexate 
Maintenance treatment 
Bone marrow 
suppression 
Musculoskeletal symptoms Liver inflammation 
Hydroxychloroquine All patients 
Haemolytic anaemia in 
patients with G6PD 
Rituximab 
Second line induction therapy in moderate to 
severe disease 
Infusion reactions 
Increased risk of 
infection 
Potential malignancy risk 
Long term data in 
children not available 
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1.1.9.2.4. Treatment of relapses 
Disease relapses require thorough investigation followed by treatment 
according to the severity of organ involvement. Disease activity tools can 
categorize flares into mild, moderate and severe (75). Milder flares may 
respond to a dose increase of their maintenance therapy or a short-term 
increase in oral corticosteroids. Moderate to severe disease flares are likely to 
need intravenous corticosteroid therapy to achieve remission and may need 
further cytotoxic or second line treatment. Prompt recognition, intervention and 
appropriate treatment of disease flares are important as disease damage can 
occur during periods of poor control. During each disease exacerbation and at 
each annual review a meticulous calculation of the cumulative 
cyclophosphamide dose exposure is essential.  
 
1.1.9.2.5.  Newer drug therapies 
Newer Biological therapies in JSLE are usually derived from drug trials in adult 
SLE patients, which then become adapted for use in an unlicensed manner in 
children, efficacy and side effects in children are therefore not known and 
parental consent and education in this regard is recommended. Recent drugs 
undergoing phase I, II or III clinical trials and their mechanisms of action are 
highlighted in Table 6 and include Epratuzumab (76), Atacicept (77), 
Tocilizumab (78), Ocrelizumab (79), Abatacept (80), Abetimus (81) and 
Rigeromid (82).  
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Table 6: New medications under evaluation in SLE  
New biologic medicines are being investigated in lupus targeting different immunological pathways as summarised (76-82). 
Drug name Actions Studies 
Epratuzumab CD22 monoclonal antibody that inhibits B cells  Daridon, 2010 
Atacicept Recombinant fusion protein that binds with BAFF & APRIL receptors 
Pena-Rossi, 
2008 
Tocilizumab IL-6 monoclonal antibody  Illei 2010 
Ocrelizumab Targets CD20+ B cells Hutas, 2008 
Abatacept Modulates CD80/CD86:CD28, controls regulatory & inhibitory factors Merrill 2010 
Abetimus Induces B cell tolerance Cardiel 2008 
Rigeromid 
Spliceosomal peptide P140; blocks recognition of IgG antibodies and CD4+ T 
cells Muller, 2008 
 
Abbreviations: BAFF, b cell activating factor; APRIL, a proliferation-inducing ligand; IL, interleukin; Ig, immunoglobulin  
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1.1.9.3. Growth and development 
Patients with JSLE require particular consideration to their growth and 
development, with measurements and comparison to growth centile charts 
recommended every 3 months. Body mass index and pubertal assessment is 
also important during monitoring. Faltering growth and pubertal delay may be 
seen due to on going disease activity or may occur secondary to treatment 
side effects.  
 
1.1.9.4. Psychosocial wellbeing 
Health consideration in terms of physical wellbeing is essential but equally 
important is the acknowledgment of the patient’s educational, emotional and 
psychosocial needs.  
 
1.1.9.5. Other management options 
Bone marrow or stem cell transplant are considered in the rare cases of poorly 
controlled JSLE. It is reserved for severe cases and requires consensus from 
external expert reviewers, as it is associated with a significant mortality (83). 
Topical immunosuppressive treatments can be used for isolated skin 
manifestations and laser therapy can be used to treat corticosteroid-related 
straie. In cases of severe end organ involvement other interventions may be 
required, for example renal transplant for advanced glomerulonephritis.  
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1.1.10.  Prognosis in JSLE 
Over recent decades the survival of JSLE patients has improved; partly due to 
better recognition, earlier diagnosis and the use of more aggressive 
management protocols including steroid use and cytotoxic medications. 
Despite improvements, long-term morbidity and mortality remains a significant 
concern.  
 
1.1.10.1. Disease associated damage 
Disease related damage and treatment toxicity is reported to occur in up to half 
of JSLE patients over 6-year follow up (84, 85). Disease damage should be 
monitored annually using the SLICC/ACR damage index (Systemic Lupus 
International Collaborating Clinics/American College of Rheumatology 
Damage Index) (86).  
 
The highest burden of long-term damage is related to the cardiovascular, 
neurological and renal systems (87). Early atherosclerosis is well recognised, 
with traditional risk factors such as smoking, weight gain and reduced physical 
activity, not accounting fully for its occurrence (88). Increased atherosclerosis 
is likely to be multifactorial in aetiology as a result of deranged metabolic, 
inflammatory and immunological systems and the use of certain therapeutic 
interventions such as corticosteroids. There is a need to better understand 
early cardiovascular disease processes in JSLE to guide interventions and 
minimise subsequent morbidity. Neurological damage occurs more frequently 
in JSLE than in adult-onset disease (1). Bone changes such as osteoporosis 
and osteopenia are frequently seen in JSLE and are related to disease activity 
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and perhaps corticosteroid use (89). In addition other irreversible features are 
seen such as scarring alopecia (34).  
 
1.1.10.2. Mortality  
The 10-year mortality rate remains around 10%, with the greatest improvement 
in mortality seen during the introduction and routine use of immunosuppressive 
medication and corticosteroid treatment. Children with SLE have a lower life 
expectancy than the general population mainly due to the increased 
cardiovascular morbidity (90, 91).  
 
1.1.11. Organ involvement in JSLE 
JSLE is a multi-systemic condition, with a high tendency for haematological 
and immunological manifestations. The most frequently observed organ 
manifestations involve the renal, musculoskeletal and cutaneous systems (34) 
with a younger age and renal involvement being directly associated with the 
worse long term prognosis (92). 
 
1.1.12. Differences between JSLE and adult-onset SLE  
Important clinical differences occur between JSLE and adult-onset SLE 
patients; it typically has more severe organ involvement, a more active disease 
process (93), different organ manifestations and increased frequency of 
immunological and haematological involvement (94). A summary of these key 
clinical differences is given in Table 7. With regards to research, there are 
significant challenges to undertaking research in childhood-onset disease - 
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such as accounting for normal growth and development, dealing with an 
evolving immune system and the influence of sex hormones at the time of 
puberty. Despite these challenges, this is a cohort of patients with more severe 
organ involvement, allowing investigation of a severe phenotype, and the 
treatment demands are much higher. Therefore identifying important factors in 
disease characteristics or pathogenesis may provide an opportunity to improve 
our understanding of the disease pathophysiology and thereby offer a 
significant (and rewarding) opportunity to positively alter the natural disease 
course of this condition. 
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Table 7: A summary of the key differences between JSLE and adult-onset SLE 
Key differences in the disease demographics, organ manifestations, disease activity and damage are summarised using (95, 96). 
Features  JSLE Adult SLE 
Demographics Female:male ratio 5:1 Female:male 9:1 
Organ 
manifestations Nephritits > 70% Nephritis around 50% 
 
More constitutional symptoms Less constitutional symptoms 
 
Haematological involvement > 70% 
Haematological involvement less frequently 
seen 
 
Neurological involvement in 10-20% Neurological involvement rare 
 
Cardiorespiratory involvement rare Cardiorespiratory involvement frequently seen 
 
Ophthalmic involvement <10% Ophthalmic involvement 
 
Serositis <5% Serositis >20% 
Disease activity Higher mean disease activity scores More controlled disease activity  
 
Anti-dsDNA antibodies in 61-93% Anti-dsDNA antibodies in 25-78% 
Medications Over 90% steroid use Up to 70% steroid use 
 
25% cyclophosphamide use 10% cyclophosphamide use 
Disease damage Morbidity neurological, renal Cardiovascular morbidity 
Other Poor growth with active disease Growth not applicable 
   
 
Abbreviations: Anti-dsDNA, anti-double stranded deoxyribonucleic acid
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1.1.13. Pathophysiology of JSLE 
A dysregulated, exaggerated immune response, with abnormalities in both the 
innate and adaptive immune system, resulting in an immune reaction directed 
against the nuclear components of ones own cells underpins the 
pathophysiology of JSLE.  
 
In health, the production and clearance of cells within the body is highly 
regulated to balance the rate of cell division with the rate of cell death. JSLE is 
believed to occur due to 
 An increase in the production of nuclear debris exposure, due to both 
overproduction and inefficient clearance  
 The detection of nuclear debris as foreign 
 A pro-inflammatory environment 
 The production of auto-antibodies 
 A lack of tolerance to self-nuclear components 
 
Each of these processes subsequently contributes to an immune cascade 
involving a pro-inflammatory innate response and specific adaptive immune 
response directed against self-nuclear components and destruction of healthy 
host tissue.  
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1.1.13.1. Increased nuclear debris exposure 
Increased cell death, occurring by apoptosis and necrosis, is believed to 
expose self-nuclear cell debris to the immune system in SLE (97-101). More 
recently a process called neutrophil extracellular traps (NETosis) has been 
recognised as assisting in the inflammatory process in SLE by distributing 
cellular contents into the local environment, which in health usually assists with 
microbial cell death (102-104).  
 
These three processes each have unique pathways and if increased, without 
ineffective clearance, would expose nuclear components to the immune 
system. Upon cell death or activation, the clearance of debris is usually swift 
and effective allowing little time for inflammatory stimuli. In lupus this process 
is impaired and occurs for a number of reported reasons, many more of which 
may not be fully understood. Phagocytes recognise phosphatidylserine 
expressed on the apoptotic cell surface that is expressed as an “eat me signal” 
and lysophosphatidylcholine (LPC) that is a “come get me” signal (105).  
Inefficient phagocytosis is seen in JSLE (106-109) and factors interfering with 
the recognition of these signals are present at abnormal concentrations, such 
as the T-cell immunoglobulin and mucin-domain-containing molecule (TIM4) 
and milk fat globule EGF factor 8 (MFG-E8) leading to inefficient clearance of 
cellular debris (110, 111). Autophagy, a process of allowing cells to self 
degrade, is exaggerated in lupus due to an up regulation of the autophagy 
regulator, the mammalian target of rapamycin (mTOR) (112). A lack of DNase, 
an enzyme associated with degrading cellular DNA, also occurs (113, 114). 
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DNase deficient mice accumulate undigested DNA, producing large amounts 
of pro-inflammatory cytokines and clinical features of lupus (115).  
 
1.1.13.2. Increased detection of nuclear debris  
In lupus, excessive nuclear components can bind to TLRs leading to their 
activation (116). Intracellular located TLRs are responsible for detecting 
nucleic acids (such as TLR 3, 7, 8, 9) through the use of co-factors. Netting 
neutrophils can produce HMGB1 and LL37 that act as co-factors assisting with 
intracellular TLR activation in lupus (117), with an increased expression of 
TLRs also described (118). TLR activation then leads to the transcription of 
inflammatory cytokines.  
 
In health immature DCs circulate, in lupus NFkB production activates DCs to 
mature and become sophisticated APCs that over express MHC II and FCγR’s 
(able to detect the Fc region of immune complexes) at their surface leading to 
T lymphocyte activation and the production of cytokines and antibodies (112, 
119).  
 
1.1.13.3. Pro-inflammatory environment 
Following the detection of self-nucleic acid as foreign, IFN’s and pro-
inflammatory cytokines are expressed through a number of mechanisms as 
detailed earlier (section 1.1.13.2). In lupus, the most commonly encountered 
type 1 IFN is IFN-α and type II is IFN-γ (120). IFN-α induces the maturation of 
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DCs, activates CD8+ T cells and, in conjunction with IL-6, can differentiate B 
cells (121-123). IFN-γ is secreted by Th1 cells and promotes skewing of CD4+ 
T cells to become Th1 cells using a positive feedback mechanism; NK and NK 
T cells also produce IFN-γ (124). It acts to augment IFN-α responses, 
differentiates plasma B cells, facilitates antigen presentation, increases MHC 
expression, promotes leukocyte migration and produces nitric oxide (125, 
126). 
 
Circulating pro-inflammatory cytokines are increased in patients with lupus 
and, along with immune complexes, complement components and acute 
phase reactants, are responsible for changes in the vascular permeability 
coagulation dysfunction, erythrocyte aggregation, cell infiltration to organs, and 
subsequent inflammation and tissue damage.  
 
Pro-inflammatory cytokines are increased in patients with lupus including IFN-
α, IFN-γ, IL-6, TNF-α, IL-1, IL-12, IL-13, IL-17 and IL-18. Different cytokine 
expression profiles may contribute to the differing clinical symptoms 
experienced by patients, with increased IL-12, IL-18, IL-6, TNF-α and IFN-γ 
associated with LN (127-129).  
 
1.1.13.3.1. Tumour necrosis factor alpha 
One of the most important cytokines in immune regulation is TNF-α, which is 
produced in small quantities in quiescent cells, but becomes one of the major 
factors secreted in activated cells. Its actions are mediated through two distinct 
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but structurally homologous receptors, TNF receptor (TNFR) 1 and 2 (see 
Figure 1), the extracellular domains of which are very similar. However their 
intracellular domains are involved in very diverse signaling pathways (as in 
Table 8) (130). 
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Figure 1: Tumour necrosis factor alpha signalling. 
Tumour necrosis factor alpha (TNF-α) acts through two main receptors, tumour necrosis factor receptor type 1 (TNFR1) and type 2 
(TNFR2), present in the extracellular region on the cell surface and have different signalling molecules with the potential for some 
cross talk. TNFR1 activation promotes the up regulation of cell apoptosis through caspase activation and TNFR2 activation promotes 
the transcription of NFkB, cIAP and JNK pathways (130).   
 
Abbreviations: BID, beta interaction domain; cIAPs, cellular inhibitors of apoptosis; IKK, IκB kinase; JNK, c-Jun N-terminal kinase; MAP3K, mitogen-activated 
protein 3 kinase; RIP, receptor-interacting protein; TRAF2-associated kinase; TANK, TRAF family member associated NF-κB activator; TRADD, TNF receptor-
associated death domain protein; TRAF, TNF receptor-associated factor.  
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Table 8: Properties of the tumour necrosis factor alpha receptors (TNFR). 
TNFR 1 and 2 share many similarities however they have distint down stream signalling actions (130).  
Feature TNFR1 TNFR2 
Cells expressing Present almost ubiquitously on cells 
Present on the majority of cells but mainly endothelial 
cells and haematopoietic cells 
Cellular location Transmembrane glycoprotein Transmembrane glycoprotein 
Molecular mass 60 kDa 80 kDa 
Role in immunity 
Apoptosis, cytotoxicity, fibroblast proliferation, 
prostaglandin synthesis 
Proliferation of thymocytes, cytotoxic T cells, 
mononuclear cells, induce GM-CSF, inhibits early 
haematopoiesis, downregulated activated T cells 
Soluble form 
sTNFR1 present in blood or urine, produced by 
monocytes, macrophages, cleaved off surface by LPS, IL-1, 
and TNF 
sTNFR2 present in blood or urine, produced by 
monocytes, macrophages, cleaved off surface by LPS, IL-1, 
and TNF 
Ligands TNF-α, lymphotoxin (LT) TNF-α, lymphotoxin (LT) 
Down stream 
signalling 
TNF trimerizes TNFR1 upon binding inducing TRADD, that 
recruits molecules TRAF-2 and RIP. TRADD leads FADD 
mediated apoptosis using caspade cascade, and also can 
cross function to activate the JNK and NF-kB pathways 
TNF trimerizes TNFR2 inducing the NF-κB pathway via the 
NIK, IKK, and I-κB pathway,JNK pathway is induced 
through MAP3K pathway, inhibitors of apoptotic pathway 
are also produced 
   
 
Abbreviations: GM CSF; granulocyte macrophage colony stimulating factor, sTNFR; soluble TNFR, LPS; lipopolysaccharide, IL-1; interleukin-1, TNF tumour necrosis factor; IKK, 
IκB kinase; JNK, c-Jun N-terminal kinase; MAP3K, mitogen-activated protein 3 kinase; RIP, receptor-interacting protein; TRAF2-associated kinase; TRADD, TNF receptor-
associated death domain protein. 
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Nuclear material and immune complexes activate the complement pathway, 
consuming the early complement pathway proteins (leading to reduced 
circulating C1-C4) and resulting in the MAC (C5-C9) that causes local tissue 
injury and destruction (131). Antibodies to, or genetic deficiency of, C1q 
promotes inflammasome production, macrophage differentiation and 
perpetuates the complement cascade (132, 133). Acute phase reactants are 
stimulated contributing to the systemic inflammatory response. 
Macrophages have direct anti-microbial activity (134-136) and they can be 
distinguished by two different subtypes; activated macrophages (the M1 class) 
and the inactivated macrophages (termed the M2 class). 
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Table 9: Properties of the macrophage cell. 
The macrophage has many roles in the immune system and can be 
subclassified into M1 and M2 phenotypes depending on their state of 
activation (defined according to the cytokines subsequently expressed) (134-
136). 
Function 
Macrophage 
subtype 
Process 
Microbe killing M1  
Phagocytosis, complement 
activation, Fc receptor activation, 
cellular activation, cytokine, 
chemokine, growth factors released 
Tumorigenesis M1, M2 
M1 cells activate tumour-killing 
mechanisms, M2 cells suppressed in 
metastatic cancer, IL-4, IL-13 can 
promote tumour progression 
Activating 
neutrophils 
M1  Using IL-8, TNF-α 
Tissue surveillance  M1  Phagocytosis of redundant cells 
Fever M1 IL-1, prostaglandin secretion 
Tissue repair M2 
Attracts Treg and Th2 responses. 
Growth factors (TGF-β, PDGF) 
stimulate epithelial cells and 
fibroblast differentiation, block 
extracellular matrix degradation 
Adipose tissue 
macrophages 
M1 
Impaired M2 function in adipose 
tissue leads to impaired glucose 
tolerance, insulin sensitivity 
Allergy, asthma M2 
Overproduction can exacerbate 
airway inflammation and IL-13 
production 
Atherosclerosis 
formation 
M1 
Macrophages lodge in intima of 
arteries forming obstructive plaques 
that rupture, thrombose, and with 
IFN-γ can become unstable and 
highly activated. These augment LDL 
uptake 
Fibrosis, scarring M1 
Production of IL1-β, TGF-β, PDGF, 
insulin-like growth factor 1 are pro-
fibrotic  
M1 macrophage class 1; M2 macrophage class II; IL interleukin; TNF tumour 
necrosis factor; Treg T regulatory cells; Th2 T helper cell 2; TGF transforming 
growth factor; PDGF platelet derived growth factor; IFN interferon; LDL low 
density lipoprotein 
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1.1.13.4. Production of auto-antibodies 
Mature dendritic cells identify self-nucleic acid as antigen and present it to 
plasma B cells leading to the production of self-nuclear antibodies (137, 138). 
These form immune complexes that deposit within tissues and cause a type III 
hypersensitivity reaction that is able too; aggravate the complement cascade 
(with direct MAC damage), promote chemo-attraction and vasodilation (139) 
and lead to T cell activation (140). Plasma B cells demonstrate prolonged 
survival, supported by factors such as B cell activating factor (BAFF) that is 
increased in lupus (141, 142). In turn, these encourage further plasma B cell 
maturation with more antibody production, and hence an ever increasing 
inflammatory surge. 
 
1.1.13.5. Impaired immune tolerance 
In addition to the pro-inflammatory cascade described in JSLE, normal 
regulatory mechanisms are reduced resulting in a general loss of control within 
the immune system. In lupus, T cells that react with self epitopes emigrate 
from the thymus, the regulation of T cell egress is in part due to a sphingosine-
1-phosphate gradient (143) – increased systemic levels of which are seen in 
lupus (144) and drive early egress and inefficient self recognition. Increased 
mTOR and TLR 7 expression reduce FOXP3, a transcription factor for Treg 
cells, leading to reduced Treg proliferation and fewer anti-inflammatory 
cytokines (118). 
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Figure 2: An illustration of the dysregulated immune system in SLE 
In SLE, self-nucleic material from cell death is thought to initiate the immune cascade. These are detected by toll like receptors (TLR) that up regulate cytokines 
including interferon-α or -γ. Cytokines activate macrophages and dendritic cells, further promoting the release of cytokines, chemokines and growth factors 
throughout the body. Dendritic cells present the antigen to the B cells were specific antibodies (self-nucleic antibodies) are formed and immune complexes 
occur.  Inflammatory substances and immune complexes lead to complement and coagulation pathway activation and red cell agglutination causing 
vasodilation, inflammatory cell infiltrate and further cell death leading to multisystemic symptoms. Adapted using (137, 139, 140). 
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1.2. Lupus Nephritis  
Renal involvement in JSLE, LN, is a severe organ manifestation that is seen 
more frequently than in adult-onset disease.  It presents with a wide range of 
severities and typically requires aggressive management. Recently, the 
presence of renal involvement in SLE has been directly linked to a worse 
overall long-term prognosis (145). 
 
1.2.1. The kidney  
The kidney has an important role in immune regulation and is a common target 
for immune mediated diseases such as SLE. The kidney has several important 
role’s within the body: filtering blood and eliminating waste products into urine, 
controlling water and electrolyte balance, retaining important blood 
constituents such as albumin, maintaining acid-base balance, and regulating 
and secreting hormones. The immune functions of the kidney are less 
frequently reported, but essential to understanding immune mediated renal 
diseases.  
 
The kidney is made up of millions of nephrons, each one containing a 
glomerular and a tubular region. Tubules are divided into separate 
components and are involved in the fine-tuning of water and electrolyte 
reabsorption and elimination. The glomerulus is a dense ball of blood 
capillaries arising from the afferent arteriole and re-joining on leaving the 
glomerulus as the efferent arteriole. Blood passing through the dense 
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glomerular capillaries are under high pressure; this forces waste substances to 
move through pores within the glomerular endothelial wall of the capillaries into 
the glomerular capsule (Bowman’s capsule)   
 
The glomerular basement membrane (GBM) is situated beneath endothelial 
cells, upon which, are the glomerular epithelial cells – the podocytes, see 
Figure 3, Figure 4. The podocytes encase the basement membrane and have 
projections called foot processes, between which are narrow slits called slit 
diaphragms that contain proteins to produce a modified adherens junction 
(146, 147), Figure 3. Important podocyte derived slit diaphragm molecules 
include nephrin, podocin, neph1 and CD2AP (148), originally identified as they 
each can cause congenital nephrotic syndrome if genetically deficient (149). 
They are dependent on intracellular signalling networks to maintain cell polarity 
and perform endocytosis and can be modified by many factors including 
calcium, angiotensin (150).    
 
In amongst glomerular capillaries are mesangial cells, specialised pericytes 
that function to regulate blood flow through contraction and are able to perform 
phagocytosis. The glomerular filtration barrier, consisting of three layers 
(endothelial, basement membrane and podocyte), functions to filter only 
appropriately sized and appropriately charged molecules (151). Molecules 
must be of a suitable size to pass through the endothelial pores and slit 
diaphragm junctions, and they must be of a positive charge so that they are 
not repelled away by the highly negatively charged GBM (152). Disruption to 
any part of this barrier therefore permits the excretion of molecules into the 
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urine that would normally be retained within the circulation. An example of this 
is the passage of albumin – a large, negatively charged molecule – into the 
urine in renal diseases, producing proteinuria (153).  
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Figure 3: A cross sectional image of the glomerulus and the glomerular filtration barrier 
The dense glomerular capillaries are contained within the glomerulus and are encased by a glomerular basement membrane and 
podcyte cells making up the glomerular filtration barrier. Mesangial cells intersperse the glomerular capillaries. Outer to the glomerular 
filtration barrier is Bowman’s capsule and parietal epithelial cells.  Substances filtered across the filtration barrier pass into this region 
to progress to the tubular cells and ultimately form constituents of urine (146, 151, 152).  
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Figure 4: Electron microscopy image of the glomerular basement membrane 
An electron microscopy image of the glomerular basement membrane demonstrating the multiple layers that makes up an effective 
filtration barrier. The capillary is lined with endothelial cells that have fenestrations lining the glomerular basement membrane on the 
outer surface of which are the podocytes that encase the capillaries and project into bowman’s capsule (152). 
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1.2.2. Immune functions of the glomerulus  
As well as adapting to changes in the systemic immune system, the kidney has 
a key role in driving the local immune environment. Mesangial cells and 
podocytes express TLRs and Fc receptors for IgG, leading to the up regulation 
of inflammatory mediators, and they have a local ability to perform 
phagocytosis and antigen presentation.  
 
1.2.2.1.1. Glomerular toll like receptor expression 
In health, the presence of glomerular TLRs allows direct detection of foreign 
pathogens, and activates a local innate immune response within the 
glomerulus. Mesangial cells have been shown to express TLR 3, 4, 7, 9, and 
podocytes express TLR 1-6, 9 (154-156). 
 
1.2.2.1.2. Glomerular fragment crystallisable region (Fc) receptors 
Fc receptors are able to bind to the Fc region of specific antigens. Fc subtypes 
are specific for the class of Ig presented (that is, IgG, IgA or IgM). Fc activation 
promotes elimination of these complexes through phagocytosis or cytotoxic 
methods. FcRn (termed neonatal Fc receptors) are present in the glomerulus 
and have an ability to actively transport IgG (and albumin) away from the GBM 
(157).  
 
1.2.2.1.3. Glomerular expression of cytokines, chemokines and growth 
factors 
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Locally activated immune response, through TLR activation, Fc receptor 
interaction or antigen presentation, mediates the production of inflammatory 
cytokines, chemokines and growth factors (158).  Cytokines that can be 
expressed from the glomerulus include; anti-inflammatory cytokines (that act to 
reduce pro-inflammatory cytokines) such as IL-4, IL-6, IL-10, IL-13, TGF-β; 
and pro-inflammatory cytokines, TNF-α and IL-1; and cytokine receptors 
present include the TNF receptor 1 (TNFR1), TNFR2 and IL-1R (159, 160). 
 
These have multiple effects on the local environment, for example TLR 
activation will lead to the up regulation of vascular adhesion molecules - 
intracellular adhesion molecule 1 (ICAM) and vascular cell adhesion molecule 
1 (VCAM) - promoting cell aggregration, vessel vasodilation and allowing 
inflammatory cell entry into the GBM (161).   
 
1.2.2.1.4. Glomerular phagocytosis 
Mesangial cells and podocytes are able to perform phagocytosis and assist 
with the direct removal of invading pathogens (162). Mesangial cells perform 
phagocytosis under the regulation of TGF-β that is inhibited by high glucose 
concentration or disruption of integrin molecules (163).  Podocytes can perform 
phagocytosis and also control their own autophagy. Several factors may 
contribute to this process and autophagy is increased in the presence of pro-
inflammatory factors and angiotensin II (164). 
 
1.2.2.1.5. Antigen presentation 
  47 
Glomerular endothelial cells, mesangial and tubular cells can present antigens 
with HLA molecules as surface peptides for T cell recognition and activation of 
immune responses (165). 
 
Dysregulation of the process of glomerular immune regulation can lead to 
renal inflammation and/or cell infiltrate within the glomeruli and is termed 
glomerulonephritis.  
 
1.2.3. Pathophysiology of Lupus Nephritis 
One of the first clinically overt signs of active LN is the onset of proteinuria. 
Proteinuria is caused by disruption of the GBM permitting the passage of large, 
negatively charged molecules and abnormal clearance, through endocytosis, 
of infiltrating molecules. 
 
Recent scientific advances have confirmed the essential role for type 1 IFN’s 
(especially the subtype IFN-) in the immunopathogenesis SLE (166, 167). 
Cell death through apoptosis, necrosis and netosis, induces the production of 
IFN-, through TLR stimulation, by nucleic acid components of the cellular 
contents or through products expressed by the inflammasome (101, 104, 131, 
168, 169). A study by Miyake et al, demonstrated how the PBMC’s in patients 
with LN overexpress IFN- and were associated with a genetic IFN- allele 
(170). This IFN- predominance is supported in the finding of a skewed T cell 
balance toward the Th1 subtype producing pro-inflammatory cytokines and 
chemokines IFN-γ, IL-1, IL-6, IL-12, IL-18, TNF-α that are frequently observed 
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systemically and intra-renal in LN (as discussed in section 1.2.3) (171). This 
theory is supported by the findings of Xiaoqian et al, who looked at the serum 
and glomeruli of 46 patients with LN and identified an up regulation of IL-18 
which drives a Th1 predominance, when compared to healthy controls (172). 
This is further confirmed in a study by Edelbauer et al, where isolated JSLE T 
cells demonstrated Th1 and Th17 skewing with high IFN- expression and a 
reduction in regulatory T cells (173). The imbalance in T cell subtype and 
subsequent systemic blood cytokine expression and may be one explanation 
for the variety of disease manifestations seen (174, 175). 
 
Macrophages are known to be one of the first cells to enter the kidney in active 
LN (176, 177) and they are found in the classically activated state (M1 type) 
(178). M1 macrophages are activated by IFN- through the IFN-R leading to 
transcription of IFN- related genes (Janus kinase (JAK)–signal transducer, 
activator of transcription (STAT) signaling pathway). In contrast IFN-α 
antagonises the IFN-R resulting in macrophage apoptosis and a reduction in 
their classically activated behaviour (179). The M1 phenotype produces a 
variety of chemokines including IL-8, IP-10, macrophage inflammatory protein 
(MIP)-1α, MIP-1β, and RANTES, that act as chemoattractants for inflammatory 
cells (neutrophils, immature dendritic cells, natural killer cells, and activated T 
cells) (180).  
 
Furthermore, pro-inflammatory cytokines are released by the M1 cells, 
including IL-1β, IL-6, and TNF-α (181). TNF-α contributes to the pro-apoptotic 
activity of the classically activated macrophage, is accompanied by NO release 
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and releases proteolytic enzymes including MMPs, which degrade the ECM 
components - collagen, elastin and fibronectin (182). Their survival is 
sustained by the systemic and local production of the growth factor, 
granulocyte colony stimulating factor-1, which is elevated in murine LN and 
has been shown to directly aggravate kidney injury, as murine deletion 
prevents LN progression (183-186). M1 macrophages therefore lead to local 
glomerular tissue destruction (187).  
 
IFN- produced by Th1 cells produce M1 phenotype macrophages that 
produce TNF-α (as seen in Figure 18). TNF-α is important in LN; it can be 
produced from many cells in the immune system (see section 1.1.13.3.1) 
including activated macrophages, and more locally within the kidney; the renal 
cells - mesangial cells, podocytes and the tubular cells (188-191). In a study 
looking at rat mesangial cells, an up regulation of TNF-α was seen in response 
to LPS (188) and in human mesangial cell lines serum from patients with IgA 
nephropathy induced mesangial-derived TNF-α (192). Human renal tubular 
cells have been shown to secrete mRNA and protein TNF-α in the process of 
cellular apoptosis, influenced by the presence of aldosterone (193). 
 
Within the diseased kidney TNF-α typically locates to the area under insult. In 
murine in vivo models of glomerulonephritis, TNFα, and not IFN- nor IL-1, 
amplifies the production of complement (C3) from the glomerular endothelial 
cells (194). 
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TNFα regulation and signalling is complex (see Figure 1). As a cytokine 
expressed by many cells of the immune system, it is well known for its pro-
inflammatory effects.  It has a key role in early innate immune response 
against bacterial invasion, bearing both innate and adaptive immune properties 
(195, 196) – see 1.1.13.3.1. TNFα acts through two receptors – TNFR1 (p55) 
and TNFR2 (p75) - both of which have distinct signalling actions and 
differential expression depending on the cell of interest (197, 198) – see Figure 
1.  
 
Within healthy glomerular histology TNFR1 is detectable at low levels but 
TNFR2 is not present (199). In disease states such as renal transplant 
rejection, drug-induced nephrotoxicity and LN, TNFR2 is found to be up 
regulated in the glomeruli, particularly crescents, and renal tubular cells, and is 
found located in the proximity of TNF-α and its pathway components (200-
203). In a study by Jacob et al, lupus prone mice (New Zealand white x New 
Zealand black mice) were produced with TNFR1 and 2 deficiencies; doubly 
deficient mice had accelerated disease (204), implying that complete removal 
of the TNFR signalling pathways may be detrimental to LN. In renal tubular 
cells TNFR2 up regulates in models of renal graft rejection and acts through a 
phosphorylated endothelial/epithelial tyrosine kinase (Etk) pathway (205), a 
pathway that is over expressed in the glomeruli of patients with LN (206). 
TNFR1 is required for host resistance to mycobacterial infection(207). In 
contrast, in a mouse model of immune-complex mediated glomerulonephritis 
TNFR2 deficient mice have a significant reduction in proteinuria and immune 
complex deposition (208).   
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The dual signalling pathways and expression, may explain in part its differing 
effects in clinical practice. For example in patients with arthritis (eg: juvenile-
onset arthritis or rheumatoid arthritis) anti-TNFα therapies are generally well 
tolerated (209, 210). However, they can also promote inflammation and drive 
the onset of lupus-like symptoms (211). For these reasons, the potential 
advantages and disadvantages of systemic suppression of anti-TNFα in SLE 
remains ambiguous (212). However studies have demonstrated its 
advantageous effect in patients with difficult-to-treat LN (213). 
 
TNF-α is highly implicated in the pathogenesis of LN. In a large study involving 
653 patients with SLE, serum concentrations of TNF-α were found to be 
elevated in patients with SLE compared to other rheumatological conditions 
and directly correlated with serum IFN-α concentration (214). Furthermore, 
Sabry et al, noted that serum TNF-α and IL-6 concentrations correlated with 
SLE disease activity in a cohort of 40 patients (215). In a study involving 21 
children with different forms of glomerulonephritis, TNF-α was found to be 
overexpressed in the renal histology of children with LN and more specifically it 
was found to be located within the cytoplasm of the glomerular epithelial cells 
(podocytes) (216). The presence of increased serum TNF-α and its soluble 
TNFRs were increased in patients with SLE, and correlated with disease 
activity (217). It is unknown exactly what regulates TNFR expression on the 
podocyte in LN. 
 
  52 
Increased TLR expression is seen in LN, leading to the local production and 
activation of the renal innate immune response (218). Machida et al, 
histologically identified the up regulation of podocyte TLR 9 in children with 
active LN (219). An increased systemic IFN-α, and local TLR induced IFN-α, 
promotes an increase in the mesangial cell Fc receptors that attract immune 
complexes to the region (220). These immune complexes deposit within the 
GBM and trigger complement activation. Components of the complement 
system are detected by receptors and the final MAC (C5b-9) can insert into the 
membrane of glomerular cells promoting cell activation, epithelial-
mesenchymal transformation and inflammatory properties (139). Additionally, a 
reduction in podocyte markers, including nephrin and podocin, is seen early in 
LN (221), perhaps resulting from the accumulation of oxidation products (222, 
223). This contributes to the onset of proteinuria by altering glomerular 
permeability through the effacement of podocyte foot processes, reduction in 
the actin cytoskeleton and reduced the Rho family of GTPase’s – small G 
coupled proteins essential for maintaining a healthy functioning slit diaphragm 
(224).  
 
The podocyte has a potential key role in the regulation of inflammatory signals 
that may be detected as urinary biomarkers, the most promising of which are 
MCP1 and NGAL (discussed in 1.2.11). MCP1 plays a leading role in the 
recruitment and migration of monocytes/macrophages to sites of inflammation 
(225). MCP1 is thought to have a detrimental role on the podocyte as: it is able 
to reduce the expression of nephrin (226); it enhances motility; it can rearrange 
the actin cytoskeleton and it can increase the permeability of the GBM to 
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albumin (227). However, to date it is unknown whether the urine biomarker 
MCP1 originates from the podocyte in patients with active LN. 
 
NGAL has a key role in the early innate immune response against bacterial 
infection and the modulation of oxidative stress (228). The presence of urinary 
NGAL in LN and other conditions, such as in urinary tract infection (229), is 
related to the expression of NGAL from the renal tubular epithelial cells. In 
contrast to MCP1, it appears to have a protective role in the kidney by 
reducing tubular cell apoptosis and assisting with cell repair (230). NGAL is 
expressed in many cells throughout the body including bronchial epithelial 
cells(231), cardiac myocytes and the vascular wall cells (232). The podocyte 
expression of NGAL has not been explored to date and despite its strength as 
a lupus biomarker, its contribution to the pathophysiology of LN is still not 
clear. 
 
Regulation of these systems such as the complement pathway is normally 
maintained through circulating regulatory proteins; disruption of these proteins 
can precipitate glomerulonephritis (233).  
 
The importance of the podocyte in LN pathophysiology and the influence of 
TNF-α on disease development illustrate the importance of investigating 
podocyte TNFR expression that in turn may provide a key insight into LN 
pathophysiology and guide future treatments. Each of these processes leads 
to inflammatory cell infiltration, which together with resident cells, including 
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podocytes, increases the release of cytokines, chemokines, vasodilatory 
substances, activators of coagulation and growth factors. These further 
perpetuate the inflammatory process and lead to direct cell changes and 
disruption to the glomerular filtration barrier resulting in the passage of 
substances such as albumin into the urine (as summarised in Figure 5).  
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Figure 5: The pathophysiology of lupus nephritis 
The increased presence of cell nucleic material can directly activate glomerular 
toll-like receptors (TLR) that are up regulated in lupus nephritis. Nuclear 
material, with cell T, B, macrophage and dendritic cell activation produces 
inflammatory cytokines, chemokines and growth factors which can be detected 
directly by receptors present in the kidney, such as the tumour necrosis factor 
alpha receptor. Immune complexes interact with glomerular Fc receptors and a 
local complement cascade occurs from interaction with C3 receptors. Together 
these produce vasodilation, tissue inflammation and injury, and the influx and 
deposition of inflammatory cells. 
  56 
 
1.2.4. Clinical presentation and diagnosis of Lupus nephritis  
The clinical presentation of LN is varied, ranging from mild urine abnormalities 
to nephrotic or nephritic syndrome. Nephrotic syndrome, a triad of proteinuria, 
oedema and hypoalbuminaemia, is seen in up to 75% of childhood patients, 
much more frequent than its adult onset counterpart (39).  
 
Lupus nephritis, like systemic symptoms of SLE, is characterised by periods of 
clinical remission and episodes of clinical flares with around a third of patients 
experiencing a renal flare over an 8-year period (234).  
 
The diagnosis of LN relies on histological analysis, as current laboratory 
markers are not able to accurately predict the extent of the underlying 
histological disease. 
 
1.2.4.1. Histological classification of Lupus nephritis 
The gold standard in diagnosing and classifying LN is through histological 
analysis obtained from a renal biopsy sample. Histological analysis typically 
reveals mesangial expansion, hyper cellularity, complement and 
immunoglobulin deposition, and in more severe cases glomerular scarring and 
crescent formation.  
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Based on the 1982 classification by the World Health Organization (235), the 
ISN/RPS have produced internationally recognised classification criteria which 
divides the histological appearances into distinct classes (57). The 
classification is based on the presence of morphologic lesions, (Table 10) the 
extent and severity of the involvement (focal <50% glomerular involvement, 
diffuse>50%), and features of activity and chronicity.  
 
Acitve lesions typically have cellular crescents and extensive fibrinoid necrosis; 
chronic lesions consist of glomerular sclerosis, fibrous crescents, tubular 
atrophy, and interstitial fibrosis (57, 236). 
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Table 10: The histological classification of lupus glomerulonephritis 
The International Society of Nephrology/Royal Pathology Society (ISN/RPS) 2003 histological classification of SLE glomerulonephritis 
(57). 
Class Features       
Class I Minimal mesangial lupus nephritis 
 Class II Mesangial proliferative lupus nephritis 
 Class III Focal lupus nephritis 
  Class IV Diffuse segmental (IV-S) or global (IV-G) lupus nephritis 
Class V Membranous lupus nephritis 
 Class VI Advanced sclerosing lupus nephritis   
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On immunofluorescence, staining for IgG is typical, with some patients having 
IgA or IgM deposits. Complement components early in the pathway (C4, C1q) 
are seen along with C3. The term “full house” is used to describe renal 
biopsies that have deposits including IgG, IgA, IgM, C4, C1q and C3. 
Downstream complement components can also be seen (237).  
 
LN affects all components of the kidney, including the endothelial cells and 
tubular renal cells. The ISN-RPS classification, recommends grading (mild, 
moderate, severe) tubular atrophy, interstitial inflammation and fibrosis and the 
severity of any arteriosclerosis or other vascular lesions, however, the exact 
classification criteria and prognosis are linked to the glomerular findings 
exclusively. Endothelial cell changes are well described with leucocyte 
accumulation, cell injury and endocapillary proliferation (238-240). Renal 
tubular-interstitial cell abnormalities are seen with an abundance of interstitial 
cell infiltrate, tubular atrophy, and interstitial fibrosis (241). 
 
Histological analysis provides important prognostic information and directs 
management (242). At the time of histological assessment around 50% of 
children with LN will have class IV glomerulonephritis - the most severe 
histological category, carrying the worst renal prognosis (234, 243). 
 
1.2.5. Laboratory markers in LN  
Several laboratory markers are used for routine monitoring of LN disease 
activity. These include proteinuria, glomerular filtration rate (GFR), urine 
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sediment, serum complement levels, antibodies to C1q and dsDNA. No single 
marker is robust enough to use exclusively. 
 
1.2.5.1. Proteinuria 
Proteinuria is currently the principal urinary biomarker used in clinical practice 
when screening for renal involvement. Proteinuria quantification is 
incorporated in both of the SLE disease activity tools; the SLEDAI and the 
BILAG scoring tool (44, 49).  
 
Methods employed for collecting and analyzing proteinuria in clinical practice 
vary greatly, ranging from urine dipstick analysis to 24-hour urine collection. 
Timed 24-hour urine collection remains the most accurate method of 
quantifying protein loss, however in clinical practice a prolonged urine 
collection is cumbersome and impractical - particularly in a childhood 
population, leading to the more frequent use of spot urine protein to creatinine 
measurements.  
 
Determining the exact quantity of protein loss may be superfluous, as 
proteinuria does not necessarily correlate with the histological classification of 
lupus nephritis and it is a weak indicator of underlying disease severity or 
activity (244). Despite these limitations, proteinuria has been linked to eventual 
prognosis, can signal chronic renal damage and remains a clinically useful 
indicator for the presence of renal involvement (245).  
 
  61 
1.2.5.2. Glomerular filtration rate 
The GFR is the most useful and standardized indicator in defining and 
classifying the extent of chronic kidney disease in a range of conditions 
including lupus glomerulonephritis (246).  
 
Determining a precise measure of the GFR is timely, costly and unsuitable for 
routine monitoring in JSLE. The Schwartz formula based on body habitus 
(height) and serum creatinine concentration provides an acceptable estimation 
of GFR (247). It is worth noting that estimations of renal function based on 
creatinine may be imprecise in cases of active lupus where patients may have 
experienced weight loss and may have a reduced muscle bulk.  Despite this, 
the estimated GFR is important in standardizing the classification of chronic 
kidney disease and a decrease in GFR at the time of diagnosis is associated 
with a worse renal outcome (248).  
 
1.2.5.3. The urinary sediment  
The urinary sediment is the centrifuged deposit of cells following urine 
collection that are then suitable for microscopic evaluation. It contains cells, 
bacteria or casts and is increasingly being used to guide new biomarker 
discovery in many diseases.  
 
The presence or absence of ‘active’ urinary sediment is incorporated into the 
JSLE disease activity tools with ‘active’ sediment generally being accepted as 
>5 cells (white and/or red cells) per high power field in the absence of an 
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infective organism. The urine sediment is a useful measure of disease activity, 
however there are reports involving patients with active LN who had a normal 
urine sediment and so its role as a solitary indicator may be limited (249). 
 
1.2.5.4. Serum complement levels 
Reduced serum complement levels with organ deposition of complement are 
typical of the disease. A reduction in serum complement protein levels have 
been a used as a marker of active lupus disease flares for over 30 years, with 
cross sectional studies demonstrating their relationship with overall disease 
activity (250). More recently the reduction of C3 and C4 at diagnosis of LN, has 
been linked to a worse overall mortality but no associated difference in overall 
renal survival has been described (251).  
 
On a cross sectional basis, varying reports exist regarding the ability of C3 or 
C4 to significantly identify patients with active LN. Longitudinal studies 
highlight the limitations of serum complement proteins in JSLE. A 6-year 
longitudinal study assessing complement levels in predicting LN disease flares 
demonstrated excellent negative predictive values – normal results are 
reassuring – but highlighted the need to combine these laboratory markers 
with alternative markers for a more precise estimation of flares (252).  
 
Complement proteins do have significant strengths including; a direct role in 
disease pathogenesis; helping to distinguish JSLE glomerulonephritis from 
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other renal diseases; good negative predictive value; a relationship with overall 
lupus disease activity; and they form part of disease activity monitoring tools. 
 
1.2.5.5. Anti-Complement 1q antibodies 
Complement 1q is a subunit of the C1 enzyme complex, which activates the 
serum complement system and normally allows a site for attachment of 
antibody-associated immune complexes.  
 
Although rare, complete deficiency of C1q fails to control the release of IFN-α 
by plasma DCs (253). C1q has a key role in JSLE pathogenesis, as inherited 
C1q deficiency is the strongest single genetic factor identified to predispose to 
early onset JSLE. Patients who do develop C1q-associated JSLE have a more 
severe disease course than other cases of JSLE, with a predominance of 
cutaneous and renal manifestations (18).   
 
Antibodies to C1q (anti-C1q) are detected in the blood of patients with lupus in 
around 30-50% of cases (254) and in selected LN cohorts a clear association 
with anti-C1q antibodies is seen. Whilst definitions of active nephritis may alter 
between studies, the sensitivity of anti-C1q as a marker of renal disease 
activity is generally around 40-60% (255). Large prospective unselected cohort 
studies have demonstrated that anti-C1q antibodies are more strongly 
associated with global disease activity than specifically with LN (256).  
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1.2.5.6. Anti-double stranded DNA antibodies 
Anti-dsDNA antibodies are the classical marker of lupus and form an important 
component of the diagnostic process, assisting with classification and in the 
differential diagnosis of other causes of glomerulonephritis. They are 
recommended in the regular monitoring of all patients with lupus and have 
been found to precede the onset of lupus symptoms by up to 5 years (257). 
The sensitivity of anti-dsDNA in LN is around 50% with a good specificity at 
over 80%. Recent studies have combined anti-C1q and anti-dsDNA antibodies 
to produce a stronger predictive value of renal disease flares but still at the 
cost of suboptimal sensitivity (255). 
 
1.2.5.7. Other laboratory markers 
Other autoantibodies such as anti-nucleosome antibodies, anti-ribonuclear 
protein (RNP) antibodies and other acute inflammatory markers such as 
vitamin D and ferritin, have been assessed in relation to lupus renal disease 
activity. As yet none of these have proven to have sufficient predictability in 
detecting renal disease activity.  
 
Conventional laboratory markers provide a useful adjunct in the clinical 
diagnosis of JSLE and negative results may be very informative. As individual 
markers of renal disease activity, they each perform poorly and there is a need 
for novel biomarkers of LN. 
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1.2.6. Monitoring lupus nephritis 
The renal biopsy remains the gold standard in the diagnosis and classification 
of LN. However its lack of utility for longitudinal monitoring are due to its 
invasive nature and the risk of complications. Severe complications are seen in 
around 10% of patients and the procedure includes a 0.2% risk of introducing 
infection and a high risk of bleeding seen in up to 25% of patients (258, 259), 
ranging from microscopic haematuria to perirenal haematomas (260). At 
diagnosis it provides prognostic information and guides initial treatment so 
clearly its benefits outweigh these risks; however for monitoring purposes its 
role is limited.  
 
The renal component of the BILAG2004 is an objective standardised measure 
of disease activity and allows changes to be monitored longitudinally. 
Importantly they are able to identify changes over time of specific organ 
involvement (including the kidney) and to act as outcome measures for 
research purposes. These disease activity tools are generally regarded as the 
gold standard for monitoring SLE disease activity over time, but can be 
cumbersome to complete and analyse in everyday clinical practice. The renal 
component of the BILAG2004 is based on changes in the urine sediment, 
urine protein levels, glomerular filtration rate, hypertension and features on 
renal histology as defined in Table 11.  
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Table 11: The renal components of the paediatric adaptation of the 
BILAG2004. 
The renal domain of the BILAG2004 was adapted to include parameters 
suitable for children, including hypertension according to age, sex and height 
and the more frequent use of urine protein-creatinine ratio measurements 
(adapted using (44, 261)). 
Category A - Two or more of the following (must include 1,4,5): 
1. Deteriorating proteinuria (severe) defined as;                                                    
(a) urine dipstick increase ≥2 (only if other methods not available)                    
(b) 24 hour urine protein >1gram that has not improved by >25%                      
(c) urine protein-creatinine ratio (or UACR) >100 mg/mmol that has not 
decreased by >25% 
2. Hypertension >95th centile for age, sex, height 
3. Deteriorating renal funcion defined as; (a) creatinine rise >130% of 
previous, (b) GFR<80 ml/min/m2 and fallen <67% of previous, GFR<50 
ml/min/m2 and previous was >50 ml/min/m2 
4. Active urinary sediment 
5. Histological evidence of active nephritis within last 3 months 
6. Nephrotic syndrome 
Category B - One of the following: 
1. One category A feature 
2. Proteinuria that has not fulfilled category A criteria, defined as;                     
(a) urine dipstick rised by 1 to at least 2+ (only if other methods not 
available), (b) 24 hour urine protein >0.5g that has not decreased by >25%,                        
(c) urine protein-creatinine ratio (or urine albumin-creatinine ratio) >50 
mg/min/m2 that has not decreased 
3. Creatinine risen to >115% but <130% of previous value 
Category C 
1. Mild/stable proteinuria, defined as;                                                                      
(a) urine dipstick ≥1+ but not fulfilled A or B criteria (only if other methods 
not available)                                                                                                                         
(b) 24 hour urine protein >0.25g but not fulfilled A or B criteria                          
(c) urine protein-creatinine ratio (or urine albumin-creatinine ratio) >25 
mg/mmol and not fulfilling category A or B criteria 
2. Rising blood pressure that has not fulfilled A or B criteria and has 
increased by >30mmHg 
Category D 
Any previous renal involvement 
Category E 
No previous renal involvement 
      Abbreviations:UACR urine albumin:creatinine ratio; GFR glomerular filtration rate.  
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1.2.7. Medical management of LN 
The medical management of LN is dependent on the histological findings, 
induction therapy consisting of intravenous cyclophosphamide or MMF plus 
intravenous or oral corticosteroids is recommended for the induction of class III 
or IV LN for a 6-month period (262). Maintenance therapy then usually 
consists of AZA or MMF. Previous drug exposure and patient ethnicity may 
alter management decisions – Black African patients are known to respond 
less well to cyclophosphamide (263, 264).   
 
1.2.8. Renal prognosis 
Irreversible renal damage is one of the most common long-term consequences 
seen in JSLE and the presence of renal involvement in patients with JSLE is 
independently associated with a worse disease morbidity (92, 265). The 
largest unselected cohort of patients with JSLE identified 4% of patients who 
had developed irreversible renal damage, over a 5-year recruitment period, 
including one patient with established renal failure (34).  
 
Despite LN being a rare cause of glomerulonephritis - accounting for only 1-
2% of all causes of end stage renal failure (ESRF) in the UK - the incidence of 
ESRF in JSLE associated LN is high, ranging from 4% to 44% (266, 267). In 
disease that has progressed to ESRF requiring kidney transplantation, 
subclinical disease recurrence is seen in the renal graft despite 
immunosuppressive therapy although rarely causing significant symptoms 
(268). The extent of proteinuria at disease onset, patient ethnicity (worse renal 
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outcome in non-Caucasian patients) and a failure to respond to treatment are 
all related to the eventual renal outcome (234, 269).  Children have a worse 
long-term renal outcome than adults with SLE (1). 
 
1.2.9. Lupus nephritis in childhood 
Patients with JSLE have an increased occurrence of renal involvement, 
generally a more severe disease than adults and a higher demand for toxic 
medications. In the longer term the morbidity and mortality is much greater in 
those patients with evidence of renal involvement.  
 
As described, local inflammatory processes within the glomerulus are triggered 
by a systemically dysregulated immune system arising from increased cellular 
debris activating a self-immune response with anti-nuclear antibodies 
characteristic of the disease. Within the glomerulus the endothelial, mesangial 
cells all play a role in the disease process and contribute to the local 
inflammatory cascade and infiltration of a multitude of inflammatory cells, 
characteristic of LN (as in Figure 5). The podocyte has a key role in the local 
immune regulation and the long-term consequences of active renal disease 
such as scarring and proteinuria (as discussed in section 1.2.3). 
 
Current laboratory markers used in the monitoring of renal involvement in 
JSLE over time are not sufficient to allow the clinician to accurately determine 
the underlying disease process and the renal biopsy continues to have a key 
role in confirming the diagnosis and providing prognostic information. 
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Combining our understanding of the pathophysiology of LN, and the local 
inflammatory response within the glomerulus, may allow us to identify more 
accurate markers of impending inflammation. 
 
1.2.10. Biomarkers in lupus nephritis 
1.2.10.1. Definition of a biomarker 
A biomarker is defined as a ‘characteristic objectively measured and evaluated 
as an indicator of normal biological processes, pathogenic processes or 
pharmacological responses to a therapeutic intervention’ (270). The 
relationship of biomarkers and disease activity can be seen in the illustration in 
Figure 6. 
 
In clinical practice many tests or physiological measures are used as disease 
biomarkers, for example the use of glycated haemoglobin as an indicator or 
glycaemic control in diabetic disease monitoring. The National Institute of 
Health Definition Working Group have divided biomarkers into either one that 
acts as a marker of the natural history of a disease and correlates 
longitudinally with known clinical indices, or a biomarker that captures the 
effects of a therapeutic intervention in accordance with its mechanism of action 
(270).  
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Figure 6: The role of standard and novel biomarkers in changing disease activity over time.  
An illustration demonstrating the role of novel and standard biomarkers in detecting increased disease activity (y axis) over time (x 
axis). As disease increases (purple line) there becomes a point in the disease when it can be detected clinically using current 
standard biomarker measurements (blue arrow), treatment would then hopefully be started and the disease activity should settle.  
Upon a second disease flare, the biomarker can be measured again (blue arrow), detecting increasing disease activity. With the 
creation of novel biomarkers (red arrow), disease may be detected at an early time point prior to standard markers and treatment 
could be started earlier, which may alter the subsequent natural course of the disease. 
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1.2.10.2. The ideal biomarker 
The ideal biomarker has many similar characteristics - they need to be 
accurate, show good sensitivity (identifying disease when it is present) and 
good specificity (excluding disease when it is not present), be relatively non 
invasive and be reliably reproducible. Following initial identification, biomarkers 
must demonstrate evidence of robust validation using large, longitudinal, 
prospective studies to demonstrate their predictive ability of the disease in 
question. For clinical practice, they also have to demonstrate cost-
effectiveness. 
 
1.2.10.3. Biomarker development  
A biomarker must go through several phases of development, including 
planning, discovery, validation and commercialization (see Figure 7). In reality, 
many potential biomarkers remain in the planning and discovery phase with 
few undergoing robust clinical validation.  
 
Biomarker discovery usually begins with identification of a proposed biomarker 
and cross sectional cohort analysis of its clinical utility in predicting a firm 
outcome (preferably the disease ‘gold standard’). Following cross sectional 
assessment, proposed biomarkers need to demonstrate an on going 
relationship with standard disease markers despite fluctuations in disease 
activity or interventional processes over a defined longitudinal period. The 
suspected biomarker needs to demonstrate a sound sensitivity and specificity 
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using receiver-operating characteristic (ROC) curves to determine the optimal 
biomarker concentration that achieves the most reliable interpretation (Figure 
8). In reality, very few tests are ideal biomarkers in any one disease, at every 
point in time. 
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Figure 7: The process of biomarker development 
Novel biomarkers undergo a process of development that includes planning, 
discovery, validation and then commercialisation. 
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Figure 8: An example of a receiver operating characteristic (ROC) curve  
ROC analysis is performed using the sensitivity and specificity of a biomarker to determine the area under the curve (AUC) of novel 
biomarkers.  An AUC value of 0.5 (represented by the dotted line) is no better than chance, an AUC value of 1.0 is a perfect 
biomarker with high sensitivity and high specificity. 
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1.2.10.4. Biomarker development in lupus nephritis 
In lupus nephritis, the validation of a novel biomarker on cross sectional 
analysis should be compared against the current gold standard for diagnosing 
and classifying LN - the histological LN grading. In the management of 
childhood renal disease there are significant barriers to utilitsing this approach; 
a biopsy is only conducted if there is a strong clinical suspicion of renal 
involvement and rarely routinely repeated following the initial diagnosis and 
classification.  
 
The renal biopsy is an invasive procedure, often requiring sedation or general 
anaesthesia in children. There are currently no national or international 
guidelines on when to undertake a renal biopsy in JSLE and severe 
histological findings can be seen even with minimal proteinuria or clinical signs 
(244, 271). The process of when to performing a biopsy is therefore likely to 
vary according to the centre, the country and the individual patient’s clinical 
manifestations. It is therefore not useful for monitoring purposes and the 
validation of a novel biomarker over time requires comparison with the gold 
standard for monitoring disease activity, which remains the non-invasive 
disease activity tools.  
 
1.2.11. Promising renal biomarkers in JSLE 
Validated, non-invasive biomarkers for a childhood population are particularly 
attractive for clinical use; urine is readily available and easy to process. 
Childhood-specific biomarker validation studies are important as urine cytokine 
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and proteome profiles may differ according to age (272).  A significant 
advantage in the paediatric age group is that they represent a population with 
few existing co-morbidities; as such, identified biomarkers may provide direct 
insight into renal pathophysiology, with urine sampling often reflecting local 
renal inflammation.  
 
A perfect biomarker in JSLE nephritis would be able to identify the presence of 
renal involvement, improve as the condition responds to treatment and 
anticipate subsequent disease activity changes. Over recent years, a number 
of potential LN biomarkers have been identified.  The most promising 
biomarkers are those that have been studied over a longitudinal period in 
specific JSLE cohorts.  
 
1.2.11.1. Longitudinally validated biomarkers in a paediatric cohort 
1.2.11.1.1. Urine Neutrophil gelatinase-associated lipocalin (NGAL) 
The most promising urine biomarker in predicting flares in children with lupus 
nephritis to date is NGAL. NGAL is a member of the lipocalin family of 
proteins, and is responsible for the growth and differentiation of epithelial cells 
including renal tubular and glomerular epithelial cells. It is known to exert 
bacteriostatic potential due to interference with bacterial siderophore-mediated 
iron acquisition. It is up regulated by the kidney in response to renal injury and 
has been investigated as a useful non-invasive marker of acute kidney injury in 
a number of conditions including, predicting the need for dialysis in renal 
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ischaemia following cardiac bypass and in cases of diarrhoea-associated 
haemalytic uraemic syndrome (273, 274).  
 
Preclinical studies have found that the renal tissue in murine models of LN 
overexpress NGAL in response to pathogenic anti-DNA antibodies and, more 
recently, NGAL knock-out mice have a less marked renal pathology and 
improved outcome in autoimmune nephritis, suggesting an important role in 
the pathogenesis of LN. In contrast to other sepsis-related studies, it is 
believed to play a detrimental role in LN by inducing apoptosis in mesangial 
cells and facilitating recruitment of inflammatory cells to the kidney through the 
up regulation of pro-inflammatory mediators (275),(206). 
 
Cross sectional cohorts have demonstrated the strength of NGAL in relation to 
LN flares. One of the first of these studies was by Brunner et al, which involved 
35 JSLE patients who were compared to 8 children with JIA, they found a 
significantly higher level of urinary NGAL in the JSLE patients and a trend 
towards increased urinary NGAL in those JSLE patients with biopsy proven LN 
and a high renal disease activity score (276). Since then, large prospective 
cross sectional lupus cohort studies have demonstrated the ability of NGAL to 
distinguish lupus patients with and without nephritis (277).   
 
In the next step of validation, longitudinal studies have been conducted using 
urinary NGAL as a biomarker of active LN, notably led by childhood cohorts. 
Brunner et al selected a cohort of 85 JSLE patients of which 52 had >1 follow 
  78 
up visit, compared to 30 JIA and 50 healthy control patients, and found a 
significant increase in urinary NGAL, but not plasma NGAL, in those with 
worsening renal disease activity (278). The second longitudinal cohort study 
involved 111 JSLE children, some of which were included in the above study, 
seen on at least 3 follow up visits. The investigators concluded that urinary 
NGAL is an excellent candidate as a predictive biomarker for worsening of 
childhood-onset SLE renal disease activity (279). As yet, no adult SLE 
longitudinal studies have been published. 
 
Limitations of urine NGAL include: its inability to obviously discriminate 
between histological classes of lupus nephritis; its fluctuations with global 
JSLE flares, and its non-specificity for JSLE, with rises seen in the previously 
mentioned conditions. However, it is the only single biomarker to stand robust 
longitudinal cohort investigation to date in paediatric specific cohorts, and its 
future is promising.  The next step in developing urinary NGAL as a robust 
biomarker in lupus nephritis requires validation in other large JSLE and adult 
lupus cohorts, to determine optimal thresholds and if reliable, collaboration 
with industry in designing high throughput real time testing platforms. 
 
1.2.11.2. Cross sectional biomarkers in a paediatric cohort 
1.2.11.2.1. Urine Monocyte chemoattractant protein-1 
Monocyte chemoattractant protein-1 (MCP-1, correctly known as CCL2) is 
involved in a cytokine network acting to recruit inflammatory cells to infiltrate 
the kidney in LN. MCP-1 is expressed by the mesangial, podocyte and 
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monocyte cells, in response to pro-inflammatory signals, such as TNF-α. 
These inflammatory cells and substances subsequently mediate tissue injury 
and can lead to renal dysfunction. Additionally, MCP-1 binding has been 
shown to reduce nephrin expression, an important marker in preserving kidney 
cell function (226) and antagonists to MCP-1 prevent renal disease 
progression in murine models. Marks et al demonstrated that the presence of 
MCP-1 within the glomerulus correlates with a poor renal prognosis in 
childhood LN and can distinguish more severe histological classes of the renal 
disease (280).  
 
Early studies analyzing MCP-1 as a biomarker, involved adults with SLE, 
demonstrated its correlation with histological disease and short term follow up 
showed improvement in urinary MCP-1 levels in quiescent disease (281). 
Since then, several cross sectional studies have confirmed these findings 
using larger adult SLE cohorts and a longitudinal cohort showed its strength in 
predicting renal flares up to 4 months prior to clinical detection (282). 
 
In a cross sectional childhood cohort, urinary concentrations of MCP-1 
correlate with a histological diagnosis of lupus glomerulonephritis (272). 
Limitations of urinary MCP include its association with other chronic, 
inflammatory and autoimmune renal conditions, including diabetic 
nephropathy. 
 
1.2.11.2.2. Urine transforming growth factor beta (TGF-β) 
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TGF-β has a role in the control and onset of autoimmunity. It has been shown 
to contribute to mesangial proliferation and crescent formation in several 
causes of glomerulonephritis. Reduced serum concentrations are typical of 
lupus and raised urine TGF-β is shown in adult gene expression assays at the 
time of active disease and a reduction seen in treatment responders (283).  In 
a cross sectional paediatric cohort involving 32 JSLE patients with LN, similar 
results are seen (284).  
 
1.2.11.2.3. Urine N-acetyl-beta-D-glucosaminidase (NAG) and urine retinol 
binding protein (RBP) 
Tubular interstitial disease is an important part of the pathophysiology in lupus 
nephritis. The tubular markers NAG and RBP were measured in the urine in a 
cohort of 21 JSLE patients, demonstrating their ability to distinguish between 
those with and without nephritis. Over a period of twelve months after 
biomarker evaluation, two non-nephritis patients with initially elevated RBP 
developed lupus nephritis, suggesting the potential to predict impending flares 
prior to the onset of proteinuria (285). An adult cross sectional cohort [n=24 
SLE patients] has also shown how urine NAG levels correlated with proteinuria 
and renal severity and also distinguished all SLE patients from healthy 
participants or those with rheumatoid arthritis (286). RBP has been 
investigated in small adult cohorts demonstrating a relationship with nephritis 
and potential as an early marker (287). Elevated urinary NAG is seen in other 
disorders including vesicoureteric reflux and urinary tract infections (288) and 
RBP levels can increase in drug induced toxicity (289). Their role within JSLE 
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deserves further investigation in larger, longitudinal cohorts and further 
understanding of their pathophysiological role in lupus nephritis.  
 
1.2.11.2.4. Acute phase proteins and carrier proteins  
Acute inflammatory response proteins released from the liver have been 
identified to have a role in lupus glomerulonephritis.  Proteomic studies 
highlighted the potential for alpha 1 acid glycoprotein (AGP) and transferrin as 
early biomarkers in active LN, confirmed in a cohort of 98 children with JSLE 
where AGP identified active LN patients (290). These proteins require further 
scientific investigation into their role in the pathogenesis of LN and if 
supportive, longitudinal validation in larger cohorts. 
 
1.2.11.2.5. Interferon-inducible protein 10 (IP10)  
IP10 (correctly known as CXCL10) is a cytokine up regulated in response to 
IFN and it is frequently present along with the above-mentioned potential 
biomarkers. Previous reports have shown an elevation in urinary IP10 gene 
expression in LN and large adult cohort studies have shown that urinary levels 
of IP10 protein will rise preceding a renal flare and correlate with renal disease 
activity (291). IP10 receptor expression is not significantly raised in the renal 
histology in patients with active LN (292).  
 
1.2.11.3. Adult SLE longitudinal studies  
1.2.11.3.1. Urine tumour necrosis factor-like inducer of apoptosis 
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Tumour necrosis factor-like inducer of apoptosis (TWEAK) is a cytokine and a 
member of the TNF-ligand superfamily. Its role is to up regulate inflammatory 
mediators, induce cell death and apoptosis, and enable cell survival (293). 
Stimulation of TWEAK will lead to pro-inflammatory mediators such as MCP-1 
and IP10, both of which are linked to LN pathogenesis. TWEAK is up regulated 
in glomerular and tubular renal tissue in active LN (292). Longitudinal 
multicenter analysis has been performed with good correlation between urinary 
TWEAK levels and renal flares in adult-onset SLE (294).  
 
1.2.11.4. Adult SLE cross sectional studies 
1.2.11.4.1. Intracellular and vascular cell adhesion molecules 
Cellular adhesion molecules have a role in the migration of lymphocytes to 
areas of inflammation and hence a role in autoimmune conditions. ICAM has 
been identified in the glomerular histology of patients with active LN (295) and 
associated with serum TNF-α levels. ICAM and VCAM-1 have been shown in 
small cross sectional adult cohorts to correlate with histological LN (296), but 
correlations with clinical disease activity tools have failed to confirm this finding 
(297). Whilst there is insufficient evidence, their role as a biomarker in LN may 
be limited but their role in the pathogenesis is interesting. 
 
1.2.11.5. Others – preclinical phase 
Vascular endothelial growth factor (VEGF) has shown an increased gene 
expression in the urine sediment in patients with class IV LN, and a reduced 
glomerular VEGF levels is associated with worsening LN disease (298). Its 
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involvement in the pathophysiology of the disease is appealing, its role as a 
biomarker is probably limited. Raised urinary concentrations of endothelin 1 
(ET-1) were identified in a cohort of chronic kidney disease patients, where 
ET-1 was associated with renal disease in the subgroup of patients with SLE 
and levels altered according to treatment response (299). Forkhead box p3 
(FOXP3) is a protein involved in immune responses and controls regulatory T 
cells within the immune system. Urine FOXP3 gene expression is elevated in 
patients with active LN and has been linked with a poor response to treatment 
(300), its presence in the urine and its exact relationship with disease is yet to 
be determined. Urine osteoprotegerin (OPG) forms part of the TNF super 
family and acts to inhibit NF-kB, an essential transcription factor for immune-
related genes, and a key regulator of inflammation. Large adult cohort studies 
have assessed urine OPG, as part of a range of cytokines, finding a correlation 
between urine OPG concentrations and clinical LN disease activity (301).  
 
A summary of the promising biomarkers described in JSLE associated 
nephritis and their stage in the clinical validation process can be seen in Table 
12.
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Table 12: A summary of potential novel renal biomarkers in Juvenile-
onset SLE 
Potential novel renal biomarkers under evaluation in JSLE highlighting their 
stage of validation (using (276, 278, 279, 283, 290, 298, 302)).  
 
Abbreviations JSLE juvenile-onset systemic lupus erythematosus, NGAL neutrophil gelatinase 
associated lipocalin, MCP1 monocyte chemoattractant protein-1, TGF-beta transforming 
growth factor beta, AGP alpha-1-acid glycoprotein, NAG N-acetyl-beta-D-glucosaminidase, 
RBP retinol binding protein, TWEAK Tumour necrosis factor-like inducer of apoptosis, ICAM 
intracellular adhesion molecule, VCAM vascular cell adhesion molecule, VEGF Vascular 
endothelial growth factor, FOXP3 Forkhead box p3, OPG osteoprotegerin. 
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1.2.12. Blood biomarkers in LN 
Potent inflammatory cytokines, chemokines, and infiltrating leucocytes have a 
role in LN pathogenesis. The overexpression of chemokine’s and cytokines 
direct inflammatory cells and immune complexes to reside within the renal 
parenchyma. Studies have compared the differences in the expression of 
these inflammatory substances in plasma/serum in patients with active LN in 
addition to exploring their intra-renal expression (303-306). Throughout these 
studies, it has become evident that a predominant Th1 cytokine pathway is 
expressed in patients with LN with an overexpression of IL-18 and IL-12, both 
of which are known to shift the balance of T cell expression towards a Th1 
phenotype (172, 307-311).  
1.2.12.1. Interferon-γ 
The Th1 cells are able to produce IFN-α and IFN-γ (312) both of which are 
associated with the presence of anti-dsDNA antibodies and proteinuria in SLE 
(313). A predominance of Th1 cells producing the subtype IFN-γ has been 
demonstrated in murine LN models (313).  
 
1.2.12.2. Interferon producing protein-10 
IP10 has a role in supporting this shift in T cell phenotype, toward Th1 
predominance. It is seen at elevated levels in SLE, where it correlates with the 
renal SLEDAI (173) and assists with the recruitment of lymphocytes to the 
organs (314). Increased plasma levels of IP10 have been correlated with LN 
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activity in a small series (315). Its presence in the urine and its role in JSLE 
have not yet been determined. 
 
1.2.12.3. Tumour necrosis factor alpha 
Another commonly up regulated cytokine in LN is TNF-α. Polymorphisms, and 
thus an exaggerated production, of TNF-α predispose patients to LN (26), 
TNF-α protein concentration is elevated in patients with active lupus (316) and, 
it is typically seen in LN together with other cytokines such as IL-12, IL-18, 
IFN- and IL-6 (317).   
1.2.12.4. Interleukin-6 
IL-6 is a key inflammatory mediator in lupus and its presence relates to overall 
disease activity (128, 318). IL6 knock out murine models do not have active LN 
(319) and patients with LN have a natural ability to over produce IL6 (320).  
 
1.2.12.5. Interleukin-1 
IL1 is up regulated in lupus (206, 231, 321, 322). An increased expression of 
the IL1 receptor (IL1R) is seen in the renal histology in patients, and mouse 
models of severe LN (323) (324), suggesting that the kidney directly responds 
to IL1. IL1β, a subtype of IL1, may be responsible for the formation of 
irreversible scarring and crescent formation within the kidney in other causes 
of glomerulonephritis including anti-glomerular basement membrane disease, 
IgA nephropathy, Henoch Schonlein purpura nephritis and anti-neutrophil 
cytoplasmic autoantibody (ANCA) associated nephritis (325-329). Thus it may 
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have a key role in the long-term irreversible damage that we frequently 
observe in LN.  
 
1.2.12.6. Monocyte chemoattractant protein-1 
MCP-1 is a chemokine, the glomerular over expression of which is seen in 
severe cases of childhood LN. Genetic polymorphisms of MCP-1 may lead to 
an increased susceptibility to lupus (27), although recent meta-analysis 
contradict these results (330). Elevated plasma concentrations of MCP-1 have 
been described in LN and correlate with the renal SLEDAI score (331). 
 
1.2.12.7. Interleukin-13 
The Th2 cytokine IL-13, usually associated with allergies and IgE production, 
has been shown to be elevated in SLE, in plasma and PBMC’s, and found 
isolated to the tubulo-interstitial region of the lupus kidney (332). Little is known 
about the role of IL-13 in nephropathy; it has been implicated in minimal 
change nephrotic syndrome (333, 334) and therefore may have a role in the 
occurrence of proteinuria. 
 
1.2.12.8. Vascular endothelial growth factor 
VEGF is a marker associated with endothelial function and has a role in 
preserving vessel wall permeability, its intra-renal expression is increased in 
LN (218), increased systemically in children with LN, along with its soluble 
receptors (335), and single polymorphisms are associated with the onset of LN  
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(336). It is speculated to have an early role in the occurrence of vasodilation 
leading to tissue infiltration of immune cells. Its concentration has been directly 
associated with the onset of micro-albuminuria in an Iranian SLE population 
(337). 
 
Determining the systemic control and predisposition for an up regulated 
pattern of inflammatory cytokines seen in patients with LN may inform 
knowledge of the underlying pathophysiology and provide insight for 
understanding the differing clinical manifestations of the disease. It is unlikely 
that one particular substance alone drives the disease; rather it is likely a 
complex immune mediated disease explaining the heterogeneity in symptoms 
and signs that we observe.  
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1.2.13. Summary 
JSLE is characterised by a significantly increased incidence of renal 
involvement when compared to adult-onset SLE.  A major concern is that prior 
to the onset of clinically detectable disease, irreversible renal damage may 
occur, proposing a significant risk to future renal function. A high proportion of 
children with proliferative LN develop established renal failure over a 10-year 
period, representing a significant morbidity in a young population. The 
fluctuating nature of LN, along with undetectable inflammation prior to currently 
identifiable clinical manifestations of renal flares, all contribute to renal 
damage, and highlight the importance of meticulous monitoring.  
 
The glomerular cells are able to respond to the systemic inflammatory 
response in JSLE, with podocytes responsible for several immune related 
roles, such as cytokine detection and expression, autophagy and 
phagocytosis, and complement regulation. In health these assist with 
maintaining the GBM from cell influx and inflammation. Disruption of these 
mechanisms contribute to the overwhelming cell influx and damage to the 
GBM which are classical pathological findings seen in LN. Detecting this 
disease process at an earlier stage is therefore very valuable and could lead to 
a reduction in the damage seen in LN. 
 
The majority of LN patients, typically following intensive induction treatment 
and frequent hospital visits, are monitored in an out patient setting, seen 
usually at 3 monthly intervals. In addition to being non-invasive, valid and 
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reliable, a candidate biomarker for monitoring these patients in everyday 
practice has to demonstrate changes within this time period. Despite the 
known association of renal involvement with a worse longer term prognosis in 
these patients and the wealth of identified biomarkers (338), no novel 
biomarkers have yet to be introduced into everyday clinical monitoring. 
 
1.2.14. Hypothesis 
Urine biomarkers are non-invasive methods of monitoring JSLE-related renal 
disease activity, and their expression occurs directly from the kidney, mediated 
by pro-inflammatory cytokines released from activated macrophages. 
 
1.2.15.  Aims  
The overall aim of this thesis is: 
 To identify whether selected urine biomarkers can predict the renal 
disease activity in patients with JSLE. Using cross sectional and 
longitudinal prospective analysis in a cohort of JSLE patients, the 
relationship of urine biomarkers in predicting and changing with renal 
disease activity over time will be assessed.  
 To determine whether systemic inflammatory phenotypes occurring in 
patients with JSLE impact on presence and severity of LN by 
investigating plasma concentrations of inflammatory cytokines.  
 The glomerulus plays a key contributory role towards renal immune 
responses in health and disease. Macrophages enter the kidney early in 
active LN, and therefore the macrophage effect on the glomerular 
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podocyte expression of these biomarkers and their signalling pathway 
will be assessed. 
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2. Chapter 2: Methodology 
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2.1. The UK JSLE Cohort Study & Repository  
The UK JSLE Study Group (www.liv.ac.uk/ukjsle) is a multi-disciplinary, multi-
centre collaborative network established in 2006 with the primary aim of 
improving the care and understanding of children with JSLE. It’s aims 
encompass a range of components including a clinical cohort database, 
improving patient information, facilitating clinical trials and supporting a 
programme of clinical translational research.  
 
Through the UK JSLE Cohort Study & Repository (referred to subsequently as 
the UK JSLE Cohort Study or Study), the Group collects detailed clinical data 
with a bio-bank of linked blood samples from children and young people 
across the UK with lupus. It includes detailed demographic data, ACR criteria 
at diagnosis, disease activity, and medication use and disease damage 
indices.  On an annual basis patient information with regards to disease 
classification and damage, is updated.  
 
The Study is run from a national coordinating centre within the Institute of Child 
Health, University of Liverpool at the Alder Hey Children’s NHS Foundation 
Trust Hospital, Liverpool (AHCH) with invited participation of all the paediatric 
rheumatology and nephrology centres from across the UK. A detailed analysis 
of the disease activity, severity and damage of the first approximately two 
hundred patients enrolled in the UK JSLE Cohort Study (including some 
recruited to this study) has been published (see Appendix 2). 
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2.1.1. Inclusion and exclusion criteria 
All paediatric rheumatology and nephrology centres across the UK were 
invited to participate to the UK JSLE Cohort Study. Parental consent / patient 
consent or assent to take part in the Study were obtained from all families. The 
Study had national and local ethical approval and was supported through its 
adoption onto the UK’s Clinical Research Network Study Portfolio 
(http://public.ukcrn.org.uk/search/). 
 
All patients with onset of symptoms prior to the age of 17 years old, and a 
clinician’s diagnosis of JSLE were eligible to be recruited to the Study. The 
cohort aimed, in addition to capturing JSLE disease activity, severity and 
damage, to capture potential development / evolution of lupus over time. 
 
2.1.2. Data collection and storage  
A priori data proformas were used to collect comprehensive phenotypic clinical 
data. At baseline (time of diagnosis), detailed demographic data, including sex, 
date of birth, date of onset of symptoms and date of diagnosis of lupus, family 
history of lupus and/or other autoimmune disorder and ethnicity were collected 
(Appendix 3). In addition, ACR SLE classification criteria (with duration of 
features) were collected (Appendix 4). The BILAG disease activity index, which 
has undergone preliminary validation in a UK paediatric cohort (42), was 
adapted to include parameters relevant to childhood; for example hypertension 
was interpreted using the 95th blood pressure centile dependent on age, sex 
and height of the child and referred to as pBILAG2004 (261), see Appendix 5. 
The renal aspect of the pBILAG2004 is detailed in Table 11. Details of 
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medication, parental and physician’s global assessment of disease activity, 
and standard laboratory markers of disease activity were routinely collected.  
 
At every clinical review (e.g. three monthly, or as appropriate such as at time 
of flare), a pBILAG2004 was collected, Appendix 6. Annually (nearest clinic to 
the patient’s birthday) all patients had their ACR criteria updated, and a 
SLICC/ACR damage index assessment form completed, Appendix 7. All data 
was submitted anonymously to the coordinating centre and stored 
electronically on a database.   
 
The database was programmed to calculate pBILAG2004 scores according to 
definitions (for example in Appendix 5).  For each episode, within each BILAG 
domain, a five-tiered alphabetical score was attributed reflecting lupus disease 
activity (45). A score of “A” reflects severe active disease requiring a change in 
corticosteroids and/or disease modifying immunosuppressant; a score of “B” 
reflects moderately active disease requiring low dose corticosteroids or the 
addition of hydroxychloroquine; a score of “C” reflecting disease present in this 
organ but not requiring treatment alterations; a score of “D” reflecting inactive 
disease but previous organ involvement; and lastly a score of “E” reflecting no 
organ involvement ever.  Numerical scoring was then given to each domain to 
produce an overall global BILAG score according to the original BILAG scoring 
system; A=9, B=3, C=1, D/E=0 (44) (in view of previous use in the paediatric 
age group (42, 43)).  
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2.2. Recruiting JSLE patients 
For the purposes of this specific aspect of the UK JSLE Cohort Study, an 
amendment to the ethical approval was required to permit the collection of 
further samples from the two largest recruiting centres for the purpose of this 
study of renal biomarkers. This included the addition of urine collection from 
patients at AHCH and to initiate the collection of urine and blood samples from 
patients attending Great Ormond Street NHS Foundation Trust Hospital for 
Children (GOSH). Following ethical approval, patients at these two centres 
were re-consented and a standard operating procedure (SOP) was established 
in GOSH to enable the collection of research samples in line with current 
clinical care (Appendix 8, Appendix 9). Regular attendance at the GOSH 
outpatient clinic was initially required over a period of 18 months to optimise 
this SOP and the process was then carried out independently by local staff. 
Appendix 11 shows the investigations undertaken as part of the UK JSLE 
cohort study. 
 
2.2.1. Transfer of samples 
The UK JSLE Cohort Study had material transfer agreement (MTA) to allow 
the collection and transfer of patient samples. Samples recruited from GOSH 
were stored and transferred to AHCH in regular batches (3-4 monthly) as per 
procedure (see Appendix 12, Appendix 13).  
 
2.3. Recruiting healthy control patients 
A robust system was established to identify and recruit control patients from 
AHCH, in collaboration with research nurses and the Study team. This 
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included healthy children. Patients attending for non-inflammatory day case 
surgery were identified and recruited as healthy control patients. All control 
patients were aged <17 years old and following study information (including 
age-appropriate information for patients), they were consented using parental 
consent/patient assent (an example shown in Appendix 14, Appendix 15). 
. 
2.4. Laboratory methods 
There were several laboratory methods that were used frequently throughout 
this project, including the use of enzyme linked immunoabsorbant assay 
(ELISA), the multiplex suspension array system, western blotting techniques 
and quantitative polymerase chain reaction (qPCR). The design and utility for 
each of these laboratory techniques will be discussed here, with specific 
details outlined in the relevant chapter. 
 
2.4.1. Enzyme linked immunosorbant assay 
2.4.1.1. Background 
The purpose of the ELISA technique is to determine and quantify whether a 
particular protein or antibody is present in a substance. The sandwich ELISA 
method is based on antigen to antibody reactions and starts with the addition 
of a capture antibody coating the bottom of the plate. A blocking protein is then 
added to non-specifically bind to any uncoated areas on the plastic plate. An 
unknown amount of antigen (sample) to be measured is then added. A specific 
antibody is added to attach to the sample antigen and sandwich it between the 
two antibodies. The next step involves the addition of an enzyme-linked 
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detection antibody followed by a substance containing the enzyme substrate, 
which produces a colour reaction. Between each of the stages the plate is 
washed with a buffer to remove any weakly adherent antibodies. Direct 
ELISA’s follow this process; indirect ELISA’s involve a secondary antibody 
containing an enzyme that is then detected as illustrated in Figure 9. 
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Figure 9: Direct and indirect ELISA techniques 
In the enzyme linked immunosorbant assay (ELISA) technique a capture antibody coats the bottom of a plate, a blocking protein is 
added to bind non-specific areas. An unknown amount of antigen is added and a specific antibody added to sandwich the antigen. An 
enzyme-linked detection antibody (direct) is added, or an antibody and then enzyme-linked substance (indirect), and a substrate to 
the enzyme leads to a colour reaction that is detectable by optical density.  
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Measurements are made in duplicate for each individual sample to control for 
pipetting errors and averaged. Blank wells containing only the reagent diluent 
act as a negative control. ELISA’s are typically performed in 96-well plates 
allowing the analysis of 40 samples when assessed in duplicate. Samples of 
known concentration and dilutions are added to establish a standard curve, 
which is used to calculate the concentration of the protein of interest from 
unknown samples. 
 
2.4.1.2. Calculation of unknown values 
When the enzyme reaction is complete the optical density of each of the wells 
on the plate is read using a plate reader. The amount of colour produced and 
thus the optical density for each sample is proportional to the amount of 
protein or antibody in question. Blank wells should have an optical density of 
less than 0.1. The unknown sample values can be established through 
calculation of the optical density from the standards. The standard 
concentration values can be plotted against their optical density to produce a 
standard curve with a line of best fit. The equation represents the relationship 
between the values and optical density and should ideally be 1.0 (0.9-1.1 is 
acceptable). Using the measured optical density for an unknown sample, the 
equation will allow calculation of the protein or antibody concentration. An 
example of a standard curve is illustrated in Figure 10. 
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Figure 10: A standard curve in the enzyme linked immunosorbant assay (ELISA). 
The ELISA technique uses standard antigens of a known concentration, the optical density of these samples are then plotted against 
these concentrations and the line of best fit is placed using linear logistic regression and an equation representing the slope of the line 
(R2) is produced and can be used to calculate samples of unknown antigen concentration (y) from their measured optical density (x).  
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2.4.1.3. Statistical assay validation: Coefficient of variation 
A measure of the accuracy between the values made in duplicate on an ELISA 
plate can be calculated by measuring the coefficient of variation (CV). The CV 
is a measure of the ratio of the standard deviation and the mean of the 
duplicate values (SD measurement 1 / mean measurement 1: SD 
measurement 2/mean measurement 2). The duplicate values should lie within 
15-20% of the mean values. The larger the variance the more inconsistency 
between measured values. A CV value <15% is considered acceptable. Large 
CV values usually represent pipetting errors but may also be due to cross 
contamination or temperature differences across the plate.  
 
2.4.1.4. Statistical assay validation: Spike and recovery  
A spike recovery assay is another measurement of validity, it evaluates 
whether the sample constituents are interfering with the detection of the 
substance being measured. To undertake a spike recovery assessment a 
known concentration of the standard substance is added to the sample (spiked 
sample) together with a matched well containing the same concentration of the 
standard but placed only in the appropriate diluent. The results (measured 
spiked sample value minus known spiked concentration/measured sample 
value) should lie within 80-120% of each other to represent good retrieval of 
the spiked concentration. 
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2.4.1.5. Statistical assay validation: Linearity of dilution 
The linearity of dilution is a measure of the spiked recovery of a sample over a 
series of diluted concentrations compared to the un-spiked recovery over a 
series of dilutions. A comparison of the observed values against the expected 
values is made. If the linearity is good then the assay provides a consistent 
measure across a wide range of sample concentrations. Reasons for poor 
spike recovery and a poor linearity of dilution include interference from the 
sample matrix, the assay diluent and non-specific antibody binding. In cases of 
poor assay validity, alternative methods of analysis should be employed. 
 
2.4.1.6. Commercially available kits 
The ELISA kits used for the purposes of this study are detailed in Table 13. 
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Table 13: The enzyme linked immunosorbant assays used for this study 
The table demonstrates the ELISA kits used in this study with high and low standard values and manufacturer details. 
Protein 
High 
standard 
value 
Low 
standard 
value 
Manufacturer 
Monocyte chemoattractant protein 1 2000 pg/ml 31.25 pg/ml R&D Systems Ltd, USA 
Tumour necrosis factor alpha 2000 pg/ml 31.25 pg/ml R&D Systems Ltd, USA 
Lipocalin 2 (neutrophil gelatinase associated lipocalin) 5000 pg/ml 78 pg/ml R&D Systems Ltd, USA 
Interferon inducible protein 10 500 pg/ml 7.8 pg/ml R&D Systems Ltd, USA 
Alpha 1 acid glycoprotein 200 pg/ml 3.13 pg/ml R&D Systems Ltd, USA 
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2.4.2. Creatinine assay 
The creatinine concentration was measured using the Jaffe reaction in which 
creatinine is treated with an alkaline picrate solution to yield a bright orange-red 
complex. Creatinine was measured in the urine samples that were diluted 20-fold 
(using 10 microL urine and 190 microL distilled water) using a prepared 
manufactured kit (Creatinine assay, KGE005, R&D Systems Inc, USA). Alkaline 
Picrate solution was made using the provided solutions; 2.5 mL of sodium 
hydroxide (NaOH) to 12.5 mL picric acid reagent. The solution requires mixing.  
 
A standard curve is prepared using known concentration of creatinine by serial 
diluation. A concentration of 20 mg/dL creatinine served as the high standard and 
distilled water as the zero standard (0 mg/dL). The standard curve was made up 
using the following concentrations; 20 mg/dl, 10mg/dl, 5 mg/dl, 2.5 mg/dl, 1.25 
mg/dl, 0.625 mg/dl, 0.3125 mg/dl. Samples were brought to room temperature 
before use and all samples, standards and controls were assayed in duplicate. 
Using a microplate, 50 microL of the standard, control, or sample (diluted) was 
added to each well. A volume of 100 microL of Alkaline Picrate solution is required 
per well. The plate was left to incubate for 30 ± 5 minutes at room temperature. 
The optical density was then determined for each well using a microplate reader 
set to 490 nm. Unknown values were calculated using a standard curve equation. 
 
2.4.3. Multiplex suspension array system  
The multiplex suspension array system allows the simultaneous detection of 
several biomolecules from a single sample, with technology available to allow 
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the detection of one to twenty-seven biomolecules.  It uses fluorescent-labelled 
beads each conjugated with monoclonal antibodies specific for a particular 
protein such as a cytokine. These are allowed to mix with the sample to 
produce a chemical reaction with the bead surface. A detection antibody is 
then added to make a sandwich immunoassay. The constituents of each well 
are placed through a specific multiplex reader containing lasers within a flow 
cytometer that aligns the beads and allows them to pass the laser, detecting 
any chemical reaction through a fluorescent colour change. The amount of 
fluorescence allows concentration calculations from known standard values. 
 
The advantage of the multiplex technique is the use of small quantities of 
sample to produce several results in a short timescale, which is particulary 
attractive for use in a paediatric population where blood sampling volumes are 
limited. A disadvantage may be the compromise on the accuracy of the 
concentration values when compared to other techniques (339). 
 
2.4.4. The ARCHITECT urine NGAL assay 
2.4.4.1.  The Prospective Investigation into NGAL utility 
During development of an NGAL assay for this study, a significant interest in 
measuring urine NGAL as a kidney injury biomarker in children arose in a 
variety of clinical settings across AHCH. Therefore a clinical interest group was 
formed to assess the prospective investigation into NGAL utility (PINGU group; 
Chaired by LW). Collaborative application to Abbott Laboratories, USA (led by 
LW) enabled the support of laboratory costs and reagents for use of the 
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ARCHITECT urine NGAL assay for the purposes of this and other investigator 
led projects, and the group met regularly to communicate progress. 
 
2.4.4.2. The ARCHITECT urine NGAL assay: Method 
The urine ARCHITECT NGAL assay (Abbott Laboratories, USA) is a 
chemiluminescent micro particle immunoassay for the quantitative detection of 
NGAL in human urine.  
 
The assay involves a two-step assay, in the first step the sample and wash 
buffer are combined to create a 1:10 sample dilution and then an aliquot of the 
pre-diluted sample, wash buffer and anti-NGAL coated paramagnetic micro 
particles are combined. NGAL present in the sample then binds to anti-NGAL 
coated micro particles and the reaction mixture is washed. In the second step, 
anti-NGAL acridinium-labelled conjugate is added. Following another wash 
cycle, pre-trigger and trigger solutions are added to the reaction mixture. The 
resulting chemiluminescent reaction is measured as relative light units. The 
amount of NGAL in the sample is detected by the ARCHITECT system optics. 
This process has been extensively validated and published in detail previously 
(340).  
 
2.4.5. Western blotting 
The Western blot is a technique used to determine the presence of a specific 
protein using its own molecular weight to identify it.   
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2.4.5.1. Protein separation and transfer 
The process initially involves protein separation of a sample using gel 
electrophoresis where proteins are forced through a substance 
(polyacrylamide) due to an electrical current and then the protein is transferred 
onto a membrane. Transfer can be conducted using diffusion, convectional 
transfer, vacuum transfer, capillary transfer or electrophoretic transfer. The 
most common method used is electrophoretic due to its speed and efficiency. 
The membrane and gel are placed between two conducting electrodes in 
conducting fluid and using an electric charge the protein is moved from the gel 
to the membrane where it tightly adheres. The result is a membrane that is a 
direct copy of the original gel containing proteins.  
 
2.4.5.2. Blocking and probing for the antibody 
The membrane is then blocked using a non-specific protein substance (eg: 
bovine serum albumin, BSA) to avoid non-specific binding sites for the desired 
antibody. The transferred proteins on the membrane are then probed for a 
target antibody (called the primary antibody).   
 
For Western blotting experiments carried out in this study, all antibodies were 
used in 1:100-1:50,000 dilutions from a 1mg/ml stock concentration, the 
optimal concentration needs to be established from repeat experimental 
testing. Antibody dilutions were made in the wash buffer together with a 
blocking agent (eg: 3% BSA in Tris buffered saline with tween; TBS-T). A less 
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concentrated solution will improve the sensitivity and specificity of detecting 
the target antibody. 
 
2.4.5.3. Incubation with a secondary antibody and 
chemiluminescence 
This step is followed by incubation with an enzyme complexed antibody (the 
secondary antibody) that connects with the primary protein antibody and 
allows chemiluminescence detection. The most commonly used enzymes are 
alkaline phosphatase and horseradish peroxidase (HRP). Alkaline 
phosphatase allows a linear reaction but it is lengthier than HRP. HRP is 
therefore the enzyme of choice - it is low cost and has good activity and 
stability. 
 
2.4.5.4. Reducing interference 
Between each antibody step the membrane requires thorough washing to 
reduce non-specific binding and background interference.  Insufficient washing 
will produce high background interference and over washing may reduce the 
detection of the appropriate antibody. Typical wash buffers involve 
physiologically relevant solutions such as phosphate buffered saline or TBS-T 
as used for this study. Following incubation with a chemiluminescent substrate 
HRP is detected on the immunoblot.  
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2.4.5.5. Detecting and fixing the protein product 
X-ray films are used to detect the protein as light photons collide with the film 
when they are in contact with the membrane. These are then fixed using 
developing and fixing solutions producing a fixed film as seen in Figure 11. 
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Figure 11: Western blot processed using chemiluminscence onto a x-ray film 
Western blot experiments are used for the identification of protein from a particular sample or specimen. Protein is initially extracted 
from a sample using gel electrophoresis, the protein contained within a gel is then transferred onto a membrane. The membrane is 
stained for the antibody under investigation followed by a secondary antibody to allow its detection. The protein is fixed and 
developed onto x-ray films as shown here. A control protein is typically measured during the experiment to provide evidence of the 
reliability of the transferred protein.   
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2.4.6. Polymerase Chain Reaction: General 
Real time qPCR allows the amplification, detection and quantification of a 
target nucleic acid within a sample. Samples can either be detected to assess 
their presence or be quantified either as an absolute number or as a relative 
expression when compared to a known standard marker. The process is 
undertaken in two steps: the reverse transcription and the real time 
measurement. All equipment used should be nuclease free to avoid 
contamination and the area should be prepared with ultraviolet (UV) light prior 
to processing. 
 
2.4.6.1. Polymerase Chain Reaction: Reverse transcription 
In order to detect the DNA in a specific human sample, the sample needs to be 
converted to complementary DNA (cDNA) from a messenger RNA (mRNA) 
template using reverse transcription (RT).  
 
The RT process allows a stable supply of cDNA to be produced. Three types 
of primers can be used for the RT reaction: oligo primers, random primers and 
gene specific primers. Using the nanodrop spectrophotometer 
(Thermoscientific Inc, USA) the quantity and quality of RNA can be assessed 
(0.2 μg of RNA is sufficient). The RT process starts with annealing the primer 
to the RNA. Within a sterile microcentrifuge tube, 1μl of random primers was 
added to the RNA and nuclease free water, to produce a total volume of 15μl. 
This mixture was incubated at 70°C using a thermocycler for 5 minutes to 
denature any secondary structures. For the reverse transcription reaction 5 μL 
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of RT buffer (5xMMLV), 1.25 μL nucleoties (10mM ATP, CTP, GTP, UTP), 0.5 
μL ribonuclease inhibitior, 2.25 μL nuclease free water (making 10 μL) is 
added to the sample to give a total volume of 25 μL. The reaction is then 
extended at 42°C for 1 hour to produce cDNA. At this stage the sample is 
stable and can be used immediately or stored at -20°C for later use. 
 
2.4.6.2. Polymerase Chain Reaction: Real time measurement 
Using cDNA samples, the real time PCR method initially involves the addition 
of selected primers with specific DNA nucleotide sequences. The primer 
consists of two complementary base pairs, which target the start and end of 
the sequence under interrogation that ideally occur only once in the genome.  
DNA polymerase is used to identify the primer region and multiply the DNA, 
using nucleotides in the mixture for this process.  
 
The cycling reaction is undertaken in an automated thermocycler that can be 
set to reach specific temperatures and the process is repeated for 30-40 
cycles. The first step is the denaturing of the sample (usually around 94°C) this 
splits the DNA into single stranded DNA and all enzyme reactions stop. The 
next step is the annealing stage which is performed at around 54°C, this 
process involves the primers moving about and constantly bonding then 
breaking with areas of DNA until a firm bond is made with the area of interest 
and the specific primer. Once this has occurred double stranded DNA is 
present and active DNA polymerase can attach and begins copying this area.  
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The last phase is the extension phase (at 72°C) where non-specific bonds 
(weakened by the higher temperature) are lost and specific bonds are 
replicated (see Figure 12). 
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Figure 12: The polymerase chain reaction 
The polymerase chain reaction involves a sample of DNA being mixed with a 
primer that has a specific nucleotide sequence. It begins by a process to 
denature (split) the DNA sample into single stranded DNA, this is usually 
performed at around 94°C. The next step is annealing (performed at around 
54°C) in which the primer freely moves about until if forms a strong bond with 
the specific regions on the DNA sample.  Finally, the extension phase involves 
the separation of weak bonds and the replication of strong bonds. This process 
is repeated for 30-40 cycles. 
Denaturing 
Annealing 
Extending 
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2.4.6.3. Polymerase Chain Reaction: Agarose gel electrophoresis 
After 40 cycles of cDNA synethesis the sample can be analysed by Agraose 
gel electrophoresis to assess the presence of a particular nucleic acid, if 
required. This method does not allow the quantification of cDNA product, as it 
is too insensitive, however it is useful to assess whether a product is present 
or not.  
 
A 1% Agarose gel is prepared using 1g of Agarose (Sigma Ltd, UK) in 100mls 
of TAE running buffer (Tris, acetate and ethylenediaminetetraacetic acid, 
EDTA; Sigma Ltd, UK). TAE running buffer is made up in a 10x concentrated 
stock and diluted for use (eg: 100mls of 10x TAE is mixed into 1L of distilled 
water). To make 10x TAE electrophoresis buffer the following ingredients were 
used; 
• 48.4 g of Tris base [tris (hydroxymethyl) aminomethane] 
• 11.4 mL of glacial acetic acid (17.4 M) 
• 3.7 g of EDTA, disodium salt 
• Deionized (distilled) water 
 
The Tris is dissolved with the glacial acetic acid and EDTA in 800 ml of 
deionized water and the buffer is diluated up to 1 L. The 10X buffer solution is 
stored at room temperature. 
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A 1% gel is the standard size used to detect product size 80-200 base pairs 
(bp). The solution is dissolved in the microwave for 2 minutes and 3 μL of 
ethidium bromide (Sigma Ltd, UK) is added and the solution is mixed gently. It 
is then placed into the container with a comb divider to form a gel and allowed 
to set at room temperature for 30 minutes. When the gel has set the samples 
(mixed with bromophenol blue; Sigma Ltd, UK) are placed within the groves 
made by the comb. A current is applied at 100-120 volts for 20 minutes 
following which the gel is removed and placed within a UV light box and reader 
and the PCR product can be visualised. 
 
2.4.6.4. Polymerase Chain Reaction: quantitative measurement 
Two common methods for detection of products in real-time PCR are: (1) non-
specific fluorescent dyes that intercalate with any double-stranded DNA, and 
(2) sequence-specific DNA probes consisting of oligonucleotides that are 
labeled with a fluorescent reporter which permits detection only after 
hybridization of the probe with its complementary DNA target. SYBR green is a 
non specific fluorescent dye that binds to double-stranded DNA and fluoresces 
as the PCR products are formed. 
 
2.4.6.4.1. Taqman® assays 
Taqman® assays (Applied Biosystems Inc, USA) are very sensitive and highly 
reproducible assays. A probe is designed to anneal to an area within the target 
sequence that is between the traditional forward and reverse primers. The 
probe is labelled at the 5' end with a reporter fluorochrome, (a fluorochrome is 
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a molecule that is generally fluorescent when excited) and a quencher 
fluorochrome added at any T position or at the 3' end. The probe is designed 
to have a higher melting temperature than the primers, and during the 
extension phase the probe must be 100% hybridized for success of the assay. 
As long as both fluorochromes are on the probe, the quencher molecule stops 
all fluorescence by the reporter. However, as the DNA polymerase extends the 
primer, the 5' to 3' nuclease activity of the DNA polymerase degrades the 
probe, releasing the reporter fluorochrome. The amount of fluorescence 
released during the amplification cycle is proportional to the amount of product 
generated in each cycle. 
 
The cycle threshold (CT) value is the number of cycles required for the 
fluorescent signal to reach a certain threshold. It is inversely proportional to the 
amount of target nucleic acid in the sample - the lower the CT the more target 
nucleic acid is present. The threshold is set at the region of maximum 
amplification (the steepest area of the amplification curve) and CT values are 
produced for each particular sample. A CT value of <29 is generally 
considered to be a very strong signal, 30-37 is a positive signal, 38-40 is a 
weaker signal and needs to be interpreted with caution. Figure 13 is an 
example of an amplification curve showing the CT threshold and the individual 
sample CT values. 
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Figure 13: Amplification curve in real time quantitative polymerase chain reacton (qPCR). 
Real time qPCR produces an amplification curve that is used to calculate the quantitative gene expression value for a DNA sample 
that has been mixed with a specific gene probe. A threshold is set at the point of maximum amplification allowing the cycle threshold 
(CT) to be calculated.  Negative control samples (NTC) should not demonstrate any amplification.  
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The TaqMan assay uses Taq DNA polymerase and pre-designed fluorescent 
primer-probe sequences; it is thought to be the most specific method of 
undertaking qPCR. The assay consists of a mix (20x) of unlabelled PCR 
primers and a TaqMan MGB probe (labelled with FAM dye). The cDNA sample 
is diluted 1:2 with nuclease free water and 9 μL of diluted sample is placed per 
well in a sterile 96-well plate. Taqman Universal Master Mix (10 μL per well) is 
added to the well plus the gene in question (1 μL per well). All samples are 
measured in duplicate and a negative control (NTC) is used (wells containing 
only nuclease free water). The NTC should produce no fluorescent value. The 
96-well plate is briefly centrifuged to ensure the products are contained in the 
bottom of the plate and the plate is read using a thermocycler, set to detect 
FAM dye. The thermoprofile is 1 cycle of 50 °C for 2 minutes, 1 cycle at 95°C 
for 10 minutes then thermocycling at 95°C for 15 seconds, then 60°C for 1 
minute for a total of 40 cycles.  
 
2.4.6.4.2. Delta-DeltaCT calculation of qPCR product 
The Delta-DeltaCT method is an approximation method used to analyse the 
gene expression of a PCR product in terms of its relative change in proportion 
to a housekeeping gene. It involves the CT value of the gene in question being 
subtracted from the housekeeping gene CT value and placed to the power of 2 
as they are exponentially related (eg: 2^(Housekeeping CT-Sample CT)).  
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2.4.7. Collection and processing of urine samples 
Urine samples were collected into universal containers. The samples were 
centrifuged for 10 minutes at 1000g. The supernatant was measured into 
aliquots (500 μL used) and stored at -80°C until analysis. 
 
2.4.8. Collection and processing of plasma and serum blood samples 
Whole blood was collected into lithium heparin (plasma) and plain collecting 
tubes (serum). The samples were gently inverted and centrifuged for 10 
minutes at 1000g. The supernatant was split into aliquots (200uL used) and 
stored at -80°C until analysis. 
 
2.4.9. Isolation of white blood cells from whole blood 
Whole blood (10-20mls) was collected in lithium heparin blood collecting tubes 
for the isolation of white blood cells and later monocyte cell separation. The 
blood was manually pipetted using a Pasteur pipette gently on top of the 
polymorph (Axis-Shield PoC, Norway) preparation solution in a sterile 12ml 
universal tube, using a ratio of more polymorph preparation solution to blood 
(eg: 6mls of polymorph prep and 5mls of blood).  The sample was centrifuged 
at 1000g for 30 minutes without any brake to allow cell fractional separation 
according to the cell density. Once complete the top layer of cells consisted of 
the PBMCs and the second layer consisted of neutrophils, the red cells 
appeared at the bottom of the sample (see Figure 14). 
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Figure 14: Isolation of white blood cells from whole blood 
Whole blood is layered on top of polymorph preparation and centrifuged 
(1000g, 30 minutes) to undergo fractional separation according to cell density. 
The illustration demonstrates the layers of polymorphic blood cells (PBMC), 
neutrophils and red blood cells. 
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The PBMC and neutrophil layer are gently removed using a Pasteur pipette 
and are each placed in a container with 10mls of Roswell Park Memorial 
Institute medium (RPMI) media (Lonza, UK). The sample is then centrifuged at 
1000g for 10 minutes to collect the cells into a pellet. PBMCs or neutrophil 
cells that appear to be contaminated with red blood cells can undergo a lysis 
step to remove them. This involves the addition of 9mls of 1% Ammonium 
Chloride solution and 1mls of RPMI for 3 minutes followed by a centrifuge step 
to repellet the cells (5 mintues, 1000g). The cells can then be suspended in 
1ml of RPMI media to allow them to be counted using a microscope-counting 
chamber (haemocytometer) to determine the number of cells per unit volume. 
The neutrophil cell protein or RNA were extracted for analysis straight away or 
were stored at -30 or -80°C respectively. PBMCs for use at a later date were 
suspended in freezing media (90% fetal bovine serum, FBS and 10% Dimethyl 
Sulfoxide, DMSO) and stored. 
 
2.4.9.1. Isolating human monocytes 
Human monocytes were isolated from PBMC’s using a CD14+ magnetic cell 
selection process (Miltenyi Biotec Ltd, UK). After the cells were counted 
(require >10 million PBMC’s), they were resuspended in a buffer containing 
PBS (50mls), FCS (0.5%; 2.5mls) and EDTA (2mM; 0.037g). The cells and 
buffer were kept cold on ice at all times. A volume of 85ul of buffer was used 
per 107 cells and the CD14+ beads were added at a concentration of 15ul per 
107 cells. The cells, buffer and the beads were kept cold at 4°C for 15 minutes. 
Once complete, 8mls of buffer were added to the solution and it was 
centrifuged for 10 minutes at 1000g. The cells were resuspended in 500ul of 
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buffer and the column placed in the magnetic apparatus with a waste collecting 
tube underneath. An initial wash of the column was undertaken using 500ul of 
buffer to moisten the column prior to cell separation. The sample was then 
placed in the column and allowed to pass through the magnetic apparatus. 
This was followed by 3 washes using 500ul of buffer for each one. The product 
passed through the column (CD14-ve cells) was then removed and the column 
taken away from the magnetic field. A new collecting tube was placed 
underneath and the CD14+ cells were pushed out from the column using a 1ml 
buffer wash. The cells were then used for monocyte derived macrophage 
culture.  
 
2.4.9.1.1. Purity of isolated human monocytes 
To measure the purity of the isolated monocytes the cells were stained and 
analysed for the percentage of cells bearing CD14 positivity immediately after 
the cell separation process. Using a flow cytometer the CD14+ cells were 
gated and counted. This demonstrated a very pure population of cells with a 
purity of >95%, see Figure 15, Figure 16. 
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Figure 15: Monocyte purity using flow cytometry  
Flow cytometry enables the identification of proteins, DNA, peptides, it is a 
method where labelled cells pass through a laser beam that stimulates the 
label on the cell, emitting and scattering a light source that is detectable. The 
amount of light correlates with the size of the product; measured by both the 
cell volume using the flat angle diffraction of light (forward scatter FSC) and 
the measurement of light diffraction at right angle determines the complexity of 
the cell, eg: granularity, nuclear size (side scatter SSC). This dot plot 
demonstrates the purity of isolated monocytes (96.4%) by assessing the 
number of cells that have been stained for CD14+ and identifying the cells 
according to the light scattering (measured in log values; y axis side scatter, x 
axis forward scatter). 
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Figure 16: Quantification of monocyte purity.  
Flow cytometric analysis is able to quantify the number (%) of monocytes present in the sample using the identification of CD14+ 
fluorescent stained cells and comparing them to an unstained control (y axis, cell count; x axis, fluorescence emitted). 
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2.4.9.2. Culture of isolated monocytes 
In sterile 24-well plate the CD14+ monocyte cells were seeded at a 
concentration of 1x106 cells/well. Monocytes were derived into macrophages 
using macrophage media (RPMI 1640 media, 10% FCS, 1% penicillin 
streptomycin and 10ng/ml of macrophage colony stimulating factor (M-CSF, 
R&D Systems Ltd, USA)). M-CSF is essential as it signals the monocytes to 
become macrophages. The cells were then incubated at 37°C in an 
atmosphere consisting of 5% CO2 for 6 days. 
 
2.4.9.2.1. Activating cultured monocyte-derived macrophages 
Once differentiated into macrophages the cells were washed twice with PBS 
and either exposed to IFN- or placed in new RPMI media, to produce an 
activated or inactivated state respectively. In order to optimise the 
concentration of IFN- suitable for macrophage activation the cells were 
exposed to 1 ng/ml, 10 ng/ml, 100 ng/ml of IFN- for 48 hours in RPMI media 
(n=2 repeats).   
 
2.4.9.2.2. Determining macrophage activation 
The media was then extracted and the TNF- protein expression was 
measured, as a marker of adequate activation, using ELISA techniques (R&D 
Systems Ltd, USA).  At a dose of 1ng/ml the maximum TNF-α concentration 
was achieved with cell viability maintained. This concentration was 
subsequently selected for all macrophage activation experiments (see Figure 
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17). Monocyte-derived macrophages activated with IFN-γ for 48 hours 
demonstrated a statistically significant up regulation of TNF- compared to 
inactive macrophages – see Figure 18, raw data in Appendix 25. 
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Figure 17: Optimising macrophage activation 
Macrophages were exposed to interferon gamma (IFNγ) at different concentrations for 48 hours and the TNFα concentration was 
measured in the media. The condition producing the highest concentration (1ng/ml) of TNFα was selected as the optimal 
concentration for activating macrophages for subsequent experiments. 
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Figure 18: TNFα expression from activated macrophages 
Macrophages were exposed to interferon gamma (active condition using 1 
ng/ml) or no interferon (inactive) and the TNFα protein concentration was 
measured in the media after 48 hours. 
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2.4.9.2.3. Macrophage imaging 
Images of the macrophages were taken using a confocal microscope to allow 
visualisation of differences in the appearances during cell activation (Leica 
Microsystems Ltd, UK). Upon activation macrophages altered their 
microscopic appearance by producing long protruding processes from the cell 
(see Figure 19).  
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Figure 19: Images of macrophages in their inactive or active state. 
Confocal microscope images of the macrophages were taken following culture with RPMI media alone (inactive) or following 
activation with 1 ng/ml of interferon gamma for 48 hours (active state). Images are taken at 40x magnification and demonstrate the 
protrusions seen from the macrophages when activated. 
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2.5. Establishing a Human Podocyte cell line at the 
University of Liverpool  
Through collaboration with Professor Moin Saleem, Academic Renal Unit, 
University of Bristol a human podocyte cell line culture technique was adapted 
to produce an in vitro model of lupus glomerulonephritis. The methods and 
techniques of podocyte cell culture were taught in Bristol and brought to 
Liverpool to enable the establishment of on going podocyte related 
inflammatory renal research. 
 
2.5.1. Human podocyte cell line: Background 
The human podocyte cell line is a conditionally immortalised cell line 
containing a temperature sensitive viral vector. At 33°C the podocyte cells 
proliferate and when thermoswitched to 37°C the podocyte cells terminally 
differentiate into mature podocyte cells. This method overcomes the inability of 
podocyte cells to proliferate in culture and allows scientific experimentation of 
these cells. The original podocyte cells were obtained from a whole healthy 
kidney (341). 
 
2.5.2. Human podocyte cell line: Culture techniques 
The podocyte cells were grown in RPMI media containing 10% FBS, 1% 
penicillin-streptomycin and 1% insulin transferrin selenium (ITS) (Sigma-
Aldrich, UK) liquid supplement (termed ‘podocyte cell media’ throughout). Cells 
were removed from liquid nitrogen storage and quickly hand thawed. Cells 
were seeded at a 1x105 concentration in a 25cm2 flask in 5mls of podocyte cell 
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media and placed in a 33°C incubator. Once 60% confluent the cells could be 
divided using trypsin EDTA. To divide cells, the media was poured off, the cells 
were washed twice with sterile cold PBS and 1ml of trypsin (1x concentration; 
Sigma-Aldrich Ltd, USA) was added to the flask. The cells were then placed at 
37°C for up to 5 minutes to allow cell detachment which was visible under the 
microscope as cells freely moving across the flask. Cells were then pipetted 
out into a sterile 12 ml universal container and centrifuged at 1000 g for 10 
minutes. The pelleted cells were resuspended, counted and split into fresh 
flasks for proliferation at 33°C or frozen down for storage. The cells destined 
for storage were placed into a cryovial with 1ml of freezing media (1% DMSO, 
50% FCS, 50% podocyte cell media) and were frozen gently using either a 
polystyrene insulting surround or an iso-propanol container for slower cooling, 
and placed at -80°C for 24 hours prior to moving the cells into long-term 
storage in liquid nitrogen. 
 
Cells reaching 60% confluence at 33°C that were required for experiments 
were terminal differentiated by thermo-switching them to a 37°C incubator and 
allowing them to differentiate for 10-14 days (see Figure 20). After thermo-
switching the cells can no longer be divided and are grown to maturity for 
experimental purposes. An illustration of the actin cytoskeleton maintaining the 
cell structure is shown in Figure 21. 
 
Sterile technique is maintained throughout and at either temperature the 
podocyte cell media is changed every 3-4 days.  
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Figure 20: Undifferentiated (33°C) and differentiated (37°C) podocytes 
Podocytes are incubated at 33°C where they are able to proliferate until they are approximately 60% confluent. They are 
thermoswitched to 37°C to allow the cells to undergo terminal differentiation for 10-14 days. 
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Figure 21: Podocyte actin cytoskeleton 
Podocytes were stained for actin (using anti-human actin antibody, concentration 1:1000, for 1 hour) to produce an illustration of its 
cytoskeleton. As can be seen from the figure, the actin staining is throughout the outer aspects of the cell, appearing to maintain its 
structure. 
  137 
 
2.5.3. Human podocyte cell line: Cell extraction 
Following the experimental conditions, the podocyte cell mRNA and protein 
was extracted using a lysis extraction buffer containing protease (Sigma-
Aldrich, UK) and phosphatase inhibitors (Phosphatase inhibitor III, Merck 
Chemicals, Germany; Phosphatase inhibitor II, Sigma-Aldrich, UK) and a cell 
scraper. The lysis buffer (to make 100mls) contained Tris (50mM, 0.606g), 
sodium chloride (120mM, 0.702g), β-glycerophosphate (40mM, 1.26g), 
Benzamidine (1mM, 0.016g), EDTA (1mM, 0.038g), Triton (x100, 1ml), at a pH 
of 7.5 using hydrochloric acid and made up to the final volume using distilled 
water. To extract cells 1ml of lysis buffer was aliquoted and 1% protease and 
phosphatase inhibitors were added. 
 
The scraped cells were then centrifuged at a high relative centrifugal force 
(28,400g, 10 minutes). RNA was extracted from the pelleted cell sediment 
using RNeasy RLT lysing buffer (Qiagen, UK) and the cell supernatant served 
as the intracellular protein.  
 
2.5.4. Human podocyte cell line: Cell mRNA and protein extraction 
Total RNA was isolated from the cells using the RNeasy kit according to the 
manufacturers instructions (Qiagen, UK). The total RNA concentration was 
quantified and 0.2 ug was converted to cDNA. Samples were further diluted 
1:4 using nuclease free water (Sigma-Aldrich, UK) and real time PCR was 
performed when appropriate (see section 2.4.6). The intracellular protein was 
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quantified, combined with SDS page buffer to be used for Western blot 
analysis as detailed earlier (see section 2.4.5). 
 
2.5.5. Human podocyte cell line: Cell purity 
The optimisation and purity of the cells has previously been published in detail 
(341). The cells were tested for the expression of the common podocyte 
specific cell markers (18s, Nephrin, Neph1 and podocin) using PCR Agarose 
gel techniques (see 2.4.6.3) as shown in Figure 22.  
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Figure 22: Agarose gel analysis showing the gene products of control podocytes.  
The gel analysis was performed on qPCR end products to illustrate the universal expression of 18s, nephrin, podocin and neph1 in 
cells from the human podocyte cell line.  
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2.6. Statistical techniques 
Statistical analysis required the use of appropriate software, Statistics 
Programme for Social Sciences (IBM Corporation, USA). All results using 
patient data were assessed to see whether they represent normality using the 
Shapiro-Wilk test. Data relating to cell lines are presumed to demonstrate 
normality. In non-normally distributed data (non-parametric) the results are 
represented as median values with interquartile ranges. In data that is normally 
distributed (parametric), or cell line data, the data is presented as mean values 
with the standard error of the mean (SEM) and/or standard deviation scores 
(SD). Statistical comparison between two groups used the Mann-Whitney U 
test for non-parametric data and the student t test for parametric data. Related 
samples utilised the Wilcoxon-signed ranks (non-parametric) or the paired t 
test (parametric). Comparison of more than two groups used the Kruskal-
Wallis (non-parametric) or the one-way ANOVA test (parametric). Correlation 
analysis used the Spearman rank test (non-parametric) or the Pearson 
correlation test (parametric). 
 
Graph pad Prism software was used to produce all graphical illustrations 
(GraphPad software, Inc, USA). Throughout this manuscript a statistically 
significant difference was taken as a probability (p) value of less than 0.05, 
statistically significant differences were displayed on graphical illustrations and 
further detailed statistical methodology is explained as appropriate.  
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2.7. Summary 
This chapter demonstrates the wide range of methods that were developed 
and employed for this study and places this work in context with the national 
collaborative study, the UK JSLE Cohort Study and Repository. With regards 
to the clinical cohort, successful ethical amendment, recruitment and 
consenting of patients has been achieved together with the establishment of 
standard operating procedures for the regular collection of samples from two of 
the largest recruiting sites. A robust method of collecting disease and healthy 
control patients has been described along with statistical methods that were 
utilised. The techniques to process patient samples for experimental use have 
been illustrated and explained to enable easy replication by others. The theory 
behind the experimental methods and optimised protocols has been discussed 
for techniques including ELISA, qPCR, Western blot, multiplex array and cell 
culture.  
 
Finally, the collaboration with the Academic Renal Unit, Bristol, has enabled 
the introduction of a human podocyte cell line in Liverpool, which was used for 
experimental use within the UK JSLE Cohort Study group, but which has direct 
implications with regards to improving the future of renal inflammatory 
research at Liverpool. 
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3. Chapter 3: Urine and plasma biomarkers 
in JSLE 
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3.1. Urine and plasma biomarkers in JSLE: Background 
The presence of renal involvement in patients with JSLE has significant 
consequences. At present, routine clinical and laboratory tests cannot reliably 
predict the severity of the underlying renal disease process (342). The BILAG 
scoring tool provides a non-invasive multi-system measure of disease activity 
and includes aspects of the renal system (44, 46). Validated, non-invasive 
urine biomarkers in a childhood population provide potential promise for LN 
monitoring and form the basis of this chapter.  
 
3.2. Aims and objectives 
The first aim of this study presented in this chapter is to determine whether 
the urine concentrations of selected biomarkers are related to the renal 
disease activity in patients with JSLE. The secondary aims are hypothesis 
generating and include looking at associations between each of the urine 
biomarkers and assessing whether plasma cytokines, selected on the basis of 
their action and evidence base to date, are elevated in patients with active LN.  
 
The specific objectives of this chapter are:  
1. To determine whether there are significant differences in the 
concentration of the urinary biomarkers (MCP1, AGP, IP10, NGAL) in 
patients with active LN compared to patients with inactive LN and 
healthy controls.   
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2. To determine any associations between each of the urinary biomarkers 
(MCP1, AGP, IP10, NGAL). 
3. To identify associations in plasma cytokine (IFN-γ, IP10, TNF-α, IL6, 
IL1β, MCP1, IL13, VEGF) concentrations in JSLE patients with active 
LN when compared to healthy control patients. 
 
3.3. Hypothesis 
In children with JSLE, plasma and urine biomarkers can distinguish patients 
with active renal disease from those with inactive renal disease or healthy 
children. 
 
3.4. Methods 
3.4.1. Patient cohort 
Children participating in the UK JSLE Cohort Study (www.liv.ac.uk/ukjsle) 
treated at AHCH or at GOSH were recruited to this study (see section 2.2). 
Healthy children, not on medication, attending for elective non-inflammatory 
surgery were recruited as healthy control patients (see section 2.3).   
 
3.4.2. Data collection 
Cross-sectional plasma and urine samples were collected prospectively at 
every clinical opportunity (as described in section 2.2) and processed 
accordingly (see 3.4.4 below). At the same time, detailed demographic data, 
clinical and laboratory data was collected in accordance to with the BILAG 
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documentation, previously described in 2.1.2 (44). Laboratory data included; 
haemoglobin (Hb), white cell count (WCC), lymphocyte count (lymph), 
neutrophil count (neut), ESR, C3 and C4, anti-dsDNA and urine albumin to 
creatinine ratio levels (UACR). Disease activity data was collected using the 
pBILAG2004 disease activity score; see methods in section 2.1.2 (42). 
 
3.4.3. Patient groups 
Two distinct JSLE patient groups were assessed for plasma and urine 
biomarkers. In both of the groups, JSLE patients were categorised according 
to the renal domain score of the pBILAG2004 (see Table 11).   
 Patients with a renal BILAG score of A or B were classed as having 
JSLE-associated active renal disease (termed “JSLE active renal”)  
 Patients scoring C, D or E were classed as having JSLE-associated 
non-active or never having experienced renal disease (termed “JSLE 
non-active renal”).  
 
3.4.4. Laboratory techniques 
3.4.4.1. Urine samples 
Local laboratories undertook microscopic evaluation of all the urine samples 
and subsequent culture to exclude urine infection. Urine samples with less 
than 10 white cells on microscopy and no organism cultured where 
considered free of active infection. Urine samples were centrifuged at 1000 g 
for 10 minutes. Aliquots (5 aliquots of 500 µL volume) of urine supernatant 
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were stored at minus 80°C until analysis. Samples collected at GOSH were 
batched and transferred every 3-months as described in Appendix 12.  
 
Urinary MCP1, AGP and IP10 concentrations were quantified using pre-
coated ELISA kits (R&D systems Ltd) – see Table 13.  The MCP1 and AGP 
assays are commercially validated for use in urine.  Internal validation of the 
IP10 assay demonstrated good linearity of dilution and recovery using spike-
and-retrieval techniques. Urine NGAL concentrations were measured using 
the commercially available urine ARCHITECT NGAL assay (Abbott 
Laboratories, USA), as detailed in section 2.4.4. 
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Table 14: Linearity of dilution of the IP10 ELISA 
The IP10 ELISA was validated using a linearity of dilution technique in a high 
concentration patient sample and a low concentration patient sample, 
demonstrating 80-100% sample recovery despite serial dilutions. 
Sample concentration Dilution factor (DF)
Observed 
concentration 
(pg/ml)
Expected 
concentration 
(pg/ml)
Recovery 
%
Neat 102 102 100
1:2 46 51 90.2
1:4 22 25.5 86.3
Neat 45 45 100
1:2 21 22.5 93.3
1:4 9 11.25 80
High sample
Low sample
 
Table 15: Spike and recovery analysis of the IP10 ELISA 
Eight patient samples were spiked with a known quantity (245 pg/ml) of IP10 
and the percentage recovery was calculated, showing a good recovery rate of 
>100%. 
Sample
Retrieved spike 
concentration (pg/ml)
Percentage recovery 
(%) 
1 281.8 114.9
2 263.3 107.4
3 305.6 124.6
5 284.2 115.9
6 316.1 128.9
7 288.3 117.6
8 307 125.2
Actual spiked sample = 245 pg/ml
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All biomarker results were standardised for urinary creatinine (Cr) 
concentrations quantified using a pre-standardised kit (R&D systems Ltd), as 
in section 2.4.2. Results standardised for creatinine were presented in units 
per milligram creatinine (units/mg Cr). 
3.4.4.2. Plasma samples 
Plasma samples were collected in lithium heparin blood collecting tubes and 
processed within an hour of collection. Samples were centrifuged at 1000 g 
for 10 minutes, divided into 200uL aliquots and frozen at minus 80°C until 
analysis.  
 
The eight cytokines were identified following an extensive literature search 
into their potential role in renal, inflammatory or lupus pathophysiology as 
discussed earlier.  These were; IFN-γ, IP10, TNF-α, IL-6, IL-1β, MCP-1, IL-13 
and VEGF, which were used to produce a custom-made eight-cytokine, 
multiplex suspension array system (Bio Rad Laboratories Ltd, UK) and 
analysed on a multiplex array reader (Bioplex, Bio Rad Laboratories Ltd, UK) 
– see section 2.4.3. 
 
3.4.5. Statistical analysis 
Data was analysed using Statistics Package for Social Sciences (SPSS Ltd, 
USA) version 18.0. Probability (p) values <0.05 were considered significant. 
Demographic and biomarker data were non-parametric and concentrations 
were therefore expressed as median values with interquartile ranges (IQR). 
The Mann Whitney U statistical test was used to compare the median values 
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of plasma and urine biomarker concentrations between groups, as the data 
was non-parametric.  
 
Using Spearman’s correlation coefficient analysis, relationships between 
urinary biomarkers and standard laboratory markers were explored. Results 
were expressed with p values and a correlation coefficient value (rho), which 
can range from -1 (strong negative relationship) to 0 (no relationship) to +1 
(strong positive relationship). 
 
3.5. Results 
3.5.1. Urine biomarkers 
3.5.1.1. Demographic data 
Eighty-three patients were recruited for urine biomarker analysis: 60 with 
JSLE and 23 healthy controls. Of the 60 JSLE patients recruited, 45 were 
female (75%).  Patients were aged 14.7 (12.2-16.1) years.  All had ≥ 4 SLE 
ACR classification criteria with a median score of 5 (range 4-9).  The median 
length of disease was 3.3 (1.3-4.7) years. Ethnic groups were as followed; 
62% (37/60) were Caucasian, 15% (9/60) African, 15% (9/60) Asian, 7% 
(4/60) mixed race and 2% (1/60) were Caribbean. Sixteen JSLE patients 
(16/60; 27%) had previously undergone a renal biopsy: Class IV 
glomerulonephritis (n= 7), Class III (n=5), and Class II (n=4) (57). 
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Eight patients were classed as “JSLE active renal” disease and 52 as “JSLE 
non-active renal”. Within the JSLE active renal group there were 4 African 
patients, 3 Asian patients and 1 Caucasian patient. There was a trend 
towards more active renal involvement in non-Caucasian patients, although 
this was not statistically significant (p=0.057), however there was a significant 
difference seen between the groups with regards to the patients of African 
ethnicity, who were more likely to have active renal disease than inactive 
renal disease (p=0.002, Table 16). 
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Table 16: Demographic and clinical characteristics of JSLE patients 
The key demographic and clinical characteristics of the JSLE patients divided according to the presence of active renal disease. 
This shows a statistically significant difference between the groups with regards to the British Isles Lupus assessment group 
(BILAG) score, ESR and proteinuria (p<0.05 is regarded as statistically significant).  
Laboratory Marker 
JSLE Active Renal n=8, 
median (interquartile 
range) 
JSLE Inactive Renal 
n=52, median 
(interquartile range) 
Statistical 
difference (p 
value) 
 Age at diagnosis (yrs) 13.6 (8.0-14.0) 10.9 (8.1-13.5) p=0.43 
 Current age (yrs) 15.2 (12.4-16.0) 14.6 (12.5-16.6) p=0.97 
 Black african ethnicity (%) 4 (50%) 5 (9.6%) p=0.002* 
 Latest ACR score 5 (4-6) 5 (4-6) p=0.86 
 BILAG score 4 (4-8) 2 (1-3) p=0.009* 
 Length of disease (yrs) 1.7 (0.5-4.2) 3.3 (1.1.-5.2) p=0.16 
 Complement 3 (g/L) 0.7 (0.4-1.0) 1.0 (0.9-1.3) p=0.02* 
 Erythrocyte sedimentation rate (mm/hr) 26 (11-41) 9 (3-19) p=0.07 
 WCCx109/L 6.1 (2.4-9.7) 5.2 (1.1-2.0) p=0.51 
 Lymphocyte countx109/L 1.23 (1.0-1.5) 1.7 (1.2-2.1) p=0.16 
 eGFR (ml/min/m2) 99.6 (66-147) 112 (106-128) p=0.58 
 Proteinuria (UACR) mg/mmol 370 (2.7-456) 1.0 (0.7-1.7) p=0.000* 
 Anti-dsDNA IU/L 48 (24-82) 1 (0-25) p=0.34 
 *statistically significant p<0.05 
   American college rheumatology; ACR, British isles lupus assessment group assessment group; BILAG 
 White cell count; WCC, estimated glomerular filtration rate; eGFR, anti-double stranded DNA tites; anti-dsDNA 
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3.5.1.2. Standard disease activity markers 
JSLE active renal patients had a significantly higher overall BILAG score 
(JSLE active renal BILAG median score 4 (range 3-10); JSLE inactive renal 
BILAG median score 2 (range 1-8); p=0.009) and higher urine albumin-to-
creatinine ratio (370 mg/mmol (2.7-456); 0.95 mg/mmol (0.7-1.7) respectively; 
p<0.001).  
 
3.5.1.3. Urinary Biomarker results 
Urinary MCP1 concentration was statistically significantly higher in patients 
with JSLE active renal disease compared to JSLE non-active renal disease 
patients (582 (251-2100) pg/mgCr; 207 (121-280) pg/mgCr; p=0.018) and 
healthy controls (117 (68-193) pg/mgCr; p=0.005). As illustrated in Figure 23, 
urinary concentrations of AGP were also statistically significantly higher in 
patients with JSLE active renal disease compared to JSLE non-active renal 
disease (1517 (753-2389) ng/mgCr, 485 (212-967) ng/mgCr; p=0.027) and to 
healthy controls (313 (108-729) ng/mgCr; p=0.013).  
 
Urinary IP10 showed no significant difference between JSLE active renal 
disease, JSLE non-active renal disease or healthy controls (28 (16-70) 
pg/mgCr, 16 (3-37) pg/mgCr; p=0.55, 25 (11-34) pg/mgCr; p=0.13).  
 
On a cross sectional basis, urinary NGAL showed no significant difference 
between JSLE active renal disease, JSLE non-active renal disease or healthy 
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controls (17 (6-64 ng/mg Cr, 12 (5-27) ng/mg Cr; p=0.47, 12 (5-27) ng/mg Cr; 
p=0.48). Raw data results can be seen in the appendix. 
 
A subset analysis comparing patients with active LN (defined as a renal 
BILAG score A or B) and resolved LN (defined as a BILAG score C or D), 
excluding patients without ever having renal involvement (defined as a BILAG 
score E) was also undertaken. Within the JSLE inactive-renal group, only 
seven patients had never experienced renal involvement. A subgroup analysis 
of patients with JSLE active renal and JSLE resolved renal (excluding BILAG 
score E) demonstrated similar statistical findings.  
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Figure 23: Urine biomarker concentrations in patient groups 
The urine biomarker (MCP1, AGP, IP10, NGAL) concentrations in active, non-
active renal JSLE and healthy control patients. 
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3.5.1.4. Correlation between urine biomarkers 
Using Spearman’s correlation analyses, two of the urine biomarkers (MCP1, 
AGP) demonstrated a relationship with the urine albumin:creatinine ratio 
(MCP1 rho=0.41, p=0.01; AGP rho=0.44, p=0.004).  
 
A statistically significant correlation was found between several of the 
biomarkers, namely uMCP1 and uAGP concentrations (rho=0.54, p<0.001, 
Figure 24), uMCP1 and uIP10 concentrations (rho=0.38, p=0.009, Figure 24), 
uMCP1 and uNGAL (rho=0.38, p=0.005, Figure 24) and, uAGP and uIP10 
(rho=0.33, p=0.021, Figure 24). Urinary concentrations of MCP1, IP10, AGP, 
NGAL did not correlate significantly with C3, C4, ESR, dsDNA, Creatinine, 
eGFR, WCC, or lymphocyte count. 
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Figure 24: Correlation between urine biomarker concentrations in JSLE 
patients 
The correlation between each of the urine biomarkers demonstrated a 
statistically significant relationship with each other as shown in the correlation 
graphs. 
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3.5.2. Plasma cytokines 
3.5.2.1. Demographic data 
A group of twenty-five selected JSLE patients and ten healthy control patients 
had plasma cytokine analysis performed. The JSLE patients were identified 
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sequentially according to their renal BILAG domain and consisted of 12 
patients with JSLE active renal disease and 13 patients with JSLE non-active 
renal disease. Twenty-one JSLE patients were female (84%) with a median 
age of 14.9 years (range 6.0-17.9; IQR 13.8-16.2 years). Fourteen patients 
(56%) were Caucasian in ethnicity. JSLE active and non-active renal patients 
did not differ statistically with regards to their demographic data, however 
JSLE active renal patients had a significantly increased ACR SLE score and 
ESR concentration as seen in Table 17. 
  158 
 
Table 17: JSLE patients recruited for plasma cross sectional biomarker analysis 
Parameter 
JSLE Active Renal n=12, median 
(interquartile range) 
JSLE Inactive Renal n=13, median 
(interquartile range) 
Statistical difference (p 
value) 
 
Age at diagnosis (yrs) 11.9 (10.0-13.4) 9.1 (8.2-12.1) p=0.15 
 
Current age (yrs) 15.7 (14.2-16.2) 15 (13.5-16.5) p=0.20 
 
Sex (female) 10 (83%) 11 (85%) p=0.93 
 
Caucasian ethnicity (%) 4 (33%) 7 (54%) p=0.31 
 
Latest ACR score 6 (4.5-7) 4 (4-6) p=0.006* 
 
BILAG score 3 (3-6) 1 (0-3.8) p=0.19 
 
Erythrocyte sedimentation rate 
(mm/hr) 
11 (9.5-26) 6.5 (0-15) p=0.04* 
 
eGFR (ml/min/m
2
) 128 (109-135) 125 (110-144) p=0.90 
 
Proteinuria (UACR) mg/mmol 2.4 (1.3-7.9) 0.8 (0.5-2.6) p=0.10 
 
Anti-dsDNA IU/L 1 (0-44) 0.5 (0-12.8) p=0.27 
 
*statistically significant p<0.05 
   
American college rheumatology; ACR, British isles lupus assessment group index; BILAG, White cell count; WCC, estimated glomerular filtration rate; eGFR, anti-
double stranded DNA antibodies; anti-dsDNA 
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Ten healthy controls, recruited consecutively, had a median age of 14.0 years 
(range 9.2-16.6; IQR 12.6-15.6 years), 6 (60%) were female, all were 
Caucasian in ethnicity (100%). There was no significant difference with 
respect to the age (p=0.86) or the sex (p=0.78) between JSLE and healthy 
control groups. 
 
3.5.2.2. Plasma cytokine results 
Table 18 presents the median (IQR) plasma cytokine concentrations of JSLE 
active renal disease, JSLE non-active renal disease and healthy controls for 
each of the eight selected cytokines of interest (raw data in Appendix 18).  
 
Figure 25 presents plots of the plasma cytokine concentrations of JSLE active 
renal disease, JSLE non-active renal disease and healthy controls for each of 
the eight selected cytokines of interest along with median values for each 
group. 
 
Overall there were apparent increases in all of the selected cytokine 
concentrations in those patients with JSLE active renal disease compared to 
JSLE non-active renal disease or healthy controls. Analysis of the eight 
selected plasma cytokines revealed a statistically significant elevation in the 
plasma concentration of IL-13 in patients with JSLE active renal disease when 
compared to patients with JSLE non-active renal disease or healthy controls 
(IL-13 JSLE active renal 8.1pg/ml, 1.6-21.8pg/ml, non-active renal 1.8 pg/ml, 
0.6-4.0pg/ml, p=0.028) as seen in Table 18. There was also a trend toward 
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increased plasma concentration of IFN-γ, TNF-α, IL-6 and VEGF in patients 
with JSLE active renal disease compared to those with JSLE non-active renal 
disease. Plasma concentrations of IL-1β, IP-10 and MCP-1 showed no 
significant difference between the patient groups.  
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Table 18: The plasma cytokine concentration in each of the patient groups 
The plasma concentration of selected cytokines in patients with JSLE active renal disease compared to JSLE non-active renal 
disease and the healthy control cohort, with statistical comparison (p<0.05 significant). 
Plasma cytokine 
JSLE active renal 
concentration pg/ml 
(median; IQR) 
JSLE non-active renal 
concentration pg/ml 
(median; IQR) 
Healthy controls pg/ml 
(median; IQR) 
JSLE active 
renal v. non-
active renal (p 
value) 
JSLE active renal 
v. healthy 
control (p value) 
IFNγ 34.97 (23.77-888.92) 0 (0-101.06) 12.52 (0-166.7) 0.07 0.18 
IP10 582.5 (180.79-1149.9) 319.25 (153.95-529.76) 365.58 (252.49-854.95) 0.17 0.51 
TNFα 127.26 (20.85-390.49) 14.28 (6.25-108.35) 22.52 (2.8-105.02) 0.83 0.06 
IL6 25.46 (9.17-81.82) 3.88 (0-33.32) 7.19 (0-34.89) 0.08 0.04* 
IL1β 1.98 (0.81-17.85) 0.85 (0.64-2.41) 0.83 (0.52-2.69) 0.16 0.11 
MCP1 74.95 (37.11-199.4) 59.75 (24.95-119.87) 46.58 (35.61-66.36) 0.59 0.26 
IL13 8.13 (1.62-21.78) 1.27 (0.62-4.0) 1.22 (0.45-1.9) 0.028* 0.008** 
VEGF 9.92 (0-39.43) 0 (0-4.97) 0 (0-1.13) 0.05 0.026* 
 
     *Statistically significant at p<0.05; **Statistically significant at p<0.01 
  
 
  162 
Figure 25: Plasma cytokine concentration in patients with JSLE active 
renal, JSLE non-active renal and healthy controls.   
The median plasma cytokine concentrations, for each of the eight cytokines 
measured – interferon gamma; IFNγ (a), interferon producing protein 10; IP10 
(b), tumour necrosis factor alpha; TNFα (c), interleukin 6; IL6 (d), interleukin 1 
beta; IL1β (e), monocyte chemoattractant protein 1; MCP1 (f), interleukin 13; 
IL13 (g), vascular endothelial growth factor; VEGF (h) - in patients divided into 
active renal and non-active renal JSLE compared to healthy control patients. 
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3.6. Discussion  
The primary aim of this chapter was to assess the hypothesis that 
urinary biomarkers can distinguish patients with active LN. In this cohort 
of JSLE patients, urinary concentrations of MCP-1 and AGP were able to 
distinguish patients with JSLE active renal disease (peer reviewed 
publications in Appendix 21
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Appendix 22). Surprisingly, on cross sectional evaluation, no difference in the 
urine concentrations of IP10 or NGAL in patients with active LN was 
demonstrated.  
 
Previously, Marks et al have demonstrated that expression of MCP-1 within 
the glomerulus and the urine was associated with histological class III and IV 
LN in a cohort of children with JSLE (280). This present study has confirmed 
that MCP-1 distinguishes patients with active LN when compared to patients 
with inactive renal disease using a disease activity tool as a monitoring 
standard. Within the kidney, MCP-1 can be secreted from the glomerular 
podocyte in response to pro-inflammatory stimuli including TNF-α, and MCP-1 
knockout mice have no inflammatory cell infiltrate typical of LN (343). As anti-
MCP-1 therapies reduce the T cell expression of IFN-γ (344) it can be 
suggested that MCP-1 has a key role in LN.  
 
This cross sectional analysis is the first to investigate the use of AGP as a 
urinary biomarker in JSLE, demonstrating significantly elevated 
concentrations in patients with active renal disease. This cytokine was first 
linked to LN by mass spectrometry along with several other markers of iron 
regulation (290). AGP acts to protect the glomerulus and, similar to MCP-1, is 
activated by a network of plasma cytokines like we have described in our 
cohort, including IL-1β, TNF-α and IL-6 (345). Although urine AGP was 
significantly increased in our active renal cohort, its role as a specific LN urine 
biomarker may not be as strong as MCP-1, as it may have a significant role in 
  166 
systemically active non-renal JSLE. Further analysis using larger cohorts and 
matched global disease activity would assist in determining this.  
 
Previous studies reported an increased IP10 mRNA expression within the 
glomerulus and the urinary sediment and indicated its potential role in disease 
pathogenesis (283, 290, 292). In contrast to these studies, this study did not 
find significantly elevated urinary IP10 protein concentrations in children with 
active LN. The urinary sediment, containing numerous cell types including 
leucocytes, glomerular and tubular cells, can make gene expression assays 
difficult to relate directly to the kidney. Inability to detect elevated IP10 may be 
due to protein degradation despite high gene expression described in 
previous studies, differences in childhood cytokine expression, too early a 
marker so as not to capture on a cross sectional basis, differences in patient 
cohort characteristics, or the assay employed for use. Whilst this study did not 
detect significantly raised IP10 protein concentrations, a strongly significant 
correlation between IP10 and the other biomarker concentrations was 
demonstrated, supporting its role in the pathogenesis of LN. 
 
The final urine protein that was assessed was NGAL. Preclinical studies have 
found that the renal tissue in murine models of LN overexpress NGAL in 
response to pathogenic anti-DNA antibodies, and NGAL knock-out mice have 
a less marked renal pathology and improved outcome in autoimmune 
nephritis, suggesting an important role for NGAL in the pathogenesis of LN 
(346). In contrast to sepsis-related studies, it is believed to play a detrimental 
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role in LN by facilitating recruitment of inflammatory cells to the kidney 
through the up regulation of pro-inflammatory mediators (275). Despite the 
strong evidence for its role in LN, surprisingly a significantly elevated 
concentration of urine NGAL in active renal JSLE on this cross sectional 
analysis was not evident. Only one study has reported a similar lack of 
association (347). This lack of association may be that urine NGAL is peaking 
earlier than can be clinically detected using the pBILAG2004 and 
subsequently normalising at the time of disease flare or may be that this 
present cohort was too small or too diverse to provide it justification. To date, 
urine NGAL is the only single biomarker to stand robust longitudinal cohort 
investigation in other paediatric specific cohorts (278, 279) and therefore the 
next step in determining whether urinary NGAL is a robust biomarker in active 
renal JSLE requires longitudinal validation.  
 
Finally, in each of the urine markers assessed, the JSLE patients without 
active renal disease had similar concentrations of the urinary biomarkers to 
healthy controls, suggesting that biomarkers return to a baseline comparable 
to healthy children in the absence of renal inflammation.  
 
The secondary aim of this chapter sought to demonstrate whether patients 
with JSLE active renal disease had differing plasma cytokine profiles when 
compared to patients with JSLE non-active renal disease. Using a selected 
panel of cytokines in a small group of JSLE patients, we have shown a 
significant increase in the plasma concentration of IL-13 and described a 
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trend toward increased concentration of IFN-γ, TNF-α, IL-6 and VEGF in 
patients with active LN.  
 
Despite a small, heterogeneous group, within this cohort of JSLE patients with 
active renal disease, there was a tendency for an increased systemic 
expression of IL-13, IFN-γ, IL-6, TNF-α, and VEGF. In agreement with 
findings from this study, previous studies have also described a significant 
overexpression of IFN-γ in SLE patients who primarily have renal 
manifestations (308, 313). Additionally, others have described the IFN-γ over-
expression and a specific IFN-γ genotype in LN patients that can be 
associated with the amount of leucocyte infiltration and the differing 
histological classes of LN (170, 303, 305). IFN-γ therefore has a leading role 
in the onset of LN. The polarisation of peripheral cells towards a Th1 
phenotype, and thus IFN-γ over-expression, in LN is regulated by the 
presence of IL-12 and IL-18 – two cytokines seen at higher expression in LN 
(304, 308, 311). TLRs located within the kidney are activated and up-
regulated in LN (348), this may lead to the increase in pro-inflammatory 
cytokines, IFN-γ, TNF-α and IL-6, that are shown in this study and is in 
agreement with studies observing TNF-α genetic polymorphisms in patients 
with LN (26, 349).  
 
Surprisingly, this study identified a statistically significant increase in the 
expression of the Th2 cytokine IL-13. The glomerular epithelial cells express 
receptors for IL-13 and its presence is associated with a reduction in the 
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transepithelial electrical resistance (350). It may therefore have a role in 
changing the electrical potential of the glomerular basement membrane during 
active LN. 
 
Increased plasma VEGF that was noted in this study, has been previously 
described in LN patients (332). Interestingly, IL1β is able to increase the 
expression of VEGF, both of which can arise from the glomerular epithelial 
cells and have a key role in maintaining glomerular permeability (351). VEGF 
alters vessel wall permeability facilitating inflammatory cell influx into the 
glomerulus. The increase in IL-13 and VEGF deserve further attention; both 
are likely to have fundamental roles in the onset of proteinuria. 
 
Using a cohort to JSLE patients recruited using the UK JSLE cohort study this 
chapter has identified key differences in the inflammatory profile of the 
plasma. In addition, a group of urinary biomarkers of active LN have been 
identified that may have potential in providing a useful adjunct to determining 
renal involvement in current clinical practice. These can be assessed using 
longitudinal validation (Chapter 4).  
 
Limitations of this work include the cross sectional nature of the study, the 
small cohort size however recruitment was conducted at two different UK 
sites. The JSLE active renal group had a significantly increased disease 
activity at the time of assessment, which may have impacted significantly on 
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results. Regardless of these limitations the increased understanding of these 
biomarkers allows further exploration into their clinical utility. 
 
3.7. Summary 
Childhood-onset SLE is associated with a more active disease course and 
preponderance for LN. LN is difficult to diagnose clinically as current markers 
occur later in the disease process, during which time irreversible damage may 
occur within the renal parenchyma. The renal biopsy is the gold standard in 
diagnosing and classifying LN but disease activity tools are used for 
monitoring purposes. Understanding the systemic pathophysiology of LN and 
identifying early non-invasive methods of detecting impending renal flares are 
particularly attractive, especially in a childhood population. Early inflammatory 
systemic processes, including the elevated systemic IFN-γ and TNF-α 
expression in LN that have been described in this study, and the urine 
biomarkers, especially MCP-1, can provide important insight for further 
investigating the underlying pathophysiology of active LN. In addition they 
may be useful as biomarkers at a given time point or over time and may 
ultimately lead to the identification of more targeted therapies. 
 
 
4. Chapter 4: Longitudinal renal 
biomarkers in JSLE 
 
  171 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  172 
4.1. Longitudinal biomarkers in JSLE: Background 
Understanding changes in JSLE disease activity over time is important, as 
aggressive disease control is essential (352). The earlier recognition of 
increasing disease activity can lead to aggressive monitoring, conversely; 
identifying improvement may allow titration of medications. Urine may provide 
a perfect opportunity for obtaining longitudinal information about the local 
inflammatory response in the kidney in a safe and child-friendly manner (353).  
 
4.2. Aims and Objectives 
Using a longitudinal prospective observational study, the aim of this study was 
to assess the ability of biomarkers, standard and/or novel urinary biomarkers, 
to monitor [predict] changes in JSLE renal disease activity, as defined using 
the renal component of the pBILAG2004, using a cohort of patients attending 
for routine clinical monitoring.  
 
The specific objectives of this study were: 
 Using univariate and multivariate analysis to identify, from episodes 
occurring within the longitudinally recruited cohort, which biomarkers 
are independently associated with active renal disease. 
 To assess whether standard biomarkers of renal disease 
(pBILAG2004, CHAQ score, C3 and C4 concentrations, ESR, WCC, 
lymphocyte count (lymph), neutrophil count (neut), anti-dsDNA, serum 
creatinine (creat), UACR and the eGFR) and/or concentrations of novel 
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urine biomarkers (MCP1, NGAL) are able to monitor disease activity 
over time and predict subsequent improved or worsened renal disease. 
 To assess whether the change in concentration of the novel urine 
biomarkers is associated with improved or worsened renal disease. 
 
4.3. Hypothesis 
Urine biomarkers, MCP1 and NGAL, are able to predict changes in renal 
function and change as the JSLE renal disease activity changes over time.  
 
4.4. Methods 
4.4.1. Patient cohort 
Children participating in the UK JSLE Cohort Study (www.liv.ac.uk/ukjsle) and 
attending follow up at the two largest recruiting centres (Alder Hey Children’s 
NHS Foundation Trust Hospital, Great Ormond Street Hospital for Children 
NHS Foundation Trust) were recruited to this study. Patient eligibility included 
JSLE diagnosed prior to 17 years of age and those patients who had attended 
≥2 clinical reviews with corresponding samples (see section 2.1.1) Patient 
assent/consent and parental consent was obtained and the study had full 
ethical and local research and development approval.  
 
4.4.2. Clinical reviews 
At study entry demographic data, date of diagnosis and the American College 
of Rheumatology (ACR) SLE classification criteria (32) were documented as 
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previously described (2.1.2). At every clinical opportunity, laboratory data, 
clinical disease activity scores and medication use was recorded, in 
accordance with the information routinely collected as part of the UK JSLE 
Cohort Study (34) and descr. Disease activity was routinely assessed 
longitudinally by completion of the paediatric version of BILAG2004. 
Specifically, the BILAG2004 scoring system produces an alphabetical score 
(A-E) to classify the severity of disease activity in each of the organ domains 
and reflects a clinician’s intention to treat the disease (44). A numerical global 
pBILAG2004 score was calculated using each of the domains (see Appendix 
5). All patients were asked to complete a childhood health assessment 
questionnaire (CHAQ) to produce a mean domain score - 0 represents no 
disease related disability and 3 represents severe disability (354-356).  
 
4.4.3. Laboratory techniques 
Urine samples were collected at every clinical opportunity in a sterile universal 
container (as described in 2.2). Microscopic and culture evaluation excluded 
urine infection (see section 3.4.4.1). Samples were centrifuged at 1000g for 
10 minutes and the supernatant was stored at minus 80°C until analysis in 
batches.  
 
Urinary MCP1 (uMCP1) concentrations were quantified using pre-coated 
enzyme-linked immunosorbent assay (ELISA) kits (R&D systems Ltd) as 
described in Table 17. Samples were processed undiluted. Urine NGAL 
(uNGAL) concentrations were measured using the commercially available 
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urine ARCHITECT NGAL assay (Abbott Laboratories, USA; see section 
2.4.4). Urinary creatinine (Cr) concentrations were measured using a pre-
standardised kit at a 1:20 dilution (R&D systems Ltd), see section 2.4.2. 
MCP1 and NGAL results are presented as uncorrected and corrected for 
urine creatinine concentration (biomarker units/mg Cr). All standard laboratory 
markers were measured in the respective local laboratory. 
 
4.4.4. Measured biomarkers 
For the purposes of this study, novel and standard JSLE laboratory disease 
activity markers were all called biomarkers. The biomarkers measured were; 
uMCP1, uNGAL, uMCP1/Cr, uNGAL/Cr, C3 and C4 concentrations; global 
pBILAG2004 score, CHAQ score, ESR, WCC, lymphocyte count, neutrophil 
count, anti-dsDNA titre, creatinine concentration, UACR and eGFR. 
 
4.4.5. Definition of active renal disease 
Clinical review episodes were classed as active renal disease (‘active’) if they 
scored an A or B in the renal pBILAG2004 domain and ‘inactive’ as those 
reviews that scored C, D or E.  
 
4.4.6. Definition of a change in renal disease activity 
To assess whether biomarkers measured at a previous review could predict 
the subsequent renal disease activity at the next clinical review, this 
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subsequent clinical review was classed according to the change in renal 
disease activity (-activity) in the following manner: 
 Improved renal disease: reviews with a change in renal pBILAG2004 
score from a previous A or B to any of C, D or E. 
 Stable renal disease: reviews with no change between episodes in 
renal pBILAG2004 score (regardless of activity). 
 Worsened renal disease: reviews with a change in renal pBILAG2004 
score from a previous C, D or E to either A or B. 
 
4.4.7. Definition of a change in biomarker concentration 
Assessments were made to assess whether biomarkers changed (-
concentration) with -activity. Biomarker -concentration was calculated as 
the follow up episode (second) biomarker concentration subtracted from the 
initial episode (first), expressed as a percentage of the first episode  - a 
negative value therefore indicated biomarker improvement (decrease over 
time) and positive value represented worsening biomarker concentration 
(increase over time).  
 
4.4.8. Statistical analysis 
Demographic data were descriptive and following Shapiro Wilk testing and Q-
Q plots (as discussed in section 2.6) were not normally distributed and as 
such were expressed as percentages or median values with interquartile 
ranges (median, IQR). The assumption was made that reviews and laboratory 
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markers were independent of each other. Univariate analysis was used to 
assess whether biomarkers were related to renal disease activity using non-
parametric testing (Mann-Whitney U). 
 
Multivariate linear regression analysis was used to determine which 
biomarkers were independent predictors of JSLE active renal disease (the 
model outcome). A stepwise approach was undertaken eliminating variables 
that least demonstrated a relationship with the outcome until all remaining 
variables demonstrated statistical significance. Only values independent of 
the renal disease activity classification and with a p<0.1 on univariate analysis 
were entered into the model. Values that were not normally distributed 
(assessed using Shapiro Wilk test and Q-Q plots) were log transformed to 
produce normality for the statistical model. The results are presented as 
coefficient beta () values and 95% confidence intervals (95% CI). The model 
was able to calculate the influence of the model outcome (renal disease 
activity) per unit change of the significant variables (biomarkers). The model 
results are presented with R squared value (R2), which defines how the actual 
values compare to the mean, the model F-statistic value (F), the degrees of 
freedom associated with the sources of variance (dF) and a statistical 
probability value (p) (357, 358). 
 
Receiver operating characteristic (ROC) curves determined area under the 
curve (AUC) values. AUC values of 1.0-0.9, 0.9-0.8, 0.8-0.7, 0.7-0.6, 0.6-0.5 
were considered outstanding, excellent, good, fair, poor respectively and 
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presented with 95% confidence intervals (CI). The optimal biomarker 
concentrations were identified using the sensitivity and specificity parameters 
and Chi square (X2, dF) analysis was used to assess whether biomarkers 
above the threshold could distinguish between -activity.  
 
All statistical analysis was performed using Statistics Package for Social 
Sciences (SPSS Ltd, USA) version 20.0. Graphical illustrations used Graph 
Pad Prism version 5 (Graph Pad software Inc, USA). P values p<0.05 were 
considered statistically significant throughout. 
 
4.5. Results 
4.5.1. Patient cohort 
Sixty-four JSLE patients were recruited to this study. JSLE patients were 
diagnosed aged 11.3 years (range 1.8-16.88; IQR 7.99-13.3) and female 
patients made up 79.7% (51/64) of this cohort. At the time of study entry the 
median age of the JSLE cohort was 14.1 years (range 2.84-17.96; IQR 11.8-
15.8). The median disease duration at the time of study entry was 2.04 years 
(IQR 0.92-4.21) with a median ACR SLE classification score at latest review 
of 5 (IQR 4-6). Caucasian patients made up the numerical majority of the 
cohort and the ethnic variation consisted of; Caucasian 50% (32/64), Black 
African 14% (9/64), Indian 9% (6/64), Caribbean 8% (5/64), Asian 6% (4/64), 
Bangladeshi 4% (3/64), Mixed race 3% (2/64), Chinese 2% (1/64) and other 
white race 2% (1/64).  
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4.5.2. Clinical reviews 
The median study follow up period was 364 days (IQR 182-532 days) and the 
study captured 229 clinical reviews giving a median of 3 (IQR 2-5) reviews per 
patient. The 64 patients seen on a total of 229 clinical reviews had a median 
time between reviews of 112 days (IQR 70-182 days). Table 19 summarises 
the demographic data of the JSLE longitudinal cohort. 
 
The study cohort episodes consisted of a range of renal disease activity 
(Score A=3 (1%) reviews, B=50 (22%), C=52 (23%), D=99 (43%), E=25 
(11%)). Fifty-three reviews (23%) were classed as having JSLE active renal 
disease and 176 (77%) were classed as being inactive. JSLE patients were 
on a variety of medications during the reviews, Table 20. 
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Table 19: Longitudinal observational study: demographic data  
Demographic data, including age, ethinicity and follow up information, for the 
participants recruited to the longitudinal observational biomarker study. 
 
Demographic Number  
 Participants 64 
 Sex (female) 51 (79.7%) 
 Median age (diagnosis) 11.3 years (IQR 7.9-13.3) 
 Median age (study entry) 14.1 years (IQR 11.8-15.8) 
 Disease duration 2.04 years (IQR 0.9-4.2) 
 ACR SLE classification criteria 5 (IQR 4-6) 
 Median follow up 364 days (IQR 182-532) 
 Number of clinical episodes 3 (range 2-5) 
 Time between episodes  112 days (IQR 70-182) 
 Caucasian 32 (50%) 
 Black African 9 (14%) 
 Indian  6 (9%) 
 Caribbean 5 (8%) 
 Asian  4 (6%) 
 Bangladeshi 3 (4%) 
 Mixed race 2 (3%) 
 Chinese 1 (2%) 
 Other white  1 (2%) 
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Table 20: Longitudinal observational study: medication use 
The medications being taken at each of the clinical episodes included in this 
biomarker study. 
Medication 
Number of 
reviews (%) 
Hydroxychloroquine 178 (78) 
Mycophenolate mofetil 101 (44) 
Azathioprine 62 (27) 
Cyclophosphamide 3 (1) 
Methotrexate 17 (8) 
Intravenous 
methylprednisolone 
36 (16) 
Prednisolone 139 (61) 
Rituximab 15 (7) 
Diuretics 3 (16) 
Calcium channel blockers 20 (9) 
ARB and/or ACEi 25 (11) 
Aspirin 6 (3) 
IVIG 14 (6) 
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4.5.3. Monitoring renal disease using biomarkers 
Table 21 presents the concentration (median, IQR) of each of the biomarkers 
for active and non-active renal disease. Using univariate analysis many of the 
biomarkers were significantly increased in clinical reviews classed as active 
renal disease. Clinical review episodes associated with active renal disease 
had a statistically significantly higher uMCP1 and uNGAL concentrations, 
uMCP1/Cr and uNGAL/Cr ratios, global pBILAG2004 score, ESR, anti-dsDNA 
titres, UACR and creatinine concentrations and a statistically significant 
reduction in the C3 and C4 concentration and lymphocyte count. 
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Table 21: Longitudinal observational study: Standard and novel urine biomarkers  
Univariate analysis was undertaken assessing the association of the standard and novel urine biomarkers during all of the clinical 
episodes (longitudinal) in those patients with active and inactive renal disease. 
Disease activity marker 
Active Renal disease median 
concentration (IQR) 
Inactive Renal disease 
median concentration (IQR)  
p value 
uMCP1 pg/ml 260 (98.5-618.5) 172 (71.9-309) p<0.001** 
uNGAL ng/ml 34 (15.4-52.6) 22.2 (12.2-52.9) p=0.001** 
uMCP1/Cr pg/mg Cr 276.9 (81-649.3) 153.8 (38.2-284.1) p=0.006** 
uNGAL/Cr ng/mg Cr 28.5 (14.1-76.3) 16.5 (6.2-38.9) p=0.020* 
Global pBILAG2004 score 4 (3-8) 1 (1-3) p<0.001** 
CHAQ score 0 (0-1.2) 0.13 (0-0.66) p=0.516 
C3 g/L 0.85 (0.63-1.11) 1.12 (0.94-1.35) p<0.001** 
C4 g/L 0.14 (0.11-0.17) 0.16 (0.12-0.24 p=0.009** 
ESR mm/hr 5 (3-36.5) 10 (3-21) p=0.018* 
WCC x109/L 6.01 (4.7-8.0) 5.9 (4.3-8.0) p=0.158 
Lymph x109/L 1.06 (0.74-1.92) 1.52 (1.04-2.04) p=0.001** 
Neut x109/L 4.26 (2.85-5.4) 3.46 (2.4-6.0) p=0.684 
Anti-dsDNA IU/L 28 (0.95-87) 0 (0-17) p<0.001** 
UACR mg/mmol 10.9 (1.7-38.2) 1 (0.7-1.7) p<0.001** 
Creatinine umol/L 67 (60-85) 61 (54-64) p=0.026* 
eGFR ml/min/m2 107.8 (102.6-122.9) 113.9 (104.6-123.8) p=0.085 
*p<0.05; **p<0.01 
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Multivariate linear regression analysis excluded variables with a p value >0.10 
on univariate analysis (CHAQ score, WCC and neutrophil count). The only 
variables not independent to the model outcome were global pBILAG2004 
score and UACR as they are both directly included in the renal domain of the 
pBILAG2004. The analysis demonstrated that MCP1 ( 0.183, 95% CI 0.60-
0.305; p=0.004) and C3 ( -0.459, 95% CI -0.663-0.254; p<0.001) were the 
only biomarkers to remain statistically significant as independent predictors of 
active renal disease.  
 
The multivariate model demonstrated that 18.1% of the overall renal disease 
activity could statistically significantly be explained by the contribution of these 
two variables (R2 0.181, F 18.8, F 2-170, p<0.001). 
 
Spearmans correlation analysis demonstrated that MCP1 was not related to 
urine protein concentrations (UACR) with a correlation coefficient of 0.07, 
p=0.35 however NGAL did demonstrate a relationship with the UACR, 
coefficient 0.18, p=0.02. 
 
4.5.4. Predicting renal disease activity using biomarkers 
ROC curve analysis was used to assess whether biomarkers measured at the 
previous clinical review could predict the subsequent improved or worsened 
renal disease activity.  
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Urine MCP1 was the only biomarker that could statistically significantly 
(p=0.013) predict improved renal disease with an excellent AUC value (0.81).  
Urine NGAL was the only predictor of worsened renal disease with good AUC 
value (0.76) and reaching statistical significance (p=0.03; Table 22). The urine 
albumin:creatinine ratio (UACR) did not demonstrate a relationship with 
changing disease activity over time with a AUC value of 0.54 (0.29-0.79; 
p=0.77) with improving disease and an AUC value of 0.46 (0.19-0.65; p=0.76) 
with worsening disease activity. Therefore UACR did not track changes in 
disease activity. Other biomarkers also could not predict subsequent 
improved or worsened renal disease activity. 
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Table 22: Novel and standard biomarker area under the curve (AUC) values. 
The area under the curve (AUC) for the novel (with and without creatinine correction) and standard biomarkers are demonstrated 
along with their statistical ability to determine subsequent improved or worsened renal disease activity, demonstrating that only 
uMCP1 could statistically significantly predict improved renal disease and only uNGAL could predict worsened renal disease.  
Disease activity 
marker 
Improved renal disease Worsened renal disease 
Area under curve 
(AUC) 
95% confidence 
interval p value Area under curve (AUC) 95% confidence interval p value 
uMCP1 pg/ml 0.81 0.58-1.0 p=0.013* 0.69 0.43-0.95 p=0.12 
uNGAL ng/ml 0.56 0.32-0.80 p=0.63 0.76 0.55-0.96 p=0.04* 
uMCP1/Cr pg/mg Cr 0.55 0.39-0.64 p=0.85 0.56 0.40-0.71 p=0.44 
uNGAL/Cr ng/mg Cr 0.52 0.39-0.65 p=0.73 0.64 0.50-0.78 p=0.05 
C3 g/L 0.29 0.15-0.44 p=0.1 0.5 0.33-0.67 p=1.0 
C4 g/L 0.29 0.11-0.47 p=0.1 0.51 0.29-0.73 p=0.96 
ESR mm/hr 0.46 0.22-0.70 p=0.74 0.42 0.19-0.65 p=0.52 
WCC x109/L 0.24 0.10-0.38 p=0.06 0.39 0.21-0.58 p=0.39 
Lymph x109/L 0.35 0.10-0.61 p=0.24 0.31 0.003-0.61 p=0.12 
Neut x109/L 0.33 0.20-0.46 p=0.46 0.49 0.34-0.64 p=0.95 
Anti-dsDNA IU/L 0.55 0.29-0.82 p=0.69 0.44 0.19-0.69 p=0.62 
UACR mg/mmol 0.54 0.29-0.79 p=0.77 0.46 0.19-0.65 p=0.76 
Creatinine umol/L 0.51 0.33-0.69 p=0.90 0.52 0.37-0.67 p=0.79 
eGFR ml/min/m2 0.5 0.24-0.75 p=0.98 0.54 0.26-0.82 p=0.75 
*p<0.05; **p<0.01 
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AUC 0.81, p=0.013 AUC 0.76, p=0.04 
Figure 26: Receiver operating characteristic curves for the urine concentrations of MCP1 (a), NGAL (b) and 
subsequent improved or worsened renal disease activity. 
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Using ROC curve analysis and specificity and sensitivity values, optimal 
thresholds for MCP1 and improved renal disease and NGAL and worsened 
renal disease activity were selected. The optimal MCP1 concentration was at 
343.3 pg/ml (sensitivity 70%, specificity 71%), below which predicted 
improved renal disease activity over time. The optimal threshold value 
identified for urine NGAL concentrations was 30 ng/ml (sensitivity 61%, 
specificity 60%), above which predicted worsened renal disease activity over 
time. Chi squared analysis confirmed that the biomarker value at these 
thresholds at the earlier review could statistically significantly distinguish 
between subsequent improved, stable or worsened clinical reviews (MCP1 
X2=18.4, df=2, p<0.001; NGAL X2=9.7, df=2, p=0.008). 
 
4.5.5. Change in renal disease activity and change in biomarkers 
The relationship of MCP1 and NGAL with predicting JSLE renal disease 
activity was further confirmed by comparing the change in biomarker 
concentration (-concentration) with the change in the JSLE renal disease 
activity over time (-activity). There were 165 assessments of -activity: 24 
(14%) improved, 123 (75%) stable and 18 (11%) worsened over time. 
 
In reviews classed as improved -activity the -concentration of urine MCP1 (-
55%, IQR -90-39%) and the -concentration urine NGAL (-48%, IQR -79-
34%) decreased. In reviews classed as stable, there was an overall trend 
toward decrease in -concentration of both urine MCP1 (-24%, IQR -77-68%) 
and NGAL (-10%, IQR -63-46%). Reviews with worsened -activity had an 
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increase in -concentration of urine MCP1 (9%, IQR -40-262%) and urine 
NGAL (15%, IQR -5-230%). The -concentration of either urine MCP1 or 
NGAL was statistically significantly able to distinguish between reviews with 
improved or worsened renal disease activity as seen in Figure 27. 
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Figure 27: Change in disease activity and relationship with biomarkers MCP1 and NGAL. 
A Turkey box-and-whisker plot demonstrating the change in disease activity (-activity) and its relationship to the -concentration of 
urine MCP1 (a) and urinary NGAL (b). The line within the box represents the median and whiskers represent interquartile range.  
  191 
 
4.6. Discussion 
Using a prospective longitudinal cohort of patients recruited to the UK JSLE 
cohort study, the aim of this study was to identify biomarkers that 
demonstrated clinical utility longitudinally for monitoring and predicting JSLE 
renal disease activity in a real-world setting. This study cohort, representing a 
large unselected JSLE population reviewed on 3 (2-5) occasions over a 1-year 
follow-up period, has demonstrated that the measurement of MCP1 and C3 
are independent markers for monitoring renal disease activity and MCP1 and 
NGAL are able to predict subsequent changes in renal disease activity.  
 
LN is a complex immune mediated process. As such many laboratory markers 
can be associated with active disease. This is well demonstrated in this 
present study’s univariate analysis that include all clinical episodes recorded 
for this longitudinal analysis. This provides challenges for clinical monitoring, 
as standard disease activity markers are significantly influenced by each other 
and by the disease process. Following multivariate analysis, this study has 
demonstrated that MCP1 and C3 have great potential in their ability to 
independently identify active renal disease. There are a number of published 
reports describing the association of urine MCP1 with renal disease activity in 
LN (272, 302, 359) but none demonstrating its strength longitudinally. The 
finding of MCP1 as an independent marker of disease activity may be due to 
its key chemotactic role within the glomerulus during inflammation (360) and 
the identification of a reduction in MCP1 correlating with improving renal 
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disease over time may be signalling the termination in the inflammatory cell 
influx that is characteristic of LN. Serum C3 has previously been shown to 
relate to disease activity in LN (248, 278, 361). IFN-α – the prototypical SLE 
cytokine – will lead to the up regulation of C3 from the renal mesangial cells 
(362), the contribution of direct renal expression of C3 into the circulation may 
explain to its strong association with active LN.  
 
Predicting renal disease at an earlier time point than is currently available is 
critical to earlier intervention and more effective titration of medication. This 
study has demonstrated that MCP1 and NGAL measured at an earlier clinical 
review are able to accurately predict subsequent improved and worsened renal 
disease activity at subsequent follow up with excellent and good AUC values 
respectively. This was further confirmed by the strong correlation between the 
change in biomarker concentration and change in disease activity. This study 
is the first to report the strength of MCP1 in predicting improving renal disease 
activity over time, an important discovery that could be utilized to tailor 
management. NGAL, in addition to its strengths in monitoring LN (276, 278, 
363) and its links to histological features (359), has a clear role in predicting 
future renal flares. This study’s findings corroborate those of Hinze et al, who 
reported an AUC of 0.80 in NGAL predicting LN flares with a mean increase in 
the concentration of NGAL of 104% (279); NGAL therefore represents a good 
predictive biomarker in LN. Differences between studies in the percentage 
increase of NGAL may be due to the patient populations selected for the 
studies - an unselected population, such as as in this present study will 
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demonstrate the clinical utility in a ‘real-world’ setting, an important part of any 
validation process. 
 
Interestingly, in this study a stronger relationship between active renal disease 
and novel biomarkers was found using values uncorrected for urine creatinine 
concentration. Creatinine correction of renal biomarkers remains debatable; 
altered glomerular filtration and renal tubular reabsorption may occur in LN 
(364, 365); however these biomarkers can be directly excreted from the kidney 
and the contribution of filtration and reabsorption of them is not yet fully 
understood. Further studies in this area are required and the use of both 
methods is still recommended. 
 
With the emergence of an increasing number of studies supporting the role of 
urinary biomarkers in LN, large prospective validation studies like this one are 
important, along with studies to define normal ranges and disease defining 
thresholds. Collaboration with industry will allow the development of real-time, 
point of care testing. Biomarker-led management regimes can then be studied 
to determine whether interventions assist in reducing the renal related 
morbidity over time.  
 
Limitations of this longitudinal study include its size, combined with a relatively 
short follow-up period. Due to the lack of independence with our classification 
categories, it was necessary to exclude the global BILAG score and proteinuria 
from our multivariate modelling analysis (358). Therefore it is not possible to 
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conclude whether these factors are independent variables in disease 
monitoring. A more accurate method of assessing data over a longitudinal 
period would be to include all variables and use random effects statistical 
modelling. Proteinuria is well known to be a useful indicator in the identification 
of more severe LN histological classes (359), however the occurrence of 
chronic persistent proteinuria in non-active disease may limit its potential (145) 
but further analysis would be required to exclude it as a useful monitoring 
marker. 
 
4.7. Summary  
In summary, this study has demonstrated the longitudinal utility of renal 
biomarkers in monitoring JSLE is feasible. As JSLE patients have more renal 
involvement, more active disease, a high treatment burden and a worse long-
term outlook, a move toward MCP1- and NGAL-guided renal follow-up regimes 
may be a cost-effective way to improve the eventual clinical outcome. 
Understanding the origin of these biomarkers and whether they are 
representing direct renal inflammation is the key to identifying potential 
therapeutic targets for LN. 
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5. Chapter 5: Renal biomarkers and the 
podocyte 
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5.1. Renal biomarkers and the podocyte: Background 
Urinary biomarkers are able to distinguish patients with active LN from those 
with inactive renal disease, and include MCP1 and NGAL that we have 
previously described (Chapters 3, 4). Understanding the mechanisms of their 
action within the kidney, and in particular the podocyte, may lead to the 
identification of novel potential therapeutic targets.  
 
5.2. Aims and objectives 
The aim of this study is to determine whether the human podocyte expresses 
the biomarkers MCP1 and NGAL and to assess whether their expression is 
increased in patients with active LN using an in vitro model.  
 
The specific objectives of this chapter are; 
1. To assess whether the podocyte expresses MCP-1 and/or NGAL in 
response to macrophage media and whether its expression is increased 
in response to activated macrophage media. 
2. To assess whether the podocyte up regulates MCP-1 and/or NGAL in 
response to the pro-inflammatory cytokine TNF-. 
3. To assess whether inhibition of TNF- in the macrophage media 
reduces the podocyte expression of MCP-1 and/or NGAL. 
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5.3. Hypothesis 
The human podocyte is able to express MCP-1 and NGAL and their 
expression is up regulated in active LN. 
 
5.4. Methods 
An in vitro model of lupus glomerulonephritis was designed and developed as 
part of this study using human monocyte-derived macrophages and a human 
podocyte line, as previously described in chapter 2 (section 2.4). 
 
5.4.1. Human macrophage culture 
In brief, human monocytes were isolated using magnetic cell sorting (Miltenyi 
Biotech, USA) and seeded. Monocytes were differentiated into macrophages 
using media containing monocyte colony stimulating factor (M-CSF; Sigma-
Aldrich, UK) and were incubated at 37°C in 5% CO2 for 6 days. Media was 
removed, cells washed twice and then exposed to either RPMI alone (inactive 
cells) or RPMI containing IFN-γ (Peprotech EC Ltd, UK) at a concentration of 
1ng/ml (active cells). After 48 hours of incubation the media from the 
macrophage cells was removed, centrifuged and stored at minus -70°C until 
use. 
 
5.4.2. Human podocyte cell line  
A human podocyte cell line was established using cells as described in full in 
chapter 2 (section 2.5.2). Podocytes were seeded and placed at 33°C in 5% 
CO2 until they reached 60% confluence. Cells were thermo switched to 37°C in 
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5% CO2 for 10-14 days to allow terminal differentiation. Podocyte media was 
used and replaced every 3-4 days. Prior to the experimental conditions the 
cells were washed twice with PBS.  
 
5.4.2.1. Podocyte gene and protein analysis 
Podocyte media was extracted and frozen at -70°C following the experimental 
conditions for later analysis of the biomarker protein concentration. Cell 
supernatant protein concentrations were measured using ELISA techniques. 
MCP-1 ELISA (R&D systems Ltd, USA) and NGAL ELISA (R&D systems Ltd, 
USA) required media dilutions 50 or 100-fold. 
 
Podocytes were extracted using a lysis extraction buffer and the scraped cells 
were centrifuged. The supernatant served as the intracellular protein and the 
RNA was extracted. Samples were stored at -70°C until analysis. Following 
conversion to cDNA, real time PCR was performed. All reactions were 
performed according to the manufacturers instructions and all samples were 
measured in duplicate. The mRNA content was normalised to 18s. All 
experiments used podocytes between passage number 10-24, performed in 
duplicate and experiments were repeated ≥3 times. 
 
5.4.3. The effect of macrophage media on podocyte biomarkers 
5.4.3.1. Biomarker protein expression in macrophage media  
Macrophage media (750uL) obtained following 48 hours of either no activation 
(RPMI media only; termed “inactive” condition) or activation (RPMI media with 
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IFN-γ; termed “active” condition) was tested for MCP-1 and NGAL protein 
concentration to identify whether the macrophages alone expressed these 
markers.  
 
5.4.3.2. Podocyte biomarker expression in response to IFNγ media  
Podocytes exposed to IFN-γ (1 ng) alone for 48 hours served as a positive 
control to enable the comparison of IFN-γ media alone against the media from 
IFN-γ activated macrophages. 
 
5.4.3.3. Podocyte biomarker expression in response to macrophage 
media 
The macrophage media (both inactive and active conditioned) was then placed 
on the mature podocytes and the podocytes cultured for 48 hours. The 
podocyte RNA and protein were extracted using methods described earlier 
(sections 2.5.4) and MCP-1/NGAL measured as appropriate.  
 
To confirm the findings of the podocyte response to the macrophage media 
conditions, the podocyte intracellular protein was extracted and measured for 
MCP-1 using Western blot techniques with beta actin used as the loading 
control (see section 2.4.5 for the Western blot technique). 
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5.4.3.4.  The effect of TNF on the podocyte expression of 
biomarkers 
To assess the podocyte expression of MCP-1 and NGAL in response to TNF-α 
the cells were exposed to the following experimental conditions: 
 Dose response: Cultured in media to which recombinant TNF-α (see 
section 2.5.2) was added for 48 hours at a 10-fold dilution ranging from 
10pg/ml-10ng/ml. 
 Time response: Cultured in media to which recombinant TNF-α was 
added for 2, 4, 6, 8, 12, 24, 72 and 96 hours respectively at a 
concentration of 1000pg/ml. 
 
Podocytes cultured within normal media for 48 hours acted as an experimental 
control condition (denoted as ‘normal podocytes’ throughout).  
 
5.4.3.5. Inhibiting TNF in the activated macrophage media 
In order to determine whether the podocyte expression of MCP-1 and / or 
NGAL was directly related to TNF-α exposure, the cells were subsequently 
incubated with activated macrophage media for 48 hours with the addition this 
time of a neutralising human anti-TNF-α polyclonal antibody (R&D Systems 
Ltd, USA). Anti-TNF-α antibody was added to the activated macrophage media 
for 60 minutes prior to the media being placed on the cells for 48 hours. The 
experimental conditions were:  
 Activated macrophage media 
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 Activated macrophage media plus anti-TNF-α antibody at 1ug/ml 
 Activated macrophage media plus anti-TNF-α antibody at 0.5ug/ml  
 
5.4.4. Statistical analysis  
Graph pad Prism version 5 software was used to produce graphical 
illustrations (GraphPad software, Inc, USA) and statistical analysis was 
performed using Statistics Programme for Social Sciences version 20.0 (IBM 
Corporation, USA). Results are presented as mean values with SEM and 
statistical comparisons between two groups utilised the student t test. A 
statistically significant difference was taken as a probability (p) value of less 
than 0.05 and statistically significant differences are displayed on graphical 
illustrations. The number of experimental repeats is stated with each of the 
results and denoted as n. 
 
5.5. Results 
5.5.1. Biomarker expression in macrophage media  
The macrophage media (inactive and active) were tested for MCP-1 and NGAL 
protein concentration to identify whether macrophages expressed biomarkers 
(active macrophages were already known to increase TNF-α expression, see 
section 2.4.9.2.2). MCP-1 protein expression in the macrophage media was 
increased in the active macrophage media (n=7; 6.0+2.3ng/ml) when 
compared to the inactive macrophage media (n=6; 3.5+1.5ng/ml; p=0.42) 
although this was not statistically significant. NGAL expression was not 
statistically significantly different between the inactive (n=3; 141+122ng/ml) 
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and active media (n=3; 0+0ng/ml; p=0.2) concentrations. The raw data can be 
seen in Appendix 26, Appendix 27. 
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Figure 28: Biomarker concentration in macrophages. 
The biomarker concentration of MCP1 (a) and NGAL (b) was measured in the macrophage media following activation with 1 ng/ml of 
interferon gamma for 48 hours (active mΦ) and compared to macrophages in RPMI media (inactive mΦ) showing no statistically 
significant difference in the biomarker concentration.  
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5.5.2. Podocyte cell biomarker expression in response to IFN-γ media  
Media to which IFN-γ was added alone exposed to podocytes for 48 hours 
served as a positive control, demonstrating that podocytes increased the 
mRNA gene expression of MCP-1 in response to IFN-γ (n=4; 3.3+1.1x10-3) 
when compared to normal cell conditions (n=4; 2.0+0.5x10-5; p=0.02). The 
protein expression however was not significantly different (IFN-γ n=3; 
38.6+3.2ng/ml; normal n=6; 41.2+10.2ng/ml; p=0.87), Figure 29.  
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Figure 29: MCP-1 in podocytes exposed to interferon gamma. 
The gene (a) and protein (b) concentration of monocyte chemoattractant protein-1 (MCP-1) was measured in podocytes that were 
exposed to interferon (IFN) gamma at 1 ng/ml for 48 hours and compared to cells cultured in normal conditions. This demonstrated a 
statistically significant up regulation in the gene expression of MCP-1 (p=0.02) however no difference in the protein concentration.   
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Podocytes exposed to IFN-γ media demonstrated an increase in the gene 
expression of NGAL (n=4; 2.8+0.9x10-2) when compared to normal cell 
conditions, although this difference was not statistically significant (n=3; 
1.7+0.8x10-2; p=0.42). However, NGAL protein expression was significantly 
increased when podocytes were exposed to IFN-γ (n=3; 194.5+98.1ug/ml) 
compared to normal conditions (n=5; 0.18+0.04ug/ml; p=0.04), Figure 30. 
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Figure 30: NGAL in podocytes exposed to interferon gamma. 
The gene (a) and protein (b) concentration of neutrophil gelatinase associated lipocalin (NGAL) was measured in podocytes that were 
exposed to interferon (IFN) gamma at 1 ng/ml for 48 hours and compared to cells cultured in normal conditions. This demonstrated a 
statistically significant up regulation in the protein concentration of NGAL (p=0.04) however no difference in the gene expression.  
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5.5.3. Podocyte biomarker expression in response to macrophage media 
The podocytes exposed to active macrophage media for 48 hours 
demonstrated a strongly statistically significant up regulation of the gene 
expression of MCP-1 (n=3; 8.9+0.8x10-2) when compared to inactive media 
(n=3; 1.3+0.5x10-2; p=0.0012) or normal control conditions (n=4; 19+5.1x10-8; 
p<0.0001). Inactive macrophages also significantly up regulated MCP-1 gene 
expression when compared to normal cell conditions (p=0.03) as shown in 
Figure 31.   
 
The protein expression of MCP-1 demonstrated a slightly different pattern as 
the inactive macrophage media (n=3; 27.3+3.3ng/ml) significantly reduced the 
production of MCP-1 when compared to active macrophage media (n=3; 
40.9+2.9ng/ml; p=0.04) and there was no significant difference between the 
MCP-1 expression in active media compared to normal conditions (n=3; 
38.6+3.2ng/ml; p=0.62, see Figure 31, raw data in Appendix 32, Appendix 33. 
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Figure 31: The podocyte gene and protein expression of MCP1 in cells exposed to macrophage media 
The gene (a) and protein (b) expression of MCP1 in podocytes under control conditions (‘normal’), exposure to inactive macrophage 
(mϕ) media and active macrophage media for 48 hours showing a significant upregulation in the active macrophage media condition. 
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Using Western blot analysis, MCP-1 intracellular protein was measured in 
response to active macrophages. This demonstrated similar findings to the 
media protein with a down regulation of MCP-1 in response to inactive 
macrophages compared to normal conditions. Additionally, an up regulation of 
MCP-1 in response to active macrophages was seen in Figure 32.  
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Figure 32: Protein expression of MCP1 in podocytes exposed to macrophage media 
Western blot illustrations showing an increase in the protein expression of MCP1 in podocytes exposed to active macrophage media. 
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The podocytes exposed to either inactive or active macrophage media did not 
demonstrate any statistically significant difference in NGAL gene or protein 
expression when compared to normal conditions as shown in Figure 33. The 
mean relative gene expression of NGAL in normal podocyte cells was 
2.0+0.8x10-2 (n=3), in podocytes exposed to inactive macrophage media it was 
1.6x10-4+8.0x10-9 (n=3) and in cells exposed to active media the gene 
expression was 1.0+0.6x10-2 (n=5). The mean protein expression of NGAL in 
normal podocytes was 180.2+38.6ng/ml (n=5), inactive media 
214.2+35.8ng/ml (n=3) and active media 205.2+66.2ng/ml (n=3). The raw data 
can be viewed in Appendix 34 and Appendix 35.  
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Figure 33: Podocyte gene and protein expression of NGAL in response to macrophage media 
The podocyte gene and protein expression of NGAL in control conditions, inactive macrophage (mϕ) media and active macrophage 
media showing no significant difference between the conditions.  
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5.5.4. The effect of TNF on the podocyte expression of biomarkers  
5.5.4.1. The dose response of TNFα on podocyte biomarker 
expression 
Podocytes were exposed to TNF-α to assess whether the expression of MCP-
1 or NGAL were influenced by this cytokine.  
 
The podocyte MCP-1 expression demonstrated a clear positive relationship 
with increasing TNF-α concentration. The mean MCP-1 gene expression in the 
experimental conditions compared to normal control conditions was 
19+5.1x10-6 (n=4), with TNF-α at a concentration of 10pg/ml the MCP-1 gene 
expression was 3.4+1.8x10-5 (n=3; p=0.41), at TNF-α 100pg/ml it was 
5.7+1.0x10-5 (n=5; p=0.02), at TNF-α 1000pg/ml it was 9.8+2.4x10-5 (n=4; 
p=0.02) and at TNF-α concentration of 10ng/ml MCP-1 gene expression was 
2.2+0.31x10-4 (n=3; p=0.0007). This increase reached statistical significance at 
concentrations of 100pg/ml, 1000pg/ml and 10ng/ml of TNF-α (Figure 34). 
 
The protein concentration of MCP-1 also demonstrated an increasing trend 
with increasing TNFα concentration, reaching statistical significance at 
1000pg/ml as shown in Figure 34, raw data Appendix 36, Appendix 37. The 
mean protein concentration of MCP-1 in the experimental conditions compared 
to the normal condition was: normal 68.5+16.4ng/ml (n=5), TNF-α 10pg/ml 
126.2+51.5 (n=4; p=0.28), TNF-α 100pg/ml 141.6+42.4ng/ml (n=4; p=0.12), 
TNF-α 1000pg/ml 333.7+110.8 (n=5; p=0.045) and TNF-α 10ng/ml 
257.3+127.7 (n=7; p=0.25).  
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Figure 34: Podocyte gene and protein expression of MCP1 in response to increasing concentration of TNFα 
The podocyte gene and protein expression of MCP1 in response to increasing dose exposure of TNFα showing a statistically 
significant increase with increasing concentration (p<0.05 considered statistically significant). 
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The gene and protein expression of NGAL demonstrated no relationship with 
increasing TNF-α. The mean gene expression of NGAL was no different 
between experimental conditions and normal podocyte cells: normal conditions 
it was 1.7+0.8x10-2 (n=3); at TNF-α 10pg/ml it was 2.6+0.6x10-2 (n=3; p=0.44); 
at TNF-α 100pg/ml it was 5.3+1.3x10-2 (n=3; p=0.08); at TNF-α 1000pg/ml it 
was 2.8+0.8x10-2 (n=3; p=0.39); and at a TNF-α concentration of 10ng/ml the 
NGAL mRNA expression of NGAL was 3.9+1.5x10-2 (n=4; p=0.30). The 
protein expression showed a similar pattern:  normal conditions it was 
180.2+38.6ng/ml (n=5); at TNF-α 10pg/ml it was 88.4+41.5ng/ml (n=3; 
p=0.18); at TNF-α 100pg/ml it was 66.5+33.4ng/ml (n=5; p=0.06); at TNF-α 
1000pg/ml it was 109.6+49.3ng/ml (n=5; p=0.29); and at TNF-α concentration 
of 10ng/ml the NGAL protein concentration was measured at 113.2+50.3ng/ml 
(n=4; p=0.32). See Appendix 38, Appendix 39 for raw data. 
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Figure 35: Podocyte gene and protein expression of NGAL following exposure to increasing concentration of TNFα 
The podocyte gene and protein expression following increasing exposure of TNFα concentration, demonstrating no significant 
difference in NGAL gene (a) or protein (b) expression over time. 
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5.5.4.2. The time response of TNFα on podocyte biomarker 
expression 
The podocytes were measured for their gene and protein expression of the 
biomarkers following exposure to TNF- over different time points.  
 
The podocyte MCP1 gene and protein expression demonstrated a direct 
relationship with the time exposured to TNF as seen in Figure 36. The 
podocyte gene expression of MCP1 reached a statistically significant increase 
as soon as 6 hours after TNF exposure when compared to the normal cell 
conditions, this gene up regulation continued up until 72 hours of TNF 
exposure. The normal cells expressed a MCP1 gene expression of 
1.9+0.5x10-5 (n=4) compared to 2 hours of TNF exposure with a gene 
expression of 2.7+2.5x10-2 (n=4; p=0.33); 4 hours of TNF 8.3+4.2x10-4 (n=4; 
p=0.10); 6 hours of TNF 4.4+1.6x10-3 (n=3; p=0.02); 8 hours of TNF 
1.2+0.08x10-3 (n=4; p<0.0001); 12 hours 2.6+1.0x10-2 (n=4; p=0.04); 24 hours 
2.3+0.9x10-3 (n=4; p=0.05); 72 hours 6.3+1.8x10-3 (n=4; p=0.01); and after 96 
hours of TNF exposure the gene expression was 1.5+0.8x10-2 (n=5; p=0.15). 
 
The protein expression of MCP1 also demonstrated a direct relationship with 
TNF exposure showing a significant up regulation after 24 hours of TNF 
exposure, which continued to 96 hours as seen in Figure 36. The normal cells 
expressed a MCP1 protein concentration of 38.6+3.2 ng/ml (n=3), after 2 
hours of TNF exposure 25.4+14.6 ng/ml (n=4; p=0.48); 4 hours 16.9+7.3 
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ng/ml (n=4; p=0.06); 6 hours 51.6+23.6 ng/ml (n=4; p=0.66); 8 hours 45.9+7.0 
ng/ml (n=4; p=0.44); 12 hours 160.7+69.6 ng/ml (n=4; p=0.20); 24 hours 
301.8+80.5 ng/ml (n=4; p=0.04); 72 hours 821.8+150.9 ng/ml (n=4; p=0.007); 
and after 96 hours of TNF the protein expression of MCP1 was 1140+46.2 
ng/ml (n=4; p<0.0001). See Appendix 40, Appendix 41 for raw data. 
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Figure 36: The podocyte gene and protein expression of MCP1 following increasing time exposure to TNFα  
Podocytes were exposed to TNFα over a time period of 96 hours, demonstrating a statistically significant increase in MCP1 gene and 
protein with increasing time exposure of TNFα. 
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The podocyte expression of NGAL did not demonstrate a direct relationship 
with TNF exposure over time. However there was a tendency for an 
increased gene and protein expression of NGAL after 72 hours as seen in 
Figure 37. The protein expression of NGAL reached a statistically significant 
up regulation by 96 hours. The normal cell conditions had a NGAL gene 
expression of 1.6+0.8x10-2 (n=3), after 2 hours of TNF exposure the gene 
expression was 4.0+0.4x10-3 (n=4; p=0.13); 4 hours 3.3+0.4x10-3 (n=4; 
p=0.11); 6 hours 4.1+0.6x10-3 (n=4; p=0.24); 8 hours 6.8+2.3x10-3 (n=4; 
p=0.24); 12 hours 2.7+1.1x10-3 (n=4; p=0.10); 24 hours 4.5+1.4x10-3 (n=4; 
p=0.15); 72 hours 3.0+0.2x10-2 (n=3; p=0.21); and at 96 hours 1.2+1.2x10-3 
(n=3; p=0.14). 
 
The protein expression of NGAL showed a similar distribution with an initial 
decrease in the expression compared to the control cells and an increased 
expression seen only after 72 hours of TNF exposure. The normal cell 
condition expressed an NGAL protein concentration of 180.2+38.6 ng/ml 
(n=5), 2 hours 36.2+12.8 ng/ml (n=6; p=0.004); 4 hours 77.8+14.3 ng/ml (n=3; 
p=0.10); 6 hours 51.5+7.5 ng/ml (n=3; p=0.05); 8 hours 104.5+20.1 ng/ml 
(n=5; p=0.12); 12 hours 61.5+18.9 ng/ml (n=3; p=0.07); 24 hours 65.7+20.0 
ng/ml (n=4; p=0.05); 72 hours 294.6+39.7 ng/ml (n=6; p=0.07) and 96 hours 
358.1+57.2 (n=7; p=0.04). See Appendix 42, Appendix 43 for raw data. 
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Figure 37: Podocyte gene and protein expression of NGAL in response to increasing time exposure of TNFα 
Podocytes were exposed to TNFα over a time period of 96 hours, demonstrating no distinct relationship with increasing time. 
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To confirm whether there was a late up regulation of NGAL in response to 
TNFα additional experiments were undertaken. The conditions that promoted 
an apparent increase in NGAL from both of the dose response and time 
response experiments were selected and the experimental control condition 
was changed to directly compare 72 hours of normal media and 72 hours of 
TNFα media (concentration 10ng/ml). This demonstrated that TNFα did 
increase the gene and protein expression of NGAL from the podocyte cell as 
seen in Figure 38. The mean gene expression of the cells exposed to 72 hours 
of TNF (3.0+0.2x10-2; n=3) was statistically significantly up regulated 
compared to the normal control cells in 72 hours of podocyte media 
(1.1+0.4x10-2, n=3; p=0.02). The protein expression of NGAL was also 
significantly increased in the TNF condition compared to normal podocyte 
media for 72 hours (TNF 294.6+39.7, n=6; normal 142.9+6.2, n=3; p=0.04). 
See Appendix 44, Appendix 45 for raw data. 
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Figure 38: Podocyte gene and protein expression of NGAL after 72 hours with TNFα 
Podocytes were exposed to control conditions and TNFα (10ng/ml) exposure for 72 hours showing that TNFα up regulates NGAL 
gene (a) and protein (b) expression from the podocyte cell. 
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5.5.5. Inhibiting TNF in the activated macrophage media 
To determine whether the podocyte expression of MCP1 or NGAL was directly 
related to TNFα exposure, the podocyte cells were incubated with active media 
with the addition of a neutralising anti-TNFα antibody. The neutralisation of 
TNFα statistically significantly reduced the expression of MCP1 but did not 
alter the podocyte expression of NGAL after 48 hours exposure. The mean 
protein concentration of MCP1 in cells exposed to active macrophage media 
was 120.0+19.8 ng/ml (n=4) compared to active media plus anti-TNFα at 
1ug/ml 70.4+18.1 ng/ml (n=3; p=0.14) and active media plus anti-TNFα at 
0.5ug/ml 43.2+19.1 ng/ml (n=4; p=0.03).  
 
The mean protein concentration of NGAL did not change with anti-TNFα. Cells 
exposed to active macrophage media was 17.5+13.4 ng/ml (n=6) compared to 
active media plus anti-TNFα 1ug/ml 39.1+24.6 ng/ml (n=6; p=0.46) and active 
media plus anti-TNFα 0.5ug/ml 16.1+15.8 ng/ml (n=5; p=0.94). See Appendix 
46, Appendix 47 for raw data. 
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Figure 39: The podocyte protein expression of MCP1 and NGAL  
The podocyte protein expression of MCP1 (a) and NGAL (b) in response to active macrophage media (mϕ) and neutralising anti-
TNFα showing that neutralising TNFα reduces the podocyte protein expression of MCP1. 
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5.6. Discussion 
This study set out to determine whether the podocyte was able to express the 
biomarkers MCP1 and/or NGAL. The study data has confirmed that the human 
podocyte is able to express MCP1 and, we report for the first time, it can also 
express NGAL. The second aim in this aspect of the study was to determine 
whether activated macrophages and/or the presence of the pro-inflammatory 
cytokine TNF had a role in the expression of these biomarkers.  The findings 
have demonstrated that activated macrophages are able to up regulate the 
podocyte expression of MCP-1.  This may be attributed (in part at least) to the 
cytokine TNF- expressed by the activated macrophages as this study 
demonstrated a statistically significant relationship between podocyte MCP-1 
expression and TNF- exposure. Additionally, inhibition of TNF- significantly 
reduced the expression of MCP-1. 
 
Our data needs interpretation with caution as it has analysed mRNA and 
protein expression but this does not assess any functional assays. Additionally 
it has demonstrated that macrophages also express MCP1 and NGAL, similar 
to that found by others (366, 367). This highlights a weakness of our findings in 
that the origin of MCP1 and NGAL as LN biomarkers is likely to be 
multifactorial in origin and not solely attributable to the podocyte. This is in 
agreement with other studies, where the expression of MCP1 and NGAL has 
been reported to arise from other renal cells including mesangial and tubular 
cells (368, 369).  
 
  228 
This work utilised a human single cell line to understand the expression of 
important LN biomarkers and the inflammatory mediators leading to their 
expression. The use of a human single cell line has its limitations, whilst being 
superior to murine cell lines and allowing manipulation over the experiemental 
conditions; it remains a very simplified view of this disease pathogenesis. 
Further studies could utilise co-culture mechanisms using two or more cell 
lines and the use of patient-derived cell lines using reprogrammed patient 
fibroblast cells to produced induced-pluripotent stem cell lines transformed into 
specific cells (eg: podocyte) through specific transcription factors (370).  
 
The importance of identifying the podocyte expression of these biomarkers 
and extrapolating their relationship to LN will now be discussed. In LN, 
irreversible damage, leading to long-term renal morbidity, is due to glomerular 
crescent formation and the evolution of glomerulosclerosis (371), both of which 
are specifically related to a disruption of key podocyte markers and activation 
of Wnt/Notch signalling pathways (372-375). A greater understanding of the 
role of the podocyte in LN is therefore crucial in identifying novel therapeutic 
targets to reverse the consequences of scarring prior to the progression to 
irreversible ESRF. 
 
Earlier findings in this study emphasised the independent relationship of MCP-
1 with active renal disease in patients with JSLE and its usefulness in 
predicting improving renal disease. The direct influence of MCP-1 on the 
podocyte has previously been shown in murine studies; the presence of MCP-
1 contributes to podocyte motility, rearrangement of the actin cytoskeleton and 
  229 
increases the permeability to albumin (227). MCP-1 binding to its receptor on 
the podocyte also reduces nephrin, in a Rho-dependent mechanism (226). In a 
study by Nam et al, using a mice model of diabetic nephropathy they 
demonstrated that MCP-1 also has a role in inducing podocyte apoptosis 
(376). Collectively the processes of increased podocyte cell motility, actin 
reorganisation, increased albumin permeability, reduced nephrin and podocyte 
loss through apoptosis, each contributes to renal scarring and the 
development of glomerulosclerosis (372, 377).  Understanding the 
mechanisms leading to podocyte MCP-1 expression in LN is therefore 
important to identify early therapeutic interventions. 
 
The effect and role of NGAL on the podocyte is not fully understood. In 
patients with LN, NGAL is found to be histologically present in the renal 
glomeruli (206). The only previous study identifying podocyte-derived NGAL 
was conducted using an immortalised mouse podocyte cell line, which 
demonstrated that cells exposed to 1 and 2 weeks of high glucose, mimicking 
diabetic-like conditions, resulted in a significant reduction in the gene 
expression of NGAL (378). In renal tubular cells, NGAL is required for cell 
survival and repair through the alteration of apoptotic-regulating genes (230), it 
also has a role in reducing bacterial growth through iron mediation, and is thus 
increased early in urosepsis (379), and it has a role in inflammation by 
inducing the anti-oxidants, heme oxygenase and superoxide dismutase (380). 
If NGAL has an anti-inflammatory and protective role in the podocyte, the 
increased podocyte expression of NGAL and the early increase in urine NGAL 
concentration, seen in the biomarker aspect of this work, suggests that the 
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glomerulus may initially attempt to reverse inflammation and/or repair injury. If 
so, this could indicate a period of reversible or salvageable renal inflammation. 
The subsequent reduction in NGAL at the time of clinically evident active LN – 
thus a lack of association of urine NGAL with active LN on a cross sectional 
basis in this study – suggests that the repair potential of these cells may be 
lost, emphasising the need for an earlier diagnosis of renal flares. Although 
hypothetical in discussion, this present study produces very interesting 
preliminary data regarding NGAL expression from the podocyte.  
 
Macrophages are seen early in the course of LN and the activation of 
macrophages is important in LN. MCP-1, with its detrimental effect on 
podocytes, is clearly implicated in LN pathophysiology, in keeping with the 
finding that genetic MCP-1 polymorphisms are SLE susceptibility genes (27). 
MCP-1 is known to be expressed in relation to microparticles, small molecules 
produced by monocytes in response to TNF-, leading to an impairment in the 
podocyte’s ability to undertake endocytosis of albumin (381). Within renal 
tubular cells, MCP-1 expression is also regulated by TNF- and can be 
attenuated by the administration of bone morphogenic protein-7 (BMP-7), a 
member of the anti-inflammatory TGF-β superfamily (382) In lupus mouse 
models BMP-7 administration relieves LN disease progression (383). Other 
studies have also identified a modified podocyte inflammatory response by the 
administration of vitamin D analogues (384) and further still, combined vitamin 
D analogues and angiotensin II receptor reduced this further (385). 
Understanding the MCP-1/TNF- podocyte pathway, including the expression 
of TNFR within the podocyte, provides a realistic opportunity for intervention.  
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In contrast to MCP-1, a clear relationship between NGAL expression and the 
exposure of macrophages was not found, nor a direct relationship between 
NGAL and TNF exposure. However, following further experiments, a 
prolonged exposure of TNF (72 hours) did result in a significant increase in 
the gene and protein expression of NGAL. The lack of association between 
NGAL expression and macrophages or TNF suggests that other factors are 
linked to the signalling of this. The up regulation of NGAL that was noted after 
72 hours may be representing an indirect relationship between TNF- and 
podocyte NGAL expression. The podocyte is able to express IL-1 in response 
to macrophages and/or TNF- (386). It may be that the increase in NGAL that 
has been demonstrated here is related to increase in IL-1 concentration from 
the podocyte instead or the contribution of IL-1 and TNF- as seen in the 
PBMCs of haemodialysis patients (387). This would explain the lack of 
relationship and the delay in its up regulation. In support of this, is that IL-1 
regulates the expression of NGAL in other cells such as the renal mesangial 
cells (206) and bronchial epithelial cells (231). Further work is required to 
understand the mechanisms and consequences of podocyte NGAL expression 
and its implications for patients with LN. This would include the exploration of 
expression in response to IL-1 and other cytokines that may be expressed by 
activated macrophages.     
 
5.7. Summary 
JSLE is a severe autoimmune disease with more renal involvement when 
compared to adult onset disease. Urine biomarkers such as MCP1 and NGAL 
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are able to distinguish patients with active LN and they are able to predict 
impending changes in renal disease activity. The podocyte has a key role in 
regulating immune processes within the kidney and contributing to the long-
term irreversible renal damage. This study has demonstrated important data 
exploring mechanisms of control of MCP1, and preliminary data on NGAL, 
expression from the podocyte within an in vitro model of LN. Identification of 
factors contributing to the expression of these biomarkers, such as the 
macrophage derived products including TNF-α, offers a major opportunity for 
developing more targeted therapies. Further investigation into the podocyte 
TNFR expression would provide beneficial information on potential targeting of 
the MCP-1/TNF-α pathway. 
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6. Chapter 6: Podocyte regulation of TNF-α 
and its receptors  
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6.1. Poodcyte regulation of TNF-α and its receptors: 
Background  
The podocyte has a key role the pathophysiology of LN. Infiltration of M1 
macrophages into the glomerulus are early pathological processes seen in 
LN, where they lead to the local release cytokines and chemokines, including 
TNF-α as shown in the previous chapter (section 1.2.3). Understanding the 
receptor expression for TNF-α may provide further information into the 
pathophysiology of LN. 
 
6.2. Aims and objectives 
The aim of this study is to determine TNFR1 and TNFR2 expression in the 
podocyte and its regulation following exposure to TNF-α. 
 
The specific objectives include; 
1. To assess whether activated macrophage media, producing TNF-α, up 
regulates TNFR1 and / or TNFR2 on the podocyte. 
2. To assess the TNFR1 and TNFR2 expression following TNFα 
exposure over a designated time period.  
3. To assess the TNFR expression following increasing concentration of 
TNFα 
4. To describe the balance of TNFR2:TNFR1 expression on the podocyte 
in response to increasing time periods and concentrations of TNFα 
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5. To determine the morphological appearances of the podocytes in 
response to TNFα exposure 
 
6.3. Hypothesis 
The podocyte adopts a TNFR2 predominant pathway in response to 
macrophage media and/or TNFα and undergoes morphological changes. 
 
6.4. Methods 
An in vitro model of lupus glomerulonephritis was designed using human 
monocyte derived macrophages and a human podocyte line, as described in 
detail in Chapter 2 (section 2.5). 
 
6.4.1. Human macrophage culture 
Human monocytes were isolated using separation and magnetic sorting and 
seeded at a concentration of 1x106 cells/well in a 24 well culture plate as 
described in section 2.4.9.2. Monocytes were derived into macrophages and 
incubated at 37°C in an atmosphere consisting of 5% CO2 for 6 days. 
Following this period the media was removed, the cells were washed twice 
with PBS (Sigma-Aldrich, UK) and they were then exposed to either RPMI 
alone (inactive cells) or RPMI containing IFNγ (Peprotech EC Ltd, UK) at a 
concentration of 1ng/ml (active cells). After 48 hours of incubation the media 
from the macrophage cells was removed and stored at minus -70°C until 
exposure to the podocyte cells. 
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6.4.2. Human podocyte culture 
As previously described a human podocyte line was established using cells 
donated as a gift and published in detail (341). In brief, podocytes were 
seeded and placed at 33°C in an atmosphere consisting of 5% CO2 until 60% 
confluent. Cells were thermo switched to 37°C in an atmosphere consisting of 
5% CO2 for 10-14 days to allow terminal differentiation. Podocyte media 
(RPMI 1640 media, 10% FCS, 1% Penicillin-streptomycin solution and 1% 
ITS) was used and replaced every 3-4 days during the cell culture period. All 
experiments used podocytes between passage number 10-24 and each 
experiment was repeated >3 times and compared against the control 
condition (cells in standard podocyte media for 48 hours). 
 
6.4.2.1. Extracting podocytes 
Following each of the experimental conditions, mRNA and protein was 
extracted using a cell scraper. The scraped cells were centrifuged at a high 
relative centrifugal force (28,400g) and RNA was extracted from the pelleted 
cell sediment. See section 2.5.3 for further details.  
 
6.4.2.2. Gene expression quantification 
Total RNA was isolated and converted to cDNA. Samples were further diluted 
and real time PCR was performed. All reactions were performed according to 
the manufacturers instructions. Each sample was measured in duplicate and 
the mRNA content was normalised to the control (gene expression of 18s). 
Samples were analysed using the Strategene Mx real time PCR platform and 
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the Strategene MxPro QPCR software 3005p (Agilent technologies UK Ltd, 
UK). Section 2.5.4 describes this method in further detail. 
 
6.4.2.3. Microscopic appearances 
At the time course (concentration 1000 pg/ml for 2 hours; 4 hours; 8 hours; 48 
hours; 72 hours) and dose response (10 pg/ml; 100 pg/ml, 1000 pg/ml, 10 
ng/ml for 48 hours), of TNF-α the cells were visualised under a microscope 
and images were taken (Leica Image Manager software and Leica 
microscope DFC420, Leica Microsystems (UK) Ltd) for illustrative purposes. 
 
6.4.3. TNFR expression in podocytes exposed to macrophage media  
Macrophage media (750uL) inactive or active was placed on the podocytes 
for 48 hours and the gene mRNA expression of TNFR1 and TNFR2 was 
subsequently measured.  
 
6.4.4. TNFR expression in podocytes exposed to TNFα 
Podocytes were exposed to the respective experimental conditions using 
recombinant TNF-α (Peprotech EC Ltd, UK) at different time points or 
different doses.  
 
 The effect of TNFα exposure over time was determined by quantifying 
TNFR1 and TNFR2 mRNA expression at the following specific time 
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intervals: 2, 4, 6, 8, 12, 24, 72, 96 hours, using a concentration of 
TNFα 1000 pg/ml.  
 
 The effect of TNFα concentration was determined by quantifying 
TNFR1 and TNFR2 mRNA expression following the exposure to 
differing doses of TNFα for 48 hours. Concentrations used were 10 
pg/ml, 100 pg/ml, 1000 pg/ml and 10 ng/ml.  
 
6.4.5. Statistical analysis  
Graph Pad Prism version 5 software was used to produce all graphical 
illustrations (Graph Pad software, Inc, USA) and statistical analysis was 
performed using Statistics Programme for Social Sciences version 20.0 (IBM 
Corporation, USA). Students t test was used to analyse the results and a 
statistically significant difference was taken as a probability (p) value of less 
than 0.05. Results are expressed as mean values + the standard error of the 
mean (SEM) value. 
 
6.5. Results 
6.5.1. Podocyte TNFR expression in response to macrophage media 
Figure 40 presents podocyte TNFR1 expression in vitro in response to co-
culture with macrophage media (active and inactive). The gene mRNA 
expression of TNFR1 was not statistically significantly different between 
podocytes exposed to control media, inactive macrophage media or active 
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macrophage media. In podocytes exposed to the control condition the mean 
TNFR1 expression was 1.26+0.45x10-6 (n=3), inactive macrophage media 
27+25x10-6 (n=3; p=0.35), active macrophage media 4.7+1.5x10-6 (n=3; 
p=0.15). See Appendix 48 for raw data. 
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Figure 40: The gene expression of TNFR1 in control, inactive 
macrophage media, active macrophage media conditions 
The gene mRNA expression of TNFR1 was measured in the podocytes 
following exposure to macrophage media (48 hours) either activated with 
interferon gamma (1ng/ml) or not activated (inactive condition) demonstrating 
no significant difference in the receptor expression between the conditions. 
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The podocyte gene expression of TNFR2 increased significantly following 
exposure to active macrophages. This increase was statistically significantly 
increased when compared to control conditions and inactive macrophage 
media (Figure 41). The control condition had a mean relative expression of 
0.23+0.047x10-6 (n=3), inactive macrophage media condition 0.13+0.0094x10-
6 (n=3; p=0.43), active macrophage media 0.89+0.074x10-6 (n=3; compared 
to control p=0.003; compared to inactive media condition p=0.004). See 
Appendix 49 for raw data. 
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Figure 41: The gene expression of TNFR2 in podocytes exposed to 
control, inactive macrophage media and active macrophage media 
The gene mRNA expression of TNFR2 was measured in the podocytes 
following exposure to macrophage media (48 hours) either activated with 
interferon gamma (1ng/ml) or not activated (inactive condition) demonstrating 
a significant increase in the receptor expression when exposed to active 
macrophages. 
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6.5.2. The effect of TNF on the podocyte expression of TNFR 
6.5.2.1. The dose response of TNFα on podocyte TNFR expression 
The gene mRNA expression of TNFR1 in response to TNFα had a trend 
towards increased receptor expression however this did not reach statistical 
significance when the dose of TNFα changed (Figure 42). The mean TNFR1 
gene expression in the control condition was 3.1+0.41x10-6 (n=4), at TNFα 
10pg/ml the gene mRNA expression of TNFR1 was 100+63x10-6 (n=6; 
p=0.24); to a dose of TNFα 100pg/ml 94+62x10-6 (n=6; p=0.27); to a dose of 
TNFα 1000pg/ml 52+31x10-6 (n=7; p=0.27); to a dose of TNFα 10ng/ml 
25+16x10-6 (n=7; p=0.21). See Appendix 50 for raw data. 
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Figure 42: Tumour necrosis factor receptor 1 response to TNF-α concentration. 
The gene mRNA expression of TNFR1 was measured in podocytes exposed to increasing concentration of TNF-α demonstrating 
no significant difference in the receptor expression compared to normal conditions. 
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The podocyte gene expression of TNFR2 demonstrated a statistically 
significant increase in response to increasing doses of TNFα as seen in 
Figure 43. The control condition demonstrated a mean TNFR2 gene 
expression of 0.048+0.011x10-6 (n=4), cells exposed to TNFα at a dose of 
10pg/ml was 4.9+3.2x10-6 (n=5; p=0.10); to a dose of TNFα 100pg/ml it was 
5.0+2.5x10-6 (n=8; p=0.03); to a dose of TNFα 1000pg/ml it was 12+7.2x10-6 
(n=6; p=0.15); to a dose of TNFα 10ng/ml it was 9.6+2.3x10-6 (n=5; p=0.02). 
See Appendix 51 for raw data. 
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Figure 43: Tumour necrosis factor receptor 2 response to TNF-α concentration. 
The gene mRNA expression of TNFR2 was measured in podocytes exposed to increasing concentration of TNF-α demonstrating a 
significant increase in the receptor expression at specific concentrations (100 pg/ml; p=0.03, 10 ng/ml; p=0.02) compared to normal 
conditions. 
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6.5.2.2. The time response of TNFα on podocyte TNFR expression 
The gene mRNA expression of TNFR1 reached a statistically significant 
increase only at 72 hours of TNFα exposure (Figure 44). The control condition 
had a mean TNFR1 relative gene expression of 3.1+0.41x10-6 (n=4); after 
exposure to TNFα for 2 hours the gene expression was 18+6.7x10-6 (n=3; 
p=0.16); after 4 hours of TNFα gene expression was 35+22x10-6 (n=4; 
p=0.24); after 6 hours of TNFα it was 150+71x10-6 (n=4; p=0.09); after 8 
hours TNFα 3.5+1.5x10-6 (n=4; p=0.80); after 12 hours TNFα 4.0+1.0x10-6 
(n=4; p=0.42); after 24 hours TNFα 4.6+1.2x10-6 (n=4; p=0.28); after 72 
hours TNFα 14.7+3.0x10-6 (n=4; p=0.009); after 96 hours TNFα 17.7+6.7x10-
6 (n=4; p=0.07). See for Appendix 52 raw data. 
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Figure 44: Tumour necrosis factor receptor 1 response to TNF-α exposure. 
The gene mRNA expression of TNFR1 was measured in podocytes exposed to increasing time exposure of TNF-α (1 ng/ml) 
demonstrating no significant difference in the receptor expression compared to normal conditions except at 96 hours when an 
increase was seen (p=0.009). 
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The timing response of TNFα on podocyte TNFR2 expression showed a 
significant increase as the time exposure increased (Figure 45) which reached 
statistical significance at 8,12 and 24 hours of TNFα exposure. The mean 
gene expression of TNFR2 in the control condition podocytes was 
0.048+0.011x10-6 (n=4), the gene mRNA expression of TNFR2 in podocytes 
exposed to TNFα for 2 hours was 1.0+0.75x10-6 (n=4; p=0.08); after 4 hours 
TNFα 0.40+0.15x10-6 (n=4; p=0.11); after 6 hours TNFα 40+38x10-6 (n=4; 
p=0.374); after 8 hours TNFα 201+29x10-6 (n=4; p=0.006); after 12 hours 
TNFα 310+61x10-6 (n=4; p=0.015); after 24 hours TNFα 210+34x10-6 (n=4; 
p=0.008); after 72 hours TNFα 0.84+0.17x10-6 (n=4; p=0.055) and after 96 
hours TNFα 440+110x10-6 (n=3; p=0.41). See Appendix 53 for raw data. 
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Figure 45: Tumour necrosis factor receptor 2 response to TNF-α exposure. 
The gene mRNA expression of TNFR2 was measured in podocytes exposed to increasing time exposure of TNF-α (1 ng/ml) 
demonstrating a significant increase in the receptor expression compared to normal conditions at the time points 8 hours (p=0.006), 
12 hours (p=0.015) and 24 hours (p=0.008).  
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6.5.3. The balance of TNFR2:TNFR1 in response to TNFα on the podocyte  
The podocyte ratio of TNFR2:TNFR1 was then determined using the relative 
gene expression of each of the receptors (Figure 46). This demonstrated that 
the cells adopted an increased gene ratio of TNFR2:TNFR1 when exposed to 
TNF-α over a dosing and time response as shown in Figure 46. This reached 
a statistical significance at 8, 12, 24 and 72 hours time (p=0.01, p=0.005, 
p=0.03, p=0.006, respectively). 
 
  252 
Figure 46: The ratio of tumour necrosis factor receptor expression. 
The ratio of the gene mRNA expression of TNFR2:TNFR1, measured in 
podocytes exposed to increasing concentration of TNF-α (a) and at increasing 
time exposure showing no significant difference in the concentration changes 
but signicant increase in the TNFR2:1 ratio over time.  
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6.5.4. The effect of TNFα on the morphological appearances of the 
podocytes 
The morphological appearance of the podocytes was assessed following 
exposure to TNF-α (Figure 47, Figure 48).  This subjectively demonstrated 
visual differences in the cells with elongated projections, podocyte clustering 
and detachment at all time points beyond 24 hours exposure of TNFα (Figure 
48). At all concentrations of recombinant TNFα the human podocytes 
subjectively appeared structurally different with an elongated appearance, foci 
and stretched projections which was most apparent at a concentration of 
10ng/ml of TNF-α were a helical pattern of cell formation was observed 
(Figure 47). 
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Figure 47: Microscope images of podocytes exposed to different concentrations of TNF-α. 
The podocytes exposed to increasing concentration of TNF-α (for 48 hours) were imaged using microscopy (40x magnification) and 
demonstrate changes with increasing concentration including stretching of the cell shape and helical formation (arrows). 
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Figure 48: Microscope images of podocytes exposed to increasing exposure of TNF-α. 
The podocytes exposed to increasing time exposure of TNF-α (1 ng/ml) were imaged using microscopy (40x magnification) and 
demonstrate changes with increasing concentration including stretching of the cell shape and clusering of cells. 
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  256 
 
6.6. Discussion 
The aim of this chapter was to determine the TNFR expression on the 
podocyte in response to macrophages and TNF-α. Using an in vitro model, this 
study has demonstrated that the podocyte expresses both TNFR1 and TNFR2. 
It has also shown that the podocyte adopts a TNFR2 predominant pathway 
following exposure to activated macrophages or to exogenously administered 
TNF-α, supporting the study’s hypothesis. 
 
Experimental work undertaken for this chapter has been limited to gene mRNA 
expression assays due to time limitations, this data therefore does not provide 
information on the protein expression of the receptors nor does it assess the 
functional consequences of such receptor expression. This data should 
therefore be interpreted carefully and may be used as preliminary data for 
subsequent studies. As previously discussed, a single cell line is an over 
simplistic view of LN. Microscope images presented in this chapter are for 
illustrative purposes only and can be considered thought provoking but not 
hypothesis testing. A discussion of the potential implications of TNFR 
expression in the podocyte and in particular in active LN will now be 
undertaken in the context of these weaknesses. 
 
TNF-α has been shown to have an important role in LN – in large cohorts of 
patients with SLE an elevated serum concentration has been demonstrated 
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(388) and the renal histology in LN shows increased TNF-α and components of 
its signalling pathway (203).  
 
Distinct receptor signalling pathways make the potential role of TNF-α in 
determining the phenotypic manifestations of LN notable. It has been reported 
that its two main receptors (TNFR1 and TNFR2) can play opposite roles in the 
acute inflammatory response demonstrated in certain conditions including viral 
illnesses, sepsis, ischaemia and iatrogenic lung injury from mechanical 
ventilation (389). Understanding the organ-specific expression of the TNFR 
balance therefore plays a large role in interpreting the actions of TNF-α in a 
particular disease model (390).  
 
This variability in function in turn may explain the variable response to anti-
TNF-α treatment in multi-systemic inflammatory diseases. Currently available 
TNF-α inhibiting treatments include; the first generation anti-TNF-α treatments, 
infliximab, etanercept, adalimumab; and second generation anti-TNF-α 
treatments, certolizumab pegol and golimumab – both humanized monoclonal 
antibodies. Infliximab, a chimeric monoclonal antibody, neutralizes TNF-α and 
causes apoptosis of activated T cells. Etanercept is a recombinant fusion 
protein that acts as a decoy receptor to TNF-α, thus effectively inhibiting its 
actions by mimicking receptor interaction. Adalimumab acts in the same 
manner as infliximab except that it is a fully humanised monoclonal antibody. 
Therefore current methods of TNF-α inhibition involve neutralisation rather 
than specific TNFR targeting.  
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Case series of patients with active LN not responding to conventional SLE 
therapies have shown that anti-TNFα treatment will improve the signs and 
symptoms of renal disease (391). Clinical trials were designed but were 
subsequently terminated due to poor patient recruitment (392, 393), perhaps 
indicating a lack of clinician confidence in the treatment. In mouse models 
inhibiting TNF-α prevents renal damage however immune complexes still 
deposit within the glomerulus (394) highlighting that it is clearly not the only 
pathological factor in this condition, but TNF-α may be the factor associated 
with irreversible renal damage. 
 
Within the kidney, this study has demonstrated that the podocytes will 
significantly up regulate the TNFR2 pathway in response to TNF-α exposure.  
These data are in agreement with findings from murine studies in which 
TNFR2 is essential for immune mediated GN (395) and a genetic deficiency of 
TNFR2 has a protective effect on the lupus kidney (396). The histological 
finding of increased TNFR2 in the patients with active LN supports its pro-
inflammatory role. TNFR2 promotes the activation of NFkB transcription 
through the TRAF pathway  – see section Figure 1. Silencing the RNA of 
TRAF-2 in a lupus mouse model inhibited this pathway, and led to the up 
regulation of cell apoptosis, characteristic of TNFR1 predominance, 
attenuating the renal disease (397). Finally, TNFR2 and its down stream 
signalling molecules have been identified as lupus susceptibility genes, 
including TRAF-6, TRAF-1 and TNFR2 (398). The TNFR2 pathway therefore 
has a fundamental role in LN and leads to the transcription of NFkB and latter 
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inflammatory cytokine and chemokine production, including the chemo-
attractant protein MCP-1 that this thesis has been investigating.  
 
Inhibition of systemic TNF-α may not be effective for LN management. As 
demonstrated in the TNFR doubly deficient (TNFR1-/-, TNFR2-/-) mouse 
model (204), some level of TNF-α is required for immune tolerance; too low 
levels of TNF-α may mean that TNFR1 is not able to function in an immune-
modulatory role, by regulating cell apoptosis and tissue repair, and this may 
therefore predispose to autoimmune disease in itself. Mice treated with TNFR1 
binding proteins, or TNFR1 deficient mice, have suppression of their primary 
and secondary IgG antibody responses and cell-mediated immune function 
leading to infection-related mortality (399). With regards to the renal system, 
TNFR1 deficient mice exposed to nephrotoxic nephritis develop a worse renal 
lymphocytic infiltration and glomerular damage when compared to wild type 
models (395). These data support the essential role for TNFR1 both 
systemically and within the glomerulus.  Inhibiting the actions of TNF-α within 
the LN setting may require selectively targeting the glomerular actions of 
TNFR2.  
 
The final aim of this chapter was to produce some preliminary data illustrating 
the change in cell morphology that occurs following TNF-α exposure to the 
podocyte. The study demonstrated that there were microscopic changes that 
were consistently seen and included cell foci and a honeycomb appearance in 
distribution with increasing TNF-α exposure. Although this was performed to 
produce preliminary investigation only, it may be that our observation has 
  260 
shown that TNF-α is contributing to actin reorganisation in the podocyte and 
cell loss, as described by others (400). TNF-α is known to have a role in renal 
scar formation and crescents (401); the pattern observed may be due to cell 
migration and whether this represents in vitro formation of cellular crescents 
should be the focus of further work to validate our subjective findings.  
 
Within the literature direct inhibition of glomerular TNFR2 has not been 
reported. However there are reports of other methods of reducing the 
inflammatory response to TNF-α in lupus. Recently, a group using lupus prone 
mice, have delivered CD169(+) macrophage-specific therapy to specifically 
reduce the concentration of macrophage derived TNF-α, demonstrating a 
significant improvement in lupus-symptoms (402). Other innovative 
considerations include the use of angiotensin II receptor blockade therapies, 
as angiotensin is up regulated in LN and angiotensin II directly influences TNF-
α production in the podocyte (403). Secondly the use of statins influences the 
TNFR signalling pathway reducing NFkB production and promoting cell 
apoptosis and repair. 
 
This study provides an in vitro evidence base for potential clinical utility of 
TNFR2 inhibition as a therapeutic target for patients with LN. Further work 
required in this area includes the identification of TNFR protein expression 
using receptor staining and confocal microscopy and measurement of the 
systemic soluble receptor expression through ELISA or Western blot 
techniques. Identifying the location of the TNFRs within the podocyte and 
further identifying the expression of both TNFR1 and TNFR2 down stream 
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signalling molecules would strengthen this data. Morphological changes, 
although subjective, are interesting and require quantification and correlation 
with functional changes in the podocyte response to TNF-α. The identification 
of additional cytokines present in the activated macrophage media and their 
role on the podocyte would form the basis of a complementary project. 
Following further in vitro analyses, the findings should be validated in in vivo 
models identifying signalling molecules in the renal histology from patients with 
LN and later confirming findings using animal lupus models where the genetic 
manipulation and subsequent targeting of specific pathways can be 
undertaken. 
  
6.7. Summary 
The expression of TNF-α has been recognised as having a key role in LN, its 
receptor balance make understanding the effect of TNF-α a challenge.  This 
study has demonstrated that the podocyte adopts a TNFR2 predominant 
pathway in the mRNA expression in response to TNF-α and indicates the need 
for further protein expression assays to potentially direct the usefulness of 
targeting of this pathway. This may be more reliable than systemic blocking of 
TNFα as an effective focus of future therapeutic investigation. Further work is 
needed to understand the implications of restoring the balance of TNFR in 
inflammatory renal disease and may also provide an opportunity for early 
intervention to prevent the onset of irreversible renal damage. 
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7. Chapter 7: Clinical and research 
implications 
  263 
 
This study aimed to investigate the role of renal biomarkers in children and 
young people with JSLE. It has a number of important clinical and research 
implications for the care of children with LN. These are summarised here. 
 
7.1. Clinical implications 
7.1.1. Understanding renal involvement in JSLE 
This study has enabled detailed cross sectional and longitudinal analysis of 
>60 children with JSLE to be described with regards to their demographic data 
and renal involvement in the setting of the UK JSLE Cohort Study. This Cohort 
Study is now the largest national cohort of its kind in the world and has 
facilitated the collection of high quality clinical information and a biobank of 
samples. This study strengthens further the research collaborative links 
between the Departments of Paediatric Rheumatology and Nephrology, 
extending the ethical approval for collection of renal-related samples and 
designing and implementing successfully practical standard operating 
procedures for the collection of data and samples for this aspect of the study. 
This has provided an important platform for future collaborative studies that are 
already being planned and enhances the strengths of the UK JSLE Cohort 
Study. The availability of this resource, and its on going success, has 
positioned the Study to attract international collaborative opportunities. The 
data and sample biobank already collected in relation to LN will permit future 
students to start investigating and analysing data immediately. Together this 
will further our understanding of the pathogenesis and role of biomarkers on 
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LN and significantly improve the development of better treatment and patient 
management plans in the future. 
 
7.1.2. Translation to other conditions 
The biomarkers that we have investigated in this study are probably not unique 
to JSLE. Rather, the biomarkers investigated are likely to represent the impact 
of inflammatory insults on the kidney. They therefore have significant 
translational opportunities. Increased MCP-1 is seen in children with acute 
post-streptococcal glomerulonephritis, Henoch Schonlein Purpura (HSP), 
Immunoglobulin A (IgA) nephropathy and focal segmental glomerulosclerosis 
(FSGS) (404). Urinary NGAL is elevated in children with acute pyelonephritis, it 
is able to distinguish children who have steroid resistant nephrotic syndrome 
when compared to those with idiopathic (steroid sensitive) nephrotic syndrome 
(405) and in a multicentre pooled analysis, NGAL was able to determine which 
critically unwell children would develop acute kidney injury and have adverse 
outcomes (406). The identification of MCP-1 and NGAL as biomarkers and 
initiating investigation into the scientific factors regulating their expression may 
therefore give insight to, and in due course have direct consequences on, the 
diagnosis and management of other causes of childhood glomerulonephritis. 
 
7.1.3. Collaboration 
The success of this project has been through the effective use of the 
integration of clinical research into clinical practice through collaboration. Using 
the established links that the UK JSLE Cohort Study has provided and 
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strengthening the links with the two largest recruiting centres has enabled high 
quality data to be collected and meaningful results to be extracted. Rare 
diseases, such as JSLE, are impossible to investigate without such 
collaborations and this model can be extended also internationally. Further 
studies leading on from this work, such as the use of non-invasive biomarkers 
in clinical practice (to be discussed shortly), will benefit greatly from the 
collaborative links that have been established and enhanced by this current 
study. Future emphasis should be to focus on extending these links to 
international cohorts of children with JSLE.  
 
7.1.4. Future avenues of research and development arising from this work 
Prospective validation of biomarkers of LN: This study has demonstrated 
that it is possible to predict changes in renal disease activity in children with 
JSLE through the use of non-invasive biomarkers. These biomarkers need to 
be replicated by prospective validation in an independent prospective cohort 
either as a clinical observational study or within the context of a clinical trial.  
Development of point of care device for urinary biomarkers of LN: An 
important and next step in demonstrating the clinical utility of this panel of 
urinary biomarkers would then be to develop and prospectively evaluate 
technologies used to measure these biomarkers using high throughput real 
time testing and for them to be available as a convenient and cost-effective 
management adjunct. Point of care testing would help to detect flares, monitor 
response to treatment and provide prognostic information. It would speed up 
detection of renal activity and potentially damage and allow out-patient 
management, with improved patient experience and inevitable cost savings. 
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Currently there are no non-invasive tests that accurately and reliably monitor 
disease activity in LN. Following validation of these biomarkers, it would be 
opportune to establish collaborations with industrial Biotech partners to 
determine an appropriate technology platform that may be able to meet these 
needs. This would then require scientific validation and quality assessment, 
comparing correlation between the point of care device with clinical disease 
activity and practicality (for example within the Alder Hey and GOSH cohorts). 
Subsequently, prospective testing of it in a large cohort of patients (eg: 
nationally through the UK JSLE Cohort Study) would be required.  
Use of urinary biomarker point of care device in interventinal trials and 
management pathways: Following successful development of such a point of 
care device incorporating a panel of biomarkers for LN, commercialisation and 
patency of the product could be established. Such a non-invasive biomarker 
device could then be used to design biomarker-led care pathways and 
interventional management trials in LN. Interventional trials of therapeutic 
agents could use such a device and in parallel determine its cost-
effectiveness, clinical utility and importantly whether early intervention reduced 
the long-term renal damage in children with LN.  
Potential new therapeutic targets arising from these data: As well as 
identifying urinary biomarkers of LN, this study has also focussed on the origin 
on the biomarker MCP-1, and in particular its expression and regulation within 
the renal glomerulus. Recent data indicate that activated T cells release high 
levels of angiotensin II that drives vascular changes and facilitates 
inflammatory cell entry into organs, including increased MCP1 expression via a 
P13k/Akt pathway (407). Both MCP1 and the P13k/Akt pathway are reduced 
  267 
by angiotensin receptor blockade (ARB) treatment and this may explain the 
significant anti-proteinuric ability of these drugs (408). In view of the data 
arising from this study in relation to MCP1 expression in response to a 
systemic inflammatory response, the addition of angiotensin inhibition may be 
an ideal therapeutic intervention for glomerulonephritis identified early by 
biomarker monitoring. A biomarker-led randomised placebo controlled trial of 
the use of early angiotensin inhibition could be conducted aimed at early 
immunological intervention. For example, such a trial could utilise MCP1 as a 
marker of renal involvement in LN, randomise patients with a biomarker 
concentration above the defined threshold to receive an intervention (such as 
ARB treatment) or placebo, together with background immunosuppression, 
and measure the renal outcome in terms of biomarker improvement and the 
development of proteinuria.  
Validation within an adult cohort of SLE: Whether the findings of this study 
are replicated in an adult lupus population will require further investigation. 
Children with JSLE typically have few co-morbidities and this allows the 
findings to be more easily attributed to the disease. In adults with SLE, 
diseases such as diabetes and atherosclerosis may diminish the strength of 
these findings. This requires adult specific studies to validate. 
 
7.2. Research implications  
7.2.1. Methodology  – Disease and Healthy Controls 
In this study a number of different research methodologies were employed. 
This included cross sectional analysis, comparing JSLE patients depending on 
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the extent of renal involvement and compared to healthy controls. Further 
improvements to this method could be through the use of additional and 
perhaps more specific disease control groups together with their analysis over 
time.  A cohort of children with HSP (some of which had renal involvement) 
was recruited as part of this project, acting as a disease control group, and 
demonstrated that biomarker concentrations were not specific to LN; they were 
purposefully excluded from this final piece of work as it became too 
cumbersome. Using the BILAG scoring system as the gold standard for 
disease activity monitoring meant that proteinuria was not an independent 
measure and was excluded from the multivariate analysis. However proteinuria 
is an essential clinical marker in children with LN. Alternative strategies to this 
would be the comparison with other disease activity tools (such as the 
SLEDAI) or renal histology findings, if protocol biopsies were undertaken. The 
longitudinal study has captured a year of biomarker data, extending this 
analysis. Relating the results of this study to long-term renal outcomes, and 
especially damage would enhance the study findings significantly. A larger 
cohort, monitored over a longer period would allow the influence of potential 
confounding factors, such as medication use, to be related to the results. 
 
7.2.2. Laboratory assays  
A range of laboratory techniques was employed for this study; sample 
processing, ELISA, Western blot analysis, qPCR, multiplex analysis and cell 
culture of a human immortalised cell line. Improving sample collection could be 
made by using specific timed urine samples and the immediate analysis of 
samples to avoid freeze thawing, to prevent any sample processing factors 
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from influencing the level of measured biomarkers. Identifying specific 
biomarkers, based also on careful review of the previous published literature 
has enabled progression with the use of biomarkers nearer to practical clinical 
utility. Employment of proteomic and transcriptomic analysis (for example) of 
our patient samples would allow the evaluation of other novel markers yet to 
be tested or published in the literature.  
 
The human immortalised cell line used in this study was derived from healthy 
podocytes. Access to a cell line that is specific to lupus, or generated from 
specific lupus patients themselves, would add significantly to the strength of 
this study. Methods to undertake this include the optimisation of extracting 
podocytes from the urine samples of patients. It has been demonstrated that 
podocyte loss is measurable in the urine in patients with active LN (400) and 
other groups have cultured immortalised podocyte cell lines from podocytes in 
the urine (409). As demonstrated by Song et al recently, an alternative method 
could be the optimisation of directed differentiation of pluripotent stem cells 
(370). This could be adapted to produce patient-specific podocyte cell culture 
techniques from patient fibroblast cells (skin scrapings). Potentially this method 
could be extended to assess other cell types in JSLE. Preliminary discussions 
in relation to this development have already been made and the University of 
Liverpool’s Stem Cell Consortium could realistically support such work.  
 
7.2.3. Future avenues– Podocyte function in LN 
Following on from this study, a number of future avenues in relation to 
podocye function in LN should be should explored. These include: 
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 The identification of the signalling pathways regulating each of the 
biomarkers that have been studied.  This would include the NFkB pathway 
and the downstream TNFR signalling pathway (illustrated in Figure 1) and 
the influence of angiotensin in vitro, in keeping with proposed early 
intervention studies.  
 Functional analysis of the podocyte in inflammatory conditions (such as 
exposure to TNF-α, biomarkers or lupus serum exposure) would be the 
natural progression from this study including cell migration assays, albumin 
permeability, phagocytic ability and calcium handling.  
 Migration can be investigated using transwell assays where podocyte 
movement from one culture well to another can be quantified, or by scrape-
wound techniques where a wound of specific measurement is made in the 
cell culture plate and migration assessed after a specified time, similar to 
the approach used by Rigothier in their analysis of podocyte IQGAP 
function (410). Podocyte migration in response to biomarker exposure or 
TNF-α could be assessed. Real-time imaging would illustrate these 
techniques.  
 Podocyte permeability can be measured by assessing albumin flux with 
transwell assays and phagocytosis can be evaluated using pH sensitive 
fluroscent dyes where a change in pH during phagocytotic uptake alters the 
colour absorption of the dye detectable by flow cytometry.  
 Calcium is fundamental to slit diaphragm signalling, measuring changes in 
calcium uptake and concentration may help with understanding changes in 
the functional role of the podocyte in maintaining the slit diaphragm, 
methods similar have been described by others.   
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 Further investigation to enhance our understanding of the underlying 
disease mechanisms of LN would include evaluating podocyte TLR protein 
and mRNA expression; assessing the role of inflammatory cell signalling 
mechanisms such as sphingosine-1-phosphate receptor expression in 
lupus (144) aiding the understanding of T-cell migration and inflammatory 
cell entry into the kidney.  
 Finally understanding glomerular damage through the role of the podocyte 
in glomerular crescent formation and the onset of renal fibrosis in LN is 
required.  
 
7.3. Summary and conclusions 
JSLE is the archetypal autoimmune disease. Investigating JSLE therefore 
facilitates our understanding of the human immune system in health and 
disease and allows translation between the clinical and scientific interface. 
This work has direct clinical and biological implications to improving the care 
and understanding of JSLE related renal disease. Specific areas of learning 
from this study are highlighted below and have resulted in a contribution to the 
scientific understanding of JSLE. 
 MCP-1: MCP-1 is known to have important chemotactic abilities. This 
study has confirmed that MCP-1 is present at significant concentration 
in the urine patients with active LN. As its concentration correlated 
significantly with disease activity it suggests that it has a role in 
inflammatory cell infiltration into the kidney and hence worse disease 
activity. This study has shown that it is possible to identify urinary 
biomarkers such as MCP1 and has worked towards integration of such 
  272 
a biomarker into clinical utility using a real-life cohort of children. 
Importantly the study has added to the existing literature in 
demonstrating that the podocyte can express this biomarker and that its 
expression is regulated, at least in part, by TNF-α. This may explain 
why some patients with active LN have a clinical benefit from anti-TNF-
α therapy. However our study has progressed to understand the TNFR 
balance within the podocyte and extrapolating our results may explain 
why complete neutralisation of TNF-α is not the optimal treatment for 
patients with LN and further pathway targeting is required. 
 NGAL: This study has validated the findings previously reported by 
Brunner’s group that NGAL is a good predictor of worsening renal 
disease activity and emphasises the need for this to progress towards 
implementation into clinical use. This work has been the first study to 
show that the podocyte is able to express NGAL at both protein and 
gene concentrations and may contribute to our understanding of why it 
is such a strong indicator of LN activity. NGAL regulation in the 
podocyte has not been clearly demonstrated and should be the focus of 
further investigation, this study has however shown that TNF-α will 
increase NGAL but this may be indirectly or related to the cell death 
process.  
 Other biomarkers: Investigation into AGP and IP10 demonstrated that 
AGP does increase in patients with active LN. However its expression 
was increased in global disease and its specificity for LN may not be 
strong although its presence illustrates that it clearly has a role in lupus. 
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IP10, whilst not a candidate biomarker, correlates strongly with MCP-1, 
NGAL and AGP and it may have a role upstream of these proteins.   
 
This study has aided the establishment of renal research within the Institute of 
Child Health, Alder Hey, through the success of the UK JSLE Cohort Study, 
the collaboration with others and importantly the implementation of an 
immortalised human cell line, thereby encouraging future renal research at the 
University of Liverpool. 
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Appendix 1: BILAG2004 scoring 
Revision: 12/Jan/2007 Updated 110108 1 
BILAG2004 INDEX SCORING 
 
    · scoring based on the principle of physician’s intention to treat 
 
 
Category 
 
 
Definition 
 
 
A 
 
Severe disease activity requiring any of the following treatment: 
 
1. systemic high dose oral glucocorticoids (equivalent to prednisolone > 20  
    mg/day) 
 
2. intravenous pulse glucocorticoids (equivalent to pulse methylprednisolone  
    !  500 mg) 
 
3. systemic immunomodulators (include biologicals, immunoglobulins and  
    plasmapheresis) 
 
4. therapeutic high dose anticoagulation in the presence of high dose steroids  
    or immunomodulators 
      eg: warfarin with target INR 3 - 4 
 
 
B 
 
 
Moderate disease activity requiring any of the following treatment: 
 
1. systemic low dose oral glucocorticoids (equivalent to prednisolone " 20  
    mg/day) 
 
2. intramuscular or intra-articular or soft tissue glucocorticoids injection  
    (equivalent to methylprednisolone < 500mg) 
 
3. topical glucocorticoids 
4. topical immunomodulators 
5. antimalarials or thalidomide or prasterone or acitretin 
6. symptomatic therapy 
      eg: NSAIDs for inflammatory arthritis 
 
 
C 
 
 
Mild disease 
 
 
D 
 
 
Inactive disease but previously affected 
 
 
E 
 
System never involved 
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RENAL 
 
Category A 
Two or more of the following providing 1, 4 or 5 is included: 
 
1. Deteriorating proteinuria (severe) defined as   
 
      (a) urine dipstick increased by !  2 levels (used only if other methods of urine protein estimation not   
             available); or  
 
      (b) 24 hour urine protein > 1 g that has not decreased (improved) by !  25%; or 
      (c) urine protein-creatinine ratio > 100 mg/mmol that has not decreased (improved) by !  25%; or 
      (d) urine albumin-creatinine ratio > 100 mg/mmol that has not decreased (improved) by !  25% 
 
2. Accelerated hypertension  
3. Deteriorating renal function (severe) defined as  
 
      (a) plasma creatinine > 130 mmol/l and having risen to > 130% of previous value; or  
      (b) GFR < 80 ml/min per 1.73 m2 and having fallen to < 67% of previous value; or  
      (c) GFR < 50 ml/min per 1.73 m2, and last time was > 50 ml/min per 1.73 m2 or was not measured. 
 
4. Active urinary sediment 
5. Histological evidence of active nephritis within last 3 months  
6. Nephrotic syndrome 
 
Category B 
One of the following: 
 
1. One of the Category A feature 
 
2. Proteinuria (that has not fulfilled Category A criteria) 
      (a) urine dipstick which has risen by 1 level to at least 2+ (used only if other methods of urine  
             protein estimation not available); or 
 
      (b) 24 hour urine protein !  0.5 g that has not decreased (improved) by !  25%; or 
      (c) urine protein-creatinine ratio !  50 mg/mmol that has not decreased (improved) by !  25%; or 
      (d) urine albumin-creatinine ratio !  50 mg/mmol that has not decreased (improved) by !  25% 
 
3. Plasma creatinine > 130 mmol/l and having risen to !  115% but "  130% of previous value 
 
Category C 
One of the following: 
 
1. Mild/Stable proteinuria defined as 
 
(a) urine dipstick !  1+ but has not fulfilled criteria for Category A & B (used only if other methods  
 of urine protein estimation not available); or 
 
Revision: 12/Jan/2007 Updated 110108 10 
      (b) 24 hour urine protein > 0.25 g but has not fulfilled criteria for Category A & B ; or 
      (c) urine protein-creatinine ratio > 25 mg/mmol but has not fulfilled criteria for Category A & B; or  
      (d) urine albumin-creatinine ratio > 25 mg/mmol but has not fulfilled criteria for Category A & B 
 
 
2. Rising blood pressure (providing the recorded values are > 140/90 mm Hg) which has not fulfilled 
criteria for Category A & B, defined as 
  
(a) systolic rise of !  30 mm Hg; and  
(b) diastolic rise of !  15mm Hg  
 
Category D 
Previous involvement 
 
Category E 
No previous involvement 
 
 
Note: although albumin-creatinine ratio and protein-creatinine ratio are different, we use the same cut- 
          off values for this index 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HAEMATOLOGICAL  
 
  307 
Appendix 2: Manuscript – Disease activity, severity and damage in the 
UK JSLE Cohort 
 
 
This text box is where the unabridged thesis included the following third party 
copyright material: 
Watson L, Leone V, Pilkington C, Tullus K, Rangaraj S, McDonagh JE, Gardner-Medwin J, 
Wilkinson N, Riley P, Tizard J, Armon K, Sinha MD, Ioannou Y, Archer N, Bailey K, 
Davidson J, Baildam EM, Cleary AG, McCann LJ, Beresford MW, on behalf of the UK JSLE 
Study Group. Juvenile-onset SLE: disease activity, severity and damage - The UK JSLE 
Cohort Study. Arthr Rheumat 2012; 64(7): 2356-6 
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Appendix 3: Data collection form; demographic data 
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Appendix 4: Data collection form; ACR criteria at diagnosis  
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Appendix 5: Paediatric BILAG2004 definitions and guidance 
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Appendix 6: Data collection form; BILAG index 
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Appendix 7: Data collection form; annual assessment 
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Appendix 8: Ethical approval 
 
 
 
 
 
 
 
 
Appendix 9: Letter of access, Great Ormond Street Hospital 
 
 
This text box is where the unabridged thesis 
included: 
Ethical approval letter 
This text box is where the unabridged thesis 
included: 
Letter of access, GOSH 
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Appendix 10: Summary of JSLE data collection forms 
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Appendix 11: Summary of JSLE investigations 
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Appendix 12: Sample transfer standard operating procedure  
A protocol for the safe transfer of samples (plasma/serum/urine, as 
appropriate) from the recruiting centres to the UK JSLE coordinating centre 
(Alder Hey). 
Recruiting centre: 
1. The recruiting centre should inform Carla Roberts (UK JSLE Study 
Coordinator) via email that you would like to arrange a transfer of frozen 
samples from your centre to the coordinating centre (Alder Hey).   
2. Carla will then contact a nominated person within the Alder Hey Lupus 
research group to liaise with you directly. 
3. You will usually be asked to check whether your local hospital 
laboratory has any spare dry ice that could be used for transportation. 
4. If there is no local supply of dry ice a delivery of dry ice will be arranged 
to your local laboratory (further detail will be provided via email/phone). 
5. An appropriate box will be sent to your department containing the 
packaging labels for transfer +/- dry ice. 
6. Once the box has arrived, a set date will be arranged for the box to be 
collected by Parcel force. 
7. Please package the samples within a plastic bag in the box containing 
dry ice, place the labels on the outside and seal the box. 
8. Await collection of the box by Parcel force. 
9. Any delays in the collection please contact the parcel force head 
quarters on 08708 501150 stating your postcode. Any problems contact 
the Liverpool team directly as below. 
10. On arrival to the Alder Hey laboratories the research group will inform 
Carla about their safe arrival. 
11. Carla will send an email to the recruiting centre to confirm this. 
Liverpool Research team: 
1. When contacted by Carla about samples to be collected email the 
relevant person directly. 
2. Send an empty polystyrene box to the recruiting centre, which must be 
in a cardboard box and inside place a printed ICH address label, dry ice 
labels and biological substance labels. 
3. Explore as to whether they have a local supply of dry ice.  If not arrange 
delivery of dry ice to the local laboratory in liaison with their lab staff (we 
can arrange dry ice through Yara www.yara.co.uk, cost £63 c/o 
G.Jeffers) 
4. Arrange a suitable date for collection. 
5. Arrange collection using the University of Liverpool postal department 
(Parcelforce), fax a letter to the department requesting the collection 
date, approximate weight of package and addresses for collection and 
delivery, must include a reference name and grant code for billing. 
Postal dept fax number 0151 794 2256. Follow this up with a phonecall 
0151 794 2257 to ensure it has been received. 
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Please note all transferred samples must contain JSLE study numbers only 
and must not contain any identifiable patient data.  
Appropriate contact details for further information; 
Mrs Carla Roberts 
JSLE Administrator 
University of Liverpool 
Department of Women's and Children's Health   Institute of Translational 
Medicine (Child Health)    
Alder Hey Children's NHS Foundation Trust    
Eaton Road,  
Liverpool   
L12 2AP    
T: +44 (0) 151 293 3566  F: +44 (0) 151 293 3566 
E: robertsc@liv.ac.uk 
 
Dr Angela Midgley/Dr Lucy Ballantine 
Department of Women's and Children's Health   Institute of Translational 
Medicine (Child Health)    
Alder Hey Children's NHS Foundation Trust    
Eaton Road,  
Liverpool   
L12 2AP 
T: +44 (0) 151 252 5690 
E: angela.midgley@liv.ac.uk or Lucy.Ballantine@liv.ac.uk 
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Appendix 13: Renal biomarkers in JSLE standard operating procedure 
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Appendix 14: UK JSLE Cohort Study and Repository information sheets 
UK JSLE Cohort Study & Repository - COREC Info Sheets – Version 1.3 – 16th October 2009 13 
Hospital / Institution’s headed paper 
 
UK Juvenile Lupus Cohort Study and Repository 
 
Information sheet for Parents (Liverpool only) 
Version 1.3 – 16th October 2009 
 
1. Introduction 
· We are asking if you would agree for your child to take part in this project. 
· It is important to understand why the research is being done and what it will involve  
· Please take time to read this carefully and talk about it with your child and anyone 
you want to. 
Thank you for reading this 
 
2. Why are we doing this research? 
· Lupus can affect people in many different ways. Unfortunately we do not understand 
what causes it, especially in children. We would like to understand much more about 
lupus. 
· For this reason, we have started a “cohort study” of young people with lupus from 
across the UK. We want to learn about how lupus affects them, how they are 
treated, what causes lupus and the roles genes have. We know that white blood cells 
are important but we don’t understand why.  We are aware that the kidneys may get 
affected by lupus and we would like to know more about how to detect this kidney 
involvement. 
 
3. Why has your child been asked to take part? 
· Your child has been chosen because they have lupus.  
· Almost all the main hospitals in the UK who look after children with lupus are taking 
part. We hope to study about 500 children and young people with lupus 
 
4. Does your child have to take part? 
· No! It’s up to you and your child.  
· You and your child can change your minds at any time without giving a reason 
· If you or you child decide to stop taking part it will NOT affect the care they 
receive 
 
5. What will happen if your child takes part? 
· Your child’s doctor normally assesses how your child is, with questions, an 
examination, and some blood/urine tests.  
· We will record this information for the study. This study is an “observational study” 
as it involves carefully describing and watching what happens over time. 
· We will collect information when your child comes for routine checkups or if they 
are poorly, for as long as they are being looked after by doctors taking part in this 
study. 
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6. Will any samples be collected? 
· Results of routine tests will be recorded.   
· On two occasions when your child is having their usual blood tests, we will collect a 
little extra blood (a fifth of a teaspoon). This will be stored to measure their 
autoantibodies (antibodies the body produces against itself) in a reference 
laboratory.  
· An extra teaspoon full of blood to study white cells and kidney involvement when 
your child is well and sick, as well as a urine sample, and if only just diagnosed, 
before they start treatment and at one week, one month and three months after 
starting treatment.  
· One time when your child is having their usual blood tests, we will collect an extra 
sample of blood (1-2 teaspoons). We will invite you and your child to donate this as a 
gift to the project organisers. It will be stored and in the future used to determine 
the role of genes in lupus.  
· Your child will not need any extra needles to collect these samples.  
 
7. What will your child be asked to do? 
We are asking your permission: 
· To collect all the information your child’s doctor normally collects about their lupus 
for the purpose of the study 
· To record your child’s name and hospital numbers on a list in their doctor’s locked 
office so we know they are part of the study 
· To collect a little extra blood and urine when they are having tests anyway (see 
above) 
· To let us get in touch with your child in the future through their GP and hospital 
doctors about future studies of lupus to see if you and your child are interested in 
taking part. We would do this through your child’s hospital records and using your 
child’s own NHS number.  
· To tell your child’s GP that they are in this study 
 
8. Are there any disadvantages in taking part?  
· No.  Taking part in the study will not change how we look after your child 
· The amount of extra blood and urine we will collect is very small and will be collected 
only when your child is having tests anyway 
 
9. Are there any advantages in taking part? 
· We hope to understand more about lupus to help us treat patients better in the 
future 
 
10. Will anyone know your child is taking part? 
· Yes – your child’s GP and hospital doctors will know they are taking part. Someone 
involved in the study may check your child’s medical records to make sure the study 
is being carried out correctly 
 
11. What will happen to the results of the research study? 
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· Everything we discover from the study will be published in medical journals for 
everyone to see. Results may not be available for several years. 
 
 
12. Who is organising and funding the research? 
· It is being organised by a group of doctors and nurses from the hospitals taking 
part. The group is called the “UK JSLE Study Group.”  
· It is run from the Alder Hey Children’s NHS Foundation Trust, Alder Hey, Liverpool.  
· The collection of clinical data is not funded. No one receives any payment for being 
involved in this study. The Research and Development Department at Alder Hey and 
the charity Lupus UK are funding the study of white blood cells in lupus. The Alder 
Hey Renal Fund, Alder Hey Children’s NHS Foundation Trust is funding the Renal 
Biomarkers project.   
· Charities will be approached for funding of any other related studies.  
 
13. Who has reviewed the study? 
· The Liverpool Paediatric Research Ethics Committee has given Multicentre Research 
Ethics approval and your local Research Ethics Committee has also reviewed it. 
 
14. What will happen to the information collected about your child? 
· All information and samples collected from your child will be strictly confidential 
and anonymised. This means that no-one will know it belongs to them.  
· Forms will be kept in their doctor’s office or in the offices of the UK JSLE Study 
Group (Institute Child Health, University of Liverpool). All forms will be stored in 
locked filing cabinets in rooms that are locked when non-attended.  
· All information kept on study computers, kept in study offices, will only record data 
using your child’s unique study number and be strictly confidential. Details 
identifying who they are will not be kept on the study computer. All electronic 
transfer of data will use codes.  
· In their doctor’s locked office in a locked cabinet your child’s doctors will keep a list 
with your child’s name, hospital number and NHS number that registers them as 
taking part in the study. This will be the only place where their name and the unique 
study number are linked. No one other than their doctors will have access to this.  
 
15. What will happen to any samples my child gives? 
· Samples that are collected routinely by their doctor will be tested in the usual way 
· Study samples will be stored in your child’s local hospital until they are carefully 
transferred to the relevant laboratories.  
· Autoantibodies will be analysed in the laboratory of Dr N McHugh, Consultant 
Rheumatologist, Royal National Hospital for Rheumatic Diseases, Bath. 
· White blood cells will be tested in the laboratories of Professor S Edwards, School 
of Biological Sciences, University of Liverpool and the laboratories at the Institute 
of Child Health, Alder Hey Children’s NHS Foundation Trust 
· Detecting markers of kidney damage will be tested in the laboratories at the 
Institute of Child Health, Alder Hey Children’s NHS Foundation Trust. 
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· Samples collected for future genetic tests will be stored in the laboratories of the 
Institute of Child health, University of Liverpool, under the care of Dr M 
Beresford, Senior Lecturer and the Manchester Cell Culture laboratory 
Professor Crow, University of Manchester. These studies will need approval from an 
Ethics Committee and the UK JSLE Study Group Steering Committee. No genetic 
results will be available for your child.  
 
16. What if I have a problem or would like further information about the study? 
· Please speak to your doctor, your local hospital’s complaints department, or contact 
Dr Michael Beresford, Institute of Child Health, Alder Hey Children’s NHS 
Foundation Trust, L12 2AP (tel. 0151 252 5153, email 
m.w.beresford@liverpool.ac.uk).  
 
Thank you for reading this – please ask questions if you need to  
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Appendix 15: UK JSLE Cohort Study and Repository consent forms 
UK JSLE Cohort Study & Repository - COREC Consent Forms Version 1.3 – 16th October 2009 6 
Parental Consent Form (on local centre headed paper) 
(Liverpool only) 
UK Juvenile SLE Cohort Study and Repository  
Please INITIAL box 
1.  I have read and understand the information sheet (Version 1.3 – 16th 
October 2009) for the above study and have had the chance to ask 
questions 
 
2. I understand my child’s taking part is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my child’s medical 
care or legal rights being affected 
 
3. I understand that relevant sections of my medical notes and data collected 
during the study may be looked at by responsible individuals from the UK 
JSLE Cohort Study & Repository research team, from regulatory authorities, 
or from the NHS Trust  where it is relevant to my taking part in this 
research but understand strict confidentiality will be maintained. I give 
permission for these individuals to have access to my records. 
 
4.  I agree that a small amount of my child’s blood may be used to investigate 
white blood cells and also stored and then used to measure their 
autoantibodies 
 
5. I agree that a small amount of my child’s blood may be collected and then 
gifted to the “UK JSLE Study Group.” It will be stored for future genetic 
studies. I understand that no result on my child’s genes will be fed back to 
them or anyone else. 
 
6. I agree that a small amount of my blood and urine samples may be used to 
look into ways of detecting kidney damage in lupus.. 
 
7. I agree for my child to take part in the above study 
 
 
8. I agree to allow researchers to make contact with me and my child about 
other studies or a follow-up of this study through my child’s doctors and my 
child’s NHS number 
 
9. I give permission for my child’s GP to be informed that information about my 
child is to be held on the study database 
 
 
Name of patient 
 
    
Name of person with parental 
responsibility for patient 
 
 Date  Signature 
Name of person taking consent  
(if different from researcher) 
 
 Date  Signature 
Researcher  Date  Signature 
1 copy for patient and person with parental responsibility, 1 for researcher, 1 to be kept 
with hospital notes
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Appendix 16: TNF-α protein concentration (pg/ml) in macrophages 
exposed to interferon gamma (IFN) at different concentrations 
Experiment - TNF-α 
concentration
IFNγ 1ng/ml IFNγ 10ng/ml IFNγ 100ng/ml
1 1020 843.6 308.2
2 954.5 574.5 154.5
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Appendix 17: Plasma cytokine cohort: Demographic data 
Plasma	cohort	
number
Patient	
study	
number
Patient	group Sex Ethnicity
Age	
(years)
Age	at	
diagnosis	
(years)
ACR	SLE	
classification	
score
Global	
BILAG	
score
Urine	
Albumin:Creat
inine	Ratio
Estimated	
Glomerular	
Filtration	Rate
Anti-double	
straned	DNA	
titre	IU/L
Erythocyte	
sedimentation	
rate	(ESR)
Plasma	cohort	1 15005 Lupus F Other 13.9 8.6 4 4 0.9 MD 14 5
Plasma	cohort	2 15009 Lupus F Cauc 15.7 10.5 4 0 MD 143 10 6
Plasma	cohort	3 15010 Lupus F Cauc 13.4 1.8 4 1 1.1 MD MD 6
Plasma	cohort	4 15030 Lupus F Other 16.4 9.1 4 6 0.8 118 MD 17
Plasma	cohort	5 15033 Lupus M Cauc 12.8 8.1 4 1 0.8 148 MD 15
Plasma	cohort	6 15049 Lupus F Other 14.5 10.6 5 2 MD 140 MD MD
Plasma	cohort	7 15051 Lupus F Cauc 15.3 12.7 4 7 1.4 128 1 15
Plasma	cohort	8 15054 Lupus M Other 6.0 5.1 5 4 1.1 MD MD 10
Plasma	cohort	9 15066 Lupus F Other 9.7 8.2 4 1 0.8 104 4 15
Plasma	cohort	10 15111 Lupus F Cauc 13.8 8.3 6 0 0.7 122 39 MD
Plasma	cohort	11 15113 Lupus F Other 17.1 13.7 7 1 4.5 155 MD MD
Plasma	cohort	12 10001 Lupus F Cauc 17.9 14.5 6 0 2 112 21 7
Plasma	cohort	13 10015 Lupus F Cauc 14.6 11.4 4 3 11 103 0 3
Plasma	cohort	14 15002 Lupus	nephritis F Other 15.8 12.5 7 MD 11.1 127 MD 9
Plasma	cohort	15 15004 Lupus	nephritis F Other 14.9 8.0 5 4 51.3 MD 116 50
Plasma	cohort	16 15052 Lupus	nephritis M Cauc 14.3 10.1 6 4 4.8 131 1 10
Plasma	cohort	17 15057 Lupus	nephritis F Other 14.0 12.8 4 4 2.4 105 7 22
Plasma	cohort	18 15105 Lupus	nephritis F Other 16.3 10.0 5 3 1.2 136 MD MD
Plasma	cohort	19 15121 Lupus	nephritis F Other 7.2 6.3 5 3 2.7 160 48 11
Plasma	cohort	20 10007 Lupus	nephritis M Other 17.9 13.3 7 3 23 94 0 10
Plasma	cohort	21 10051 Lupus	nephritis F Cauc 16.0 15.9 6 25 2 128 40 13
Plasma	cohort	22 15018 Lupus	nephritis F Cauc 17.3 11.3 4 MD MD MD MD 12
Plasma	cohort	23 15026 Lupus	nephritis F Cauc 14.8 10.6 7 3 0.8 MD 20 15
Plasma	cohort	24 15036 Lupus	nephritis F Other 15.1 13.4 4 8 1.3 134 89 30
Plasma	cohort	25 15069 Lupus	nephritis F Other 16.0 15.5 8 3 MD 113 MD 30
Plasma	cohort	26 C53a Healthy	 F cauc 13.3 NA NA NA NA NA NA NA
Plasma	cohort	27 C57a Healthy	 F cauc 14.5 NA NA NA NA NA NA NA
Plasma	cohort	28 C65a Healthy	 F cauc 13.4 NA NA NA NA NA NA NA
Plasma	cohort	29 C71a Healthy	 F cauc 15.3 NA NA NA NA NA NA NA
Plasma	cohort	30 C73a Healthy	 F cauc 16.6 NA NA NA NA NA NA NA
Plasma	cohort	31 C75a Healthy	 M cauc 13.0 NA NA NA NA NA NA NA
Plasma	cohort	32 C76a Healthy	 M cauc 15.4 NA NA NA NA NA NA NA
Plasma	cohort	33 C77a Healthy	 M cauc 11.5 NA NA NA NA NA NA NA
Plasma	cohort	34 C78a Healthy	 F cauc 16.0 NA NA NA NA NA NA NA
Plasma	cohort	35 C81a Healthy	 M cauc 9.2 NA NA NA NA NA NA NA
American	college	rheumatology;	ACR,	British	isles	lupus	assessment	group	index;	BILAG,	MD;	missing	data,	NA;	not	applicable
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Appendix 18: Plasma cytokine cohort: Concentrations 
Plasma	cohort	
number
Plasma	MCP-
1	pg/ml
Plasma	IP	10	
pg/ml
Plasma	VEGF	
pg/ml
Plasma	
IFNgamma	
pg/ml
Plasma	Ilbeta	
pg/ml
Plasma	IL	13	
pg/ml
Plasma	IL	6	
pg/ml
Plasma	TNF	
alpha	pg/ml
Plasma	cohort	1 17.46 147.93 0.00 0.00 0.69 0.62 1.20 5.38
Plasma	cohort	2 183.03 546.53 34.42 1504.05 14.61 29.35 124.28 689.49
Plasma	cohort	3 70.98 488.30 0.00 0.00 0.53 0.40 0.00 6.54
Plasma	cohort	4 18.31 81.17 0.00 32.77 0.85 1.59 0.00 9.49
Plasma	cohort	5 150.74 319.25 0.00 28.31 0.59 0.51 3.14 5.96
Plasma	cohort	6 89.00 662.75 9.92 389.90 5.66 15.93 58.29 238.18
Plasma	cohort	7 75.91 512.98 22.71 169.34 3.05 0.95 46.87 154.18
Plasma	cohort	8 3.46 44.71 0.00 0.00 0.80 1.49 0.00 8.90
Plasma	cohort	9 31.59 346.70 0.00 0.00 0.59 0.62 0.00 3.08
Plasma	cohort	10 201.89 310.23 0.01 9.44 1.29 4.21 19.77 36.50
Plasma	cohort	11 59.75 855.70 0.00 0.00 1.77 3.79 15.86 62.51
Plasma	cohort	12 33.82 159.97 0.00 0.00 0.91 1.27 3.88 14.28
Plasma	cohort	13 31.78 231.30 0.00 0.00 0.75 1.17 11.88 29.63
Plasma	cohort	14 1.25 58.70 0.00 0.00 0.48 0.73 0.00 1.96
Plasma	cohort	15 6.76 78.37 0.00 0.00 0.64 1.06 0.34 6.54
Plasma	cohort	16 103.13 751.88 0.00 1009.31 19.89 13.38 79.60 411.98
Plasma	cohort	17 147.39 632.28 25.49 2318.29 37.98 38.22 170.81 580.90
Plasma	cohort	18 92.82 532.72 6.80 37.17 2.43 10.21 15.70 166.17
Plasma	cohort	19 73.33 444.25 79.97 28.31 5.14 25.51 72.72 190.27
Plasma	cohort	20 49.27 639.38 7.36 32.77 0.80 1.49 8.49 12.48
Plasma	cohort	21 124.82 1432.51 12.48 23.77 1.07 5.54 11.21 45.95
Plasma	cohort	22 33.06 116.12 0.00 23.77 0.85 2.02 22.03 49.75
Plasma	cohort	23 262.45 2470.08 18.12 4906.27 155.84 17.93 283.24 1523.83
Plasma	cohort	24 76.57 1282.58 50.01 527.75 11.72 23.07 82.57 326.02
Plasma	cohort	25 54.07 374.78 44.08 106.65 1.52 6.05 28.89 88.34
Plasma	cohort	26 47.16 1973.78 0.00 23.77 0.80 1.49 7.27 20.37
Plasma	cohort	27 46.00 333.05 0.00 0.00 0.43 0.46 0.00 0.86
Plasma	cohort	28 57.74 255.23 0.00 0.00 0.53 0.40 0.00 3.08
Plasma	cohort	29 148.31 398.11 0.00 0.00 0.64 0.40 0.00 11.28
Plasma	cohort	30 75.68 482.00 37.99 300.40 5.54 13.13 57.67 162.84
Plasma	cohort	31 36.98 258.72 0.00 122.14 1.74 0.51 8.66 42.79
Plasma	cohort	32 37.23 244.25 4.53 52.17 1.38 1.38 27.30 85.74
Plasma	cohort	33 21.89 150.58 0.00 1.28 0.85 1.06 7.10 24.67
Plasma	cohort	34 31.52 403.89 0.00 0.00 0.48 1.65 0.00 1.96
Plasma	cohort	35 63.26 2281.31 0.00 357.48 5.82 2.65 62.13 212.48
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Appendix 19: Cross sectional urine biomarkers: JSLE cohort 
Cross sectional urine 
biomarker cohort: JSLE 
patients
Patient group Ethnicity Sex Age (years)
Age at 
diagnosis 
(years)
Disease 
duration 
(years)
Average urine 
creatinine 
pg/ml
Average 
urine NGAL 
concentration 
ng/ml
Average 
urine MCP1 
concentratio
n pg/ml
Average 
urine IP10 
concentratio
n pg/ml
Avereage 
urine AGP 
concentratio
n pg/ml
JSLE cross sectional 1 Lupus Cauc F 17.95 14.51 3.45 40.30 21.20 161.00 0.00 281.00
JSLE cross sectional 2 Lupus Bangladeshi M 16.78 13.30 3.48 130.50 MD 84.00 58.00 5582.00
JSLE cross sectional 3 Lupus African F 13.92 8.58 5.34 173.00 12.80 131.00 7.00 238.00
JSLE cross sectional 4 Lupus Cauc F 15.72 10.97 4.75 69.00 50.30 306.00 23.00 317.00
JSLE cross sectional 5 Lupus Cauc F 13.44 1.80 11.64 266.00 72.90 133.00 37.00 120.00
JSLE cross sectional 6 Lupus Cauc F 9.88 7.20 2.68 MD 26.60 MD 0.00 101.00
JSLE cross sectional 7 Lupus irish F 17.25 11.32 5.93 22.00 42.30 299.00 0.00 747.00
JSLE cross sectional 8 Lupus African M 8.08 4.42 3.66 329.00 5.10 321.00 6.20 MD
JSLE cross sectional 9 Lupus Cauc F 14.75 10.58 4.17 0.60 104.00 17390.00 17792.00 5041.00
JSLE cross sectional 10 Lupus Cauc F 13.41 10.78 2.63 133.00 16.50 65.00 40.00 90.00
JSLE cross sectional 11 Lupus Mixed race F 14.67 9.00 5.67 226.00 17.00 MD MD MD
JSLE cross sectional 12 Lupus Mixed race F 16.35 9.05 7.31 417.00 23.00 63.30 MD 103.00
JSLE cross sectional 13 Lupus Cauc F 5.67 3.45 2.22 5.00 2.50 1027.00 1775.00 2636.00
JSLE cross sectional 14 Lupus Cauc M 12.83 8.11 4.72 247.00 12.90 141.00 79.00 246.00
JSLE cross sectional 15 Lupus Mixed race F 15.50 13.42 2.08 490.00 203.00 156.00 3.00 288.00
JSLE cross sectional 16 Lupus Cauc M 14.67 10.25 4.42 MD 2.30 MD MD MD
JSLE cross sectional 17 Lupus Cauc M 14.33 10.11 4.22 248.00 24.70 205.00 36.00 752.00
JSLE cross sectional 18 Lupus Caribbean F 10.75 10.17 0.58 146.00 2.40 209.00 14.00 242.00
JSLE cross sectional 19 Lupus Other asian M 6.04 5.12 0.92 171.00 20.00 400.00 20.00 1042.00
JSLE cross sectional 20 Lupus Cauc F 8.08 4.24 3.84 212.00 21.30 193.00 2.70 140.00
JSLE cross sectional 21 Lupus Indian F 14.25 12.84 1.41 38.00 7.30 251.00 MD 553.00
JSLE cross sectional 22 Lupus African F 9.72 8.18 1.54 144.00 37.00 215.00 1.00 89.00
JSLE cross sectional 23 Lupus African M 2.23 296.00 2.20 MD MD 119.00
JSLE cross sectional 24 Lupus Mixed race F 16.27 10.02 6.25 426.00 8.90 227.00 24.00 186.00
JSLE cross sectional 25 Lupus Cauc F 14.08 8.34 5.74 326.00 49.20 57.00 17.00 112.00
JSLE cross sectional 26 Lupus Cauc M 14.63 6.33 8.30 157.00 17.20 168.00 14.00 485.00
JSLE cross sectional 27 Lupus Other white F 17.45 13.63 3.83 164.00 53.60 276.00 MD 1165.00
JSLE cross sectional 28 Lupus Cauc F 14.64 11.40 3.24 78.00 2.60 265.00 0.00 1308.00
JSLE cross sectional 29 Lupus Other white M 15.02 12.44 2.58 119.00 11.50 242.00 11.00 784.00
JSLE cross sectional 30 Lupus Cauc F 18.73 16.08 2.65 164.00 44.80 57.00 31.00 381.00
JSLE cross sectional 31 Lupus Bangladeshi M 7.51 3.99 3.52 27.50 2.00 281.00 0.00 4714.00
JSLE cross sectional 32 Lupus Cauc F 17.65 15.02 2.63 108.00 11.50 99.00 24.00 150.00
JSLE cross sectional 33 Lupus Indian M 17.44 15.19 2.25 286.00 73.60 154.00 21.00 540.00
JSLE cross sectional 34 Lupus Cauc F 14.07 12.78 1.29 203.00 22.70 MD 20.00 335.00
JSLE cross sectional 35 Lupus Cauc F 12.02 10.50 1.52 81.00 MD 708.00 97.00 1682.00
JSLE cross sectional 36 Lupus Cauc F 12.16 11.08 1.08 73.00 12.30 177.00 10.00 4190.00
JSLE cross sectional 37 Lupus Cauc M 3.02 2.60 0.43 105.00 MD MD 476.70 MD
JSLE cross sectional 38 Lupus Cauc F 12.34 11.91 0.44 32.67 14.20 262.00 0.00 250.00
JSLE cross sectional 39 Lupus Cauc F 13.32 13.26 0.06 8.67 19.50 1007.00 134.00 18272.00
JSLE cross sectional 40 Lupus Indian F 15.88 15.59 0.29 34.50 21.70 204.00 0.00 829.00
JSLE cross sectional 41 Lupus Cauc F 16.04 15.91 0.13 279.00 63.80 422.00 42.00 618.00
JSLE cross sectional 42 Lupus African F 16.17 12.51 3.66 495.00 34.70 53.00 13.00 492.00
JSLE cross sectional 43 Lupus Cauc F 16.17 10.86 5.31 93.00 15.20 252.00 20.60 MD
JSLE cross sectional 44 Lupus Other F 17.09 13.71 3.38 285.50 29.50 44.00 3.00 666.00
JSLE cross sectional 45 Lupus Cauc F 17.43 8.22 9.21 13.00 MD MD MD 30547.00
JSLE cross sectional 46 Lupus Other white M 16.16 15.14 1.02 257.00 2.10 66.00 13.00 464.00
JSLE cross sectional 47 Lupus Cauc M 11.77 3.36 8.41 204.00 7.80 0.00 44.00 306.00
JSLE cross sectional 48 Lupus Cauc F 16.69 12.93 3.76 106.50 28.40 251.00 0.00 892.00
JSLE cross sectional 49 Lupus Pakistani F 14.91 14.48 0.43 79.00 15.70 267.00 44.00 5725.00
JSLE cross sectional 50 Lupus Indian F 14.14 7.81 6.33 MD 27.60 MD MD MD
JSLE cross sectional 51 Lupus Cauc M 17.63 11.28 6.35 127.00 3.70 408.00 6.00 808.00
JSLE cross sectional 52 Lupus Other F 14.47 10.59 3.88 95.00 5.10 117.00 16.00 2.00
JSLE cross sectional 53 Lupus nephritis African F 14.90 7.99 6.91 431.00 54.20 330.00 35.00 753.00
JSLE cross sectional 54 Lupus nephritis Cauc F 15.68 13.99 1.69 351.00 535.00 303.00 Md 1517.00
JSLE cross sectional 55 Lupus nephritis Bangladeshi F 16.03 15.53 0.50 251.00 15.60 46.00 16.50 231.00
JSLE cross sectional 56 Lupus nephritis African F 15.21 13.55 1.66 185.00 370.00 4480.00 145.00 1846.00
JSLE cross sectional 57 Lupus nephritis African F 18.16 13.94 4.22 66.00 9.20 833.00 21.00 2389.00
JSLE cross sectional 58 Lupus nephritis Other F 12.44 12.34 0.10 137.00 28.10 1596.00 45.00 2647.00
JSLE cross sectional 59 Lupus nephritis Other F 8.42 6.54 1.88 83.00 28.40 2268.00 MD 1354.00
JSLE cross sectional 60 Lupus nephritis African F 7.20 6.28 0.92 102.00 6.30 233.00 15.00 403.00  
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Appendix 20: Cross sectional urine biomarkers: Healthy control cohort 
Cross sectional 
urine 
biomarker 
cohort: Control 
patients
Study 
number
Patient 
group 
Ethnicity
Age 
(years)
Average urine 
creatinine 
pg/ml
Average urine 
IP10 
concentration 
pg/ml
Average urine 
MCP1 
concentration 
pg/ml
Avereage 
urine AGP 
concentration 
pg/ml
Average urine 
NGAL 
concentration 
ng/ml
Control 1 C71 Control Cauc 5.33 97.00 34.40 84.00 281.50 8.10
Control 2 C73 Control Cauc 6.58 154.00 10.10 47.00 90.50 10.20
Control 3 C74 Control Cauc 7.75 4.00 MD 1212.00 MD 32.40
Control 4 C67 Control Cauc 8.83 134.50 MD 119.00 529.00 0.00
Control 5 C81 Control Cauc 9.17 138.00 244.00 244.00 1278.50 2.10
Control 6 C68 Control Cauc 9.58 199.50 MD 57.00 374.00 0.00
Control 7 C59 Control Cauc 10.25 131.00 32.00 48.15 340.00 21.10
Control 8 C64 Control Cauc 10.33 710.00 MD MD 286.00 0.00
Control 9 C77 Control Cauc 11.25 123.00 MD 272.00 MD 0.00
Control 10 C58 Control Cauc 12.17 38.00 MD 113.10 2304.33 16.60
Control 11 C75 Control Cauc 13.00 258.00 29.70 205.00 542.00 65.60
Control 12 C80 Control Cauc 13.00 49.00 21.50 MD 1375.00 3.50
Control 13 C53 Control Cauc 13.25 142.00 199.60 MD MD 12.30
Control 14 C65 Control Cauc 13.42 203.00 11.20 121.00 791.00 7.10
Control 15 C69 Control Cauc 13.58 155.00 MD 63.00 MD 40.20
Control 16 C62 Control Cauc 13.92 130.50 9.00 121.10 1558.50 36.70
Control 17 C57 Control Chinese 14.50 550.00 12.10 36.40 88.00 0.00
Control 18 C54 Control Cauc 14.83 160.00 MD 116.80 537.00 0.00
Control 19 C56 Control Cauc 14.97 108.00 MD 94.90 63.00 0.00
Control 20 C61 Control Cauc 15.33 56.50 MD 180.30 202.00 0.00
Control 21 C76 Control Cauc 15.42 157.00 28.10 213.00 139.00 0.00
Control 22 C55 Control Cauc 15.75 108.00 MD 141.10 98.00 0.00
Control 23 C78 Control Cauc 15.92 126.00 19.40 103.00 64.50 50.90
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Appendix 21: Manuscript – Urine biomarkers in juvenile-onset SLE 
nephritis 
 
 
This text box is where the unabridged thesis included the following third 
party copyright material: 
Watson L, Beresford MW. Urine biomarkers in Juvenile-onset SLE nephritis. 
Pediatr Nephrol. 2013; Mar;28(3):363-74 
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Appendix 22: Manuscript – Urine monocyte chemoattractant protein 1 
and alpha 1 acid glycoprotein as biomarkers of renal disease activity in 
juvenile-onset systemic lupus erythematosus 
 
This text box is where the unabridged thesis included the following third 
party copyright material: 
Watson L, Midgley A, Pilkington C, Tullus K, Holt RL, Marks S, Jones CA, 
Beresford MW. Urinary Monocyte Chemoattractant protein 1 and Alpha-1-acid 
glycoprotein as biomarkers of renal disease activity in Juvenile-onset Systemic 
Lupus Erythematosus. Lupus. 2012;21:496-501 
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Appendix 23: Longitudinal biomarker cohort: Demographic data 
Longitudinal	
cohort:	JSLE	
patients
Number	of	
episodes
Sex Ethnicity
Age	at	study	
entry	(years)
Age	at	study	
end	(years)
Follow	up	
(days)
Age	at	
diagnosis	
(years)
Length	of	
disease	
(years)
Latest	ACR	
SLE	score
Longitudinal	1 2 F Caribbean 15.25 16.00 273 11.75 3.50 6
Longitudinal	2 3 F African 15.77 16.67 329 12.51 3.26 6
Longitudinal	3 2 F African 14.92 15.72 291 7.99 6.93 5
Longitudinal	4 3 F African 13.89 15.10 441 8.58 5.31 5
Longitudinal	5 2 F Cauc 15.70 15.95 91 10.97 4.73 5
Longitudinal	6 2 F Cauc 13.43 14.43 364 1.8 11.63 4
Longitudinal	7 3 F African 17.96 18.94 357 12.06 5.90 9
Longitudinal	8 2 F Cauc 9.88 10.68 294 7.2 2.68 6
Longitudinal	9 2 M African 8.03 8.31 105 4.42 3.61 5
Longitudinal	10 2 F Cauc 14.77 15.34 210 10.58 4.19 7
Longitudinal	11 3 F Mixed	race 16.35 17.02 245 9.05 7.30 4
Longitudinal	12 6 F Cauc 5.62 7.10 539 3.45 2.17 4
Longitudinal	13 3 M Cauc 12.82 13.67 308 8.11 4.71 5
Longitudinal	14 2 F Caribbean 4.05 4.39 126 2.01 2.04 3
Longitudinal	15 4 F Mixed	race 15.14 16.14 364 13.42 1.72 4
Longitudinal	16 5 F Asian 8.21 9.95 637 6.54 1.67 7
Longitudinal	17 2 F African 14.89 15.70 294 13.55 1.34 6
Longitudinal	18 2 F Cauc 15.26 15.64 140 12.72 2.54 4
Longitudinal	19 3 M Cauc 14.32 15.74 518 10.11 4.21 6
Longitudinal	20 2 F Caribbean 10.74 12.45 623 10.17 0.57 5
Longitudinal	21 5 M Asian 6.04 7.61 574 5.12 0.92 5
Longitudinal	22 2 F Cauc 8.07 8.56 182 4.24 3.83 4
Longitudinal	23 4 F Indian 14.02 15.19 427 12.84 1.18 5
Longitudinal	24 2 F Cauc 9.94 10.40 168 8.58 1.36 3
Longitudinal	25 2 F Indian 14.65 15.09 161 13.01 1.64 5
Longitudinal	26 2 F Cauc 11.61 11.92 112 9.96 1.65 3
Longitudinal	27 3 F African 9.72 11.25 560 8.18 1.54 4
Longitudinal	28 3 M African 2.84 3.93 399 2.23 0.61 7
Longitudinal	29 2 F Bangladeshi 16.01 17.12 406 15.53 0.48 9
Longitudinal	30 4 M Caribbean 12.91 13.87 350 12.7 0.21 6
Longitudinal	31 3 F Cauc 13.76 14.09 120 12.17 1.59 4
Longitudinal	32 2 F Indian 13.90 14.11 77 12.94 0.96 4
Longitudinal	33 2 F Other	white 11.97 12.22 91 4.93 7.04 7
Longitudinal	34 3 F Cauc 16.13 17.09 350 10.86 5.27 6
Longitudinal	35 3 F Cauc 16.44 17.02 210 10.16 6.28 5
Longitudinal	36 2 F Asian 11.54 12.57 378 11.86 -0.32 4
Longitudinal	37 2 F Cauc 13.78 14.05 98 8.34 5.44 6
Longitudinal	38 2 F Indian 14.13 15.22 399 7.81 6.32 5
Longitudinal	39 3 F Caribbean 13.61 14.65 378 12.98 0.63 4
Longitudinal	40 5 F Somalian 12.43 13.88 532 12.34 0.09 4
Longitudinal	41 5 F African 7.19 8.48 469 6.28 0.91 5
Longitudinal	42 2 F Cauc 17.95 18.57 119 14.51 3.44 6
Longitudinal	43 5 M Cauc 14.63 16.24 588 6.33 8.30 6
Longitudinal	44 3 M Cauc 11.77 12.78 371 3.36 8.41 9
Longitudinal	45 2 F Cauc 17.45 18.34 322 13.63 3.82 4
Longitudinal	46 4 F Cauc 14.64 16.02 504 11.4 3.24 4
Longitudinal	47 2 M Cauc 17.63 17.65 7 11.28 6.35 5
Longitudinal	48 11 M Bangladeshi 16.78 18.64 672 13.3 3.48 7
Longitudinal	49 5 F Cauc 16.69 18.30 588 14.48 2.21 6
Longitudinal	50 3 M Bangladeshi 7.51 9.18 608 3.99 3.52 8
Longitudinal	51 2 F Cauc 17.65 18.38 266 15.02 2.63 6
Longitudinal	52 5 M Indian 17.44 18.34 329 15.19 2.25 5
Longitudinal	53 6 F Cauc 14.07 15.72 602 12.78 1.29 5
Longitudinal	54 6 M Cauc 16.16 17.93 644 15.14 1.02 4
Longitudinal	55 5 F Cauc 15.68 17.45 645 13.99 1.69 4
Longitudinal	56 7 F Cauc 12.02 13.13 476 10.5 1.52 7
Longitudinal	57 5 F Cauc 12.16 13.62 532 11.08 1.08 4
Longitudinal	58 10 F Asian 14.91 16.44 560 14.48 0.43 6
Longitudinal	59 4 F Cauc 12.07 13.03 252 11.91 0.16 4
Longitudinal	60 9 F Cauc 13.32 15.06 637 13.26 0.06 6
Longitudinal	61 8 F Indian 15.81 17.57 616 15.59 0.22 5
Longitudinal	62 6 F Cauc 15.98 17.01 375 15.91 0.07 6
Longitudinal	63 5 F Chinese 16.90 17.25 117 16.88 0.02 4
Longitudinal	64 4 F Cauc 14.55 14.92 134 14.52 0.03 4
 
  341 
Appendix 24: Longitudinal biomarker cohort: Biomarker data 
Longitudinal	1 a 273 2 C 4.00 16.70 476.00 404.00 117.82 4.13
b D 13.00 40.30 636.00 260.00 244.62 15.50
Longitudinal	2 a 168 2 B 6.00 34.70 264.00 362.50 72.83 9.57
b 161 3 B 6.00 52.50 445.00 316.00 140.82 16.61
c C 2.00 26.40 265.50 349.00 76.07 7.56
Longitudinal	3 a 291 3 B 4.00 54.20 1422.00 431.00 329.93 12.58
c D 10.00 11.00 116.60 113.00 103.19 9.73
Longitudinal	4 a 182 2 D 4.00 12.80 227.00 173.00 131.21 7.40
b 259 2 D 1.00 14.10 97.10 142.00 68.38 9.93
c D 3.00 13.00 85.10 129.00 65.97 10.08
Longitudinal	5 a 91 2 D 0.00 50.30 201.50 119.00 169.33 42.27
b D 1.00 0.00 0.00 69.00 0.00 0.00
Longitudinal	6 a 364 2 C 1.00 72.90 354.00 266.00 133.08 27.41
b D 0.00 27.30 0.00 55.00 0.00 49.64
Longitudinal	7 c 21 1 C 4.00 206.70 364.00 339.00 107.37 60.97
d 182 3 B 6.00 224.00 354.00 252.00 140.48 88.89
e D 2.00 112.00 159.00 287.00 55.40 39.02
Longitudinal	8 a 294 2 D 1.00 26.60 154.00 71.00 216.90 37.46
b D 0.00 30.40 54.00 131.00 41.22 23.21
Longitudinal	9 a 225 2 C 3.00 5.10 633.00 192.00 329.69 2.66
b D 1.00 0.00 357.00 176.00 202.84 0.00
Longitudinal	10 a 210 2 E 1.00 104.00 104.00 0.60 17333.33 17333.33
b E 4.00 141.00 153.00 92.00 166.30 153.26
Longitudinal	11 a 119 1 C 6.00 23.00 207.50 281.00 73.84 8.19
b 126 3 B 4.00 82.90 91.80 279.00 32.90 29.71
c C 3.00 119.00 71.90 140.00 51.36 85.00
Longitudinal	12 a 112 2 D 1.00 2.50 51.00 5.00 1020.00 50.00
b 105 2 D MD 0.00 43.00 23.00 186.96 0.00
c 49 2 D 2.00 10.00 219.00 97.00 225.77 10.31
d 119 2 C 1.00 14.75 77.90 121.00 64.38 12.19
e 154 2 C 2.00 12.10 271.00 75.00 361.33 16.13
f D 0.00 0.00 166.00 74.00 224.32 0.00
Longitudinal	13 a 133 2 C 1.00 12.00 348.00 180.50 192.80 6.65
b 175 3 D 1.00 17.60 69.00 126.00 54.76 13.97
c B 7.00 0.00 550.00 210.00 261.90 0.00
Longitudinal	14 a 126 2 D 1.00 0.00 0.00 0.00 MD MD
b D 2.00 0.00 23.00 13.00 176.92 0.00
Longitudinal	15*a	just	need	ur	creat133 1 D 8.00 82.00 764.00 MD MD MD
b 231 3 B 11.00 38.80 1017.00 490.00 207.55 7.92
c C 2.00 236.00 122.60 119.00 103.03 198.32
Time	
between	
episodes	
(days)
Episode
Longitudinal	
cohort:	JSLE	
patients
Disease	activity	
group	(worsening	
1,	stable	2,	
improving	3)
Renal	
BILAG	
score
Global	
BILAG	score
Mean	
urine	
NGAL	
ng/ml
Mean	
urine	
MCP1	
pg/ml
Mean	
urine	
creatinine	
mg/dl
Urine	
MCP1/Cr	
(pg/mg	
Cr)
Urine	
NGAL/Cr	
(ng/mg	
Cr)
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Longitudinal	16 a 91 3 B 7.00 196.30 1386.50 108.00 1283.80 181.76
b 476 1 D 1.00 30.70 2530.00 46.00 5500.00 66.74
c 42 2 B 15.00 14.90 3039.00 45.00 6753.33 33.11
d 28 2 A 12.00 38.20 91.00 122.00 74.59 31.31
e A 12.00 46.70 2108.30 143.00 1474.34 32.66
Longitudinal	17 b 42 2 B 4.00 400.60 8288.00 185.00 4480.00 216.54
c B 4.00 1358.00 3110.00 318.00 977.99 427.04
Longitudinal	18 a 140 3 B 7.00 103.00 89.00 256.00 34.77 40.23
b D 1.00 86.50 0.00 116.00 0.00 74.57
Longitudinal	19 a 287 2 D 1.00 24.70 508.00 219.00 231.96 11.28
b 231 2 D 0.00 22.00 342.50 168.00 203.87 13.10
c D 2.00 31.40 148.20 182.00 81.43 17.25
Longitudinal	20 a 623 2 E 2.00 2.30 305.00 146.00 208.90 1.58
c C 2.00 13.10 260.80 181.00 144.09 7.24
Longitudinal	21 a 133 2 D 4.00 20.00 683.00 171.00 399.42 11.70
b 91 2 D 2.00 10.40 102.00 170.00 60.00 6.12
c 231 2 D 1.00 0.00 462.00 87.00 531.03 0.00
d 119 1 D 0.00 0.00 285.40 86.50 329.94 0.00
e B 3.00 0.00 360.00 33.00 1090.91 0.00
Longitudinal	22 a 182 2 C 2.00 21.30 310.00 86.00 360.47 24.77
b D 0.00 0.00 86.00 121.00 71.07 0.00
Longitudinal	23 a 91 2 D 0.00 84.00 95.00 254.00 37.40 33.07
b 119 1 D 6.00 7.30 0.00 38.00 0.00 19.21
c 217 3 B 4.00 96.10 461.00 252.00 182.94 38.13
d D 13.00 22.90 288.80 60.00 481.33 38.17
Longitudinal	24 a 168 2 D 2.00 0.00 31.30 17.00 184.12 0.00
b D 1.00 0.00 33.60 119.00 28.24 0.00
Longitudinal	25 a 161 2 D 2.00 26.30 263.00 154.00 170.78 17.08
b D 4.00 27.40 29.50 136.00 21.69 20.15
Longitudinal	26 a 112 2 E 5.00 25.60 191.00 199.00 95.98 12.86
b C 2.00 17.40 247.00 200.50 123.19 8.68
Longitudinal	27 a 259 2 D 1.00 37.00 309.00 144.00 214.58 25.69
b 301 2 C 5.00 45.90 153.00 161.00 95.03 28.51
c D 2.00 17.60 346.00 97.00 356.70 18.14
Longitudinal	28 b 182 2 D 3.00 2.20 136.00 20.50 663.41 10.73
c D 9.00 0.00 131.00 18.00 727.78 0.00
Longitudinal	29 a 406 2 C 2.00 15.60 153.50 112.00 137.05 13.93
d D 4.00 65.20 287.00 95.00 302.11 68.63
Longitudinal	30 a 77 2 B 11.00 12.00 986.00 68.50 1439.42 17.52
b 196 3 B 6.00 77.20 1488.00 286.50 519.37 26.95
c 78 1 D 11.00 41.40 577.10 241.00 239.46 17.18
d B 6.00 39.20 550.00 302.50 181.82 12.96
Global	
BILAG	score
Mean	
urine	
NGAL	
ng/ml
Mean	
urine	
MCP1	
pg/ml
Mean	
urine	
creatinine	
mg/dl
Urine	
MCP1/Cr	
(pg/mg	
Cr)
Urine	
NGAL/Cr	
(ng/mg	
Cr)
Longitudinal	
cohort:	JSLE	
patients
Episode
Time	
between	
episodes	
(days)
Disease	activity	
group	(worsening	
1,	stable	2,	
improving	3)
Renal	
BILAG	
score
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Longitudinal	31 a 119 2 C 3.00 13.40 258.00 206.00 125.24 6.50
b 231 2 D 4.00 11.00 184.00 116.00 158.62 9.48
c 0 D 0.00 48.00 76.40 MD MD MD
Longitudinal	32 a 77 2 B 5.00 15.90 354.00 79.50 445.28 20.00
b B 5.00 10.90 74.40 56.00 132.86 19.46
Longitudinal	33 *a 91 2 E 1.00 MD MD MD MD MD
b E 1.00 33.40 0.00 54.00 0.00 61.85
Longitudinal	34 b 106 2 D 0.00 10.50 32.00 194.00 16.49 5.41
a 350 2 C 1.00 15.20 514.00 186.50 275.60 8.15
c D 0.00 13.50 172.00 193.00 89.12 6.99
Longitudinal	35 a 147 2 C 1.00 121.00 824.00 230.00 358.26 52.61
b 63 1 C 2.00 195.00 37.00 67.00 55.22 291.04
c B 4.00 186.00 153.00 220.00 69.55 84.55
Longitudinal	36 b 224 2 D 0.00 63.20 53.00 2.00 2650.00 3160.00
d D 0.00 5.35 175.00 51.00 343.14 10.49
Longitudinal	37 a 98 1 D 0.00 45.60 287.50 110.00 261.36 41.45
b B 4.00 49.20 MD 326.00 MD 15.09
Longitudinal	38 b 210 1 D 0.00 122.00 788.00 227.00 347.14 53.74
c B 3.00 132.00 448.00 162.00 276.54 81.48
Longitudinal	39 a 378 3 B 3.00 33.80 667.00 273.00 244.32 12.38
c D 0.00 70.20 298.00 116.00 256.90 60.52
Longitudinal	40 a 133 2 B 4.00 28.10 2186.00 137.00 1595.62 20.51
b 49 2 A 9.00 0.00 0.00 68.00 0.00 0.00
c 350 2 B 3.00 57.40 361.00 91.00 396.70 63.08
e B 7.00 13.60 213.00 61.00 349.18 22.30
Longitudinal	41 a 182 2 C 1.00 6.30 237.00 102.00 232.35 6.18
b 105 2 C 1.00 33.20 411.00 133.00 309.02 24.96
c 77 2 C 1.00 66.50 306.00 171.00 178.95 38.89
d 105 2 C 4.00 39.70 514.00 176.00 292.05 22.56
e C 1.00 159.50 122.00 105.00 116.19 151.90
Longitudinal	42 c 119 2 D 0.00 21.20 65.00 40.30 161.29 52.61
d D 1.00 15.30 0.00 147.33 0.00 10.38
Longitudinal	43 d 84 2 D 5.00 17.30 264.00 157.00 168.15 11.02
e 196 2 C 1.00 12.10 506.00 244.00 207.38 4.96
f 210 2 D 1.00 17.00 66.00 204.00 32.35 8.33
i 98 2 D 0.00 0.00 521.00 192.00 271.35 0.00
j D 0.00 22.20 151.00 86.50 174.57 25.66
Longitudinal	44 *i 98 3 B 3.00 0.00 MD MD MD MD
j 273 2 D 4.00 3.90 303.50 204.00 148.77 1.91
L D 2.00 0.00 0.00 36.00 0.00 0.00
Longitudinal	45 d 322 3 B 3.00 53.60 406.50 164.00 247.87 32.68
e D 1.00 57.10 0.00 49.00 0.00 116.53
Mean	
urine	
NGAL	
ng/ml
Mean	
urine	
MCP1	
pg/ml
Mean	
urine	
creatinine	
mg/dl
Urine	
MCP1/Cr	
(pg/mg	
Cr)
Urine	
NGAL/Cr	
(ng/mg	
Cr)
Longitudinal	
cohort:	JSLE	
patients
Episode
Time	
between	
episodes	
(days)
Disease	activity	
group	(worsening	
1,	stable	2,	
improving	3)
Renal	
BILAG	
score
Global	
BILAG	score
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Longitudinal	46 b 294 1 C 3.00 2.60 197.50 78.00 253.21 3.33
c 56 3 B 3.00 23.80 804.00 345.00 233.04 6.90
d 154 2 D 0.00 173.60 0.00 71.00 0.00 244.51
e D 0.00 16.60 34.00 269.00 12.64 6.17
Longitudinal	47 d 7 2 D 1.00 3.70 589.00 127.00 463.78 2.91
e D 1.00 0.00 107.00 118.00 90.68 0.00
Longitudinal	48 f 126 2 B 3.00 29.30 141.00 130.50 108.05 22.45
g 15 2 B 3.00 30.90 200.00 58.00 344.83 53.28
h 167 3 B 4.00 31.30 0.00 45.00 0.00 69.56
k -140 1 D 0.00 26.90 0.00 76.00 0.00 35.39
i 56 2 B 4.00 34.00 488.00 338.50 144.17 10.04
j 182 2 B 3.00 43.90 106.00 154.00 68.83 28.51
L 84 2 B 3.00 42.30 192.00 220.00 87.27 19.23
m 68 2 B 3.00 38.30 45.00 40.00 112.50 95.75
n 30 3 B 4.00 25.90 551.00 199.00 276.88 13.02
p 84 1 D 1.00 23.10 0.00 55.00 0.00 42.00
q B 4.00 55.40 260.00 78.00 333.33 71.03
Longitudinal	49 c 112 2 C 2.00 28.40 278.50 95.00 293.16 29.89
d 182 2 D 2.00 56.70 275.50 36.00 765.28 157.50
e 112 2 C 2.00 28.00 245.00 81.00 302.47 34.57
f 182 2 D 1.00 15.50 206.00 91.00 226.37 17.03
g C 2.00 44.60 116.00 304.00 38.16 14.67
Longitudinal	50 e 447 2 E 3.00 2.00 153.50 27.50 558.18 7.27
h 161 2 E 3.00 0.00 88.00 116.00 75.86 0.00
i E 10.00 0.00 959.00 77.00 1245.45 0.00
Longitudinal	51 c 266 2 D 1.00 11.20 99.00 118.50 83.54 9.45
d D 1.00 54.40 606.00 183.00 331.15 29.73
Longitudinal	52 f 91 1 C 2.00 69.60 440.00 286.00 153.85 24.34
g 84 3 B 6.00 281.00 2542.00 183.00 1389.07 153.55
h 154 2 D 1.00 41.40 463.00 210.00 220.48 19.71
i D 1.00 75.40 182.00 151.00 120.53 49.93
Longitudinal	53 c 70 2 C 2.00 22.70 563.00 203.00 277.34 11.18
d 112 2 D 2.00 106.00 1117.00 80.00 1396.25 132.50
e 112 2 D 0.00 16.90 253.00 121.00 209.09 13.97
f 168 2 D 0.00 36.40 20.00 86.50 23.12 42.08
g 140 2 D 1.00 12.70 0.00 38.00 0.00 33.42
h C 1.00 40.90 341.00 MD MD MD
Global	
BILAG	score
Mean	
urine	
NGAL	
ng/ml
Mean	
urine	
MCP1	
pg/ml
Mean	
urine	
creatinine	
mg/dl
Urine	
MCP1/Cr	
(pg/mg	
Cr)
Urine	
NGAL/Cr	
(ng/mg	
Cr)
Longitudinal	
cohort:	JSLE	
patients
Episode
Time	
between	
episodes	
(days)
Disease	activity	
group	(worsening	
1,	stable	2,	
improving	3)
Renal	
BILAG	
score
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Longitudinal	54 e 98 3 B 3.00 2.10 177.33 257.00 69.00 0.82
f 112 2 C 2.00 0.00 73.00 231.50 31.53 0.00
g 112 2 C 1.00 0.00 250.00 167.00 149.70 0.00
h 196 2 D 1.00 0.00 16.00 38.00 42.11 0.00
i 126 2 D 0.00 0.00 18.00 89.00 20.22 0.00
j C 1.00 0.00 416.00 189.00 220.11 0.00
Longitudinal	55 a 182 3 B 7.00 532.70 913.50 351.00 260.26 151.77
d 168 2 D 2.00 144.00 1745.00 71.00 2457.75 202.82
e 169 2 C 8.00 53.90 1376.00 281.00 489.68 19.18
j 126 1 D 3.00 120.00 479.00 129.00 371.32 93.02
m B 6.00 147.00 1093.00 231.00 473.16 63.64
Longitudinal	56 d 42 2 D 3.00 77.05 270.00 215.00 125.58 35.84
e 77 2 D 0.00 62.40 331.00 116.00 285.34 53.79
f 35 2 D 35.40 573.00 107.50 533.02 32.93
g 56 2 C 4.00 48.70 118.90 325.00 36.58 14.98
h 98 2 D 3.00 36.50 84.00 77.00 109.09 47.40
i 98 2 C 4.00 38.50 269.00 234.00 114.96 16.45
j D 3.00 50.10 384.50 399.00 96.37 12.56
Longitudinal	57 c 70 2 D 5.00 12.30 177.00 73.00 242.47 16.85
d 238 2 D 1.00 0.00 141.10 60.00 235.17 0.00
e 154 2 C 1.00 29.30 139.00 234.00 59.40 12.52
f 70 2 D 1.00 58.90 160.00 134.00 119.40 43.96
g D 0.00 20.00 168.00 116.00 144.83 17.24
Longitudinal	58 c 9 2 B 8.00 15.70 208.00 79.00 263.29 19.87
d 11 2 B 11.00 20.50 110.00 14.00 785.71 146.43
e 35 3 C 0.00 344.00 108.00 318.52 0.00
f 100 2 C 6.00 13.00 364.00 26.00 1400.00 50.00
g 34 2 D 1.00 0.00 83.00 33.50 247.76 0.00
h 119 2 C 6.00 19.90 107.00 114.00 93.86 17.46
j 57 2 D 4.00 17.90 53.00 125.00 42.40 14.32
k 98 2 D 4.00 25.30 72.00 121.00 59.50 20.91
L 96 2 C 4.00 21.70 188.00 123.50 152.23 17.57
m D 0.00 0.00 0.00 166.00 0.00 0.00
Longitudinal	59 b 112 2 E 1.00 14.20 156.00 24.50 636.73 57.96
c 140 2 E 3.00 24.40 160.00 93.00 172.04 26.24
d E 6.00 47.50 125.00 44.00 284.09 107.95
Mean	
urine	
NGAL	
ng/ml
Mean	
urine	
MCP1	
pg/ml
Mean	
urine	
creatinine	
mg/dl
Urine	
MCP1/Cr	
(pg/mg	
Cr)
Urine	
NGAL/Cr	
(ng/mg	
Cr)
Longitudinal	
cohort:	JSLE	
patients
Episode
Time	
between	
episodes	
(days)
Disease	activity	
group	(worsening	
1,	stable	2,	
improving	3)
Renal	
BILAG	
score
Global	
BILAG	score
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Longitudinal	60 a 21 2 E 1.00 20.40 316.00 8.67 3646.15 235.38
b 14 2 E 0.00 24.20 257.50 47.50 542.11 50.95
c 28 2 E 5.00 29.20 123.67 153.00 80.83 19.08
d 84 2 E 1.00 13.70 145.00 16.00 906.25 85.63
e 98 2 C 4.00 59.20 32.00 150.00 21.33 39.47
f 70 2 D 2.00 50.90 177.00 58.00 305.17 87.76
g 210 1 C 1.00 38.00 327.00 100.00 327.00 38.00
j 112 3 B 3.00 14.10 178.50 130.00 137.31 10.85
k C 2.00 142.00 MD MD MD MD
Longitudinal	61 a 28 2 E 3.00 21.70 141.00 34.50 408.70 62.90
b 28 2 E 0.00 13.60 225.00 30.00 750.00 45.33
c 140 2 E 0.00 24.30 77.00 16.00 481.25 151.88
e 42 2 E 2.00 24.90 336.00 184.00 182.61 13.53
f 84 2 E 0.00 29.80 30.00 136.00 22.06 21.91
g* 208 2 E 1.00 96.10 MD MD MD MD
h 86 2 E 0.00 38.60 1.00 92.00 1.09 41.96
i E 0.00 20.70 0.00 33.00 0.00 62.73
Longitudinal	62 a 22 3 B 25.00 0.00 480.00 46.00 1043.48 0.00
b 83 2 C 3.00 63.80 1138.00 279.00 407.89 22.87
c 69 2 D 0.00 19.50 42.00 139.00 30.22 14.03
d 66 1 D 2.00 15.40 0.00 14.00 0.00 110.00
e 135 3 B 4.00 29.60 62.00 83.00 74.70 35.66
f C 1.00 13.10 107.00 166.00 64.46 7.89
Longitudinal	63 c 6 2 E 5.00 0.00 122.00 63.00 193.65 0.00
d 27 2 C 26.70 1938.00 200.00 969.00 13.35
e 42 2 C 1.00 56.30 147.00 126.00 116.67 44.68
f 42 2 D 1.00 55.10 0.00 58.00 0.00 95.00
g D 0.00 0.00 0.00 56.00 0.00 0.00
Longitudinal	64 a 21 3 B 21.00 49.80 1293.00 216.00 598.61 23.06
b 66 2 B 81.60 486.00 183.00 265.57 44.59
c 47 1 C 5.00 101.00 976.00 274.00 356.20 36.86
d B 9.00 82.30 686.00 98.00 700.00 83.98
Global	
BILAG	score
Mean	
urine	
NGAL	
ng/ml
Mean	
urine	
MCP1	
pg/ml
Mean	
urine	
creatinine	
mg/dl
Urine	
MCP1/Cr	
(pg/mg	
Cr)
Urine	
NGAL/Cr	
(ng/mg	
Cr)
Longitudinal	
cohort:	JSLE	
patients
Episode
Time	
between	
episodes	
(days)
Disease	activity	
group	(worsening	
1,	stable	2,	
improving	3)
Renal	
BILAG	
score
 
  347 
Appendix 25: Macrophage media TNF-α protein concentration in inactive 
or active conditions 
Experiment - 
Macrophage TNF-α 
concentration
Inactive 
macrophage 
media (n=8) 
pg/ml
Active 
macrophage 
media (n=8) 
pg/ml
1 0 351
2 0 77
3 0 317
4 0 337
5 0 20
6 0 279
7 0 110
8 0 0
 
Appendix 26: Macrophage MCP1 protein expression  
Experiment - 
Macrophage 
MCP1 protein 
(ng/ml) 
Active 
macrophage 
media 
condition 
(n=7)
Inactive 
macrophage 
media 
condition 
(n=6)
1 0.3 6.8
2 0.1 7.5
3 0 6.4
4 13.2 0
5 4.6 0.9
6 12.3 0
7 11.3 -
 
Appendix 27: Macrophage NGAL protein expression 
Experiment - 
Macrophage 
NGAL protein 
(ng/ml) 
Active 
macrophage 
media 
condition 
(n=7)
Inactive 
macrophage 
media 
condition 
(n=6)
1 383.4 0
2 40.5 0
3 0 0
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Appendix 28: Podocyte relative gene expression of MCP1 (pg/ml) when 
exposed to positive control condition (IFN gamma) 
Experiment - 
Podocyte 
MCP1 mRNA
Control 
condition (n=4)
`Podocyte 
exposed to IFN 
1ng/ml (N=4)
1 1.3 566
2 3.4 458.1
3 1.3 244.7
4 1.8 68.6
 
Appendix 29: Podocyte protein expression of MCP1 (pg/ml) when 
exposed to positive control condition (IFN gamma) 
Experiment - 
Podocyte 
MCP1 protein
Control 
condition (n=3)
`Podocyte 
exposed to IFN 
1ng/ml (N=6)
1 41.3 6.9
2 42.3 11.5
3 32.2 56
4 - 56.9
5 - 59.4
6 - 56.7
 
Appendix 30: Podocyte relative gene expression of NGAL when exposed 
to positive control condition (IFN gamma) 
Experiment - 
Podocyte NGAL 
mRNA
Control 
condition (n=3)
`Podocyte 
exposed to IFN 
1ng/ml (N=4)
1 3.3 1.7
2 0.9 0.9
3 0.8 3.8
4 - 4.6
 
Appendix 31: Podocyte protein expression of NGAL (pg/ml) when 
exposed to positive control condition (IFN gamma) 
Experiment - 
Podocyte NGAL 
protein
Control 
condition (n=5)
`Podocyte 
exposed to IFN 
1ng/ml (N=3)
1 0.11 269.9
2 0.14 313.6
3 0.11 0
4 0.31 -
5 0.23 -
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Appendix 32: Relative gene expression of MCP1 on podocytes exposed 
to macrophage conditions 
Experiment - 
Podocyte 
MCP1 mRNA
Control condition 
(n=5)
Active 
macrophage 
media (n=3)
Inactive 
macrophage 
media (n=3)
1 0.00001 9.16277 1.79102
2 0.00003 9.99208 0.24414
3 0.00001 7.44248 1.84138
4 0.00002 - -
 
Appendix 33: Protein expression of MCP1 on podocytes exposed to 
macrophage conditions 
Experiment - 
Podocyte 
MCP1 protein
Control condition 
(n=3)
Active 
macrophage 
media (n=3)
Inactive 
macrophage 
media (n=3)
1 41.3 40.4 24.7
2 42.3 36.2 23.3
3 32.2 46.2 33.9
 
 
Appendix 34: Relative gene expression of NGAL on podocytes exposed 
to macrophage conditions 
Experiment - 
Podocyte 
NGAL mRNA
Control 
condition (n=3)
Active 
macrophage 
media (n=3)
Inactive 
macrophage 
media (n=5)
1 0.033 0.000 0.011
2 0.009 0.000 0.008
3 0.008 0.000 0.001
4 - - 0.033
5 - - 0.000
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Appendix 35: Protein expression of NGAL on podocytes exposed to 
macrophage conditions 
Experiment - 
Podocyte 
NGAL protein
Control 
condition (n=5)
Active 
macrophage 
media (n=3)
Inactive 
macrophage 
media (n=3)
1 110.2 159.4 204.6
2 136.4 201.7 320.1
3 114.9 281.5 90.9
4 306.5 - -
5 233.2 - -
 
Appendix 36: Relative gene expression of MCP1 on podocytes exposed 
to TNF-α concentrations 
Experiment - 
podocyte 
MCP1 mRNA
Control condition 
(n=4)
TNF-α exposure: 
10pg/ml (n=3)
TNF-α exposure: 
100pg/ml (n=5)
TNF-α exposure: 
1000pg/ml (n=4)
TNF-α exposure: 
10ng/ml (n=3)
1 0.00001 0.00001 0.00009 0.00017 0.00024
2 0.00003 0.00007 0.00006 0.00009 0.00016
3 0.00001 0.00002 0.00003 0.00008 0.00027
4 0.00002 - 0.00005 0.00006 -
5 - - 0.00005 - -
 
Appendix 37: Protein expression of MCP1 on podocytes exposed to TNF-
α concentrations 
Experiment - 
podocyte 
MCP1 protein
Control condition 
(n=5)
TNF-α exposure: 
10pg/ml (n=4)
TNF-α exposure: 
100pg/ml (n=4)
TNF-α exposure: 
1000pg/ml (n=5)
TNF-α exposure: 
10ng/ml (n=7)
1 96174.4 173464.7 199890.3 192185.4 0.0
2 77453.7 10757.6 183697.9 0.0 438031.8
3 70651.7 76912.0 166482.1 612584.9 0.0
4 92321.9 243652.1 16115.0 524597.2 506715.1
5 5580.9 - - 338867.8 836720.0
6 - - - - 12142.1
7 - - - - 7808.1
 
Appendix 38: NGAL gene expression on podocytes exposed TNF-α 
concentrations 
Experiment - 
Podocyte 
NGAL mRNA
Control 
condition (n=3)
TNF-α 
exposure: 
10pg/ml (n=3)
TNF-α 
exposure: 
100pg/ml (n=3)
TNF-α 
exposure: 
1000pg/ml 
(n=3)
TNF-α 
exposure: 
10ng/ml (n=4)
1 0.033 0.020 0.027 0.023 0.033
2 0.009 0.019 0.069 0.043 0.082
3 0.008 0.038 0.061 0.017 0.008
4 - - - - 0.034
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Appendix 39: NGAL protein expression on podocytes exposed TNF-α 
concentrations 
Experiment - 
Podocyte 
NGAL protein
Control 
condition (n=5)
TNF-α 
exposure: 
10pg/ml (n=3)
TNF-α 
exposure: 
100pg/ml (n=5)
TNF-α 
exposure: 
1000pg/ml 
(n=5)
TNF-α 
exposure: 
10ng/ml (n=5)
1 110.2 147.0 190.3 12.6 250.9
2 136.4 109.9 9.3 3.3 10.0
3 114.9 8.1 19.9 108.3 105.4
4 306.5 - 83.2 271.0 86.6
5 233.2 - 30.0 153.0 -
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Appendix 40: MCP1 relative gene expression on podocytes exposed TNF-α time-course 
Experiment - 
Podocyte 
MCP1 mRNA
Control condition 
(n=4)
TNF-α exposure: 
2 hours (n=4)
TNF-α exposure: 
4 hours (n=4)
TNF-α exposure: 
6 hours (n=3)
TNF-α exposure: 
8 hours (n=4)
TNF-α 
exposure: 12 
hours (n=4)
TNF-α 
exposure: 24 
hours (n=4)
TNF-α 
exposure: 72 
hours (n=4)
TNF-α 
exposure: 96 
hours (n=5)
1 0.000 0.000 0.001 0.006 0.001 0.001 0.005 0.011 0.036
2 0.000 0.000 0.000 0.006 0.001 0.004 0.003 0.006 0.003
3 0.000 0.010 0.000 0.001 0.001 0.001 0.001 0.003 0.001
4 0.000 0.000 0.002 - 0.001 0.005 0.001 0.005 0.034
5 - - - - - - - - 0.001
 
Appendix 41: MCP1 protein expression on podocytes exposed TNF-α time-course 
Experiment - 
Podocyte 
MCP1 protein
Control condition 
(n=3)
TNF-α exposure: 
2 hours (n=4)
TNF-α exposure: 
4 hours (n=4)
TNF-α exposure: 
6 hours (n=4)
TNF-α exposure: 
8 hours (n=4)
TNF-α 
exposure: 12 
hours (n=4)
TNF-α 
exposure: 24 
hours (n=4)
TNF-α 
exposure: 72 
hours (n=4)
TNF-α 
exposure: 96 
hours (n=4)
1 41.3 52.4 31.1 40.2 30.4 32 387.8 1099 1140.4
2 42.3 48.7 6.3 25.2 59.3 270 180.1 547.7 1123.8
3 32.2 -3 2.5 121.3 37.7 49.2 153.9 573.9 1259.9
4 - 3.3 27.6 19.7 56 291.6 485.4 1066.4 1035.2
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Appendix 42: NGAL relative gene expression on podocytes exposed TNF-α time-course 
Experiment - 
Podocyte 
NGAL mRNA
Control 
condition (n=3)
TNF-α 
exposure: 2 
hours (n=4)
TNF-α 
exposure: 4 
hours (n=4)
TNF-α 
exposure: 6 
hours (n=4)
TNF-α 
exposure: 8 
hours (n=4)
TNF-α 
exposure: 12 
hours (n=4)
TNF-α 
exposure: 24 
hours (n=4)
TNF-α 
exposure: 72 
hours (n=4)
TNF-α 
exposure: 96 
hours (n=4)
1 0.033 0.005 0.005 0.002 0.010 0.001 0.003 0.033 0.004
2 0.009 0.003 0.003 0.004 0.005 0.006 0.008 0.027 0.000
3 0.008 0.005 0.002 0.006 0.011 0.002 0.002 0.028 0.000
4 - 0.003 0.004 0.004 0.001 0.002 0.004 - -
 
Appendix 43: NGAL protein expression on podocytes exposed TNF-α time-course 
Experiment - 
Podocyte 
NGAL protein
Control 
condition (n=3)
TNF-α 
exposure: 2 
hours (n=4)
TNF-α 
exposure: 4 
hours (n=4)
TNF-α 
exposure: 6 
hours (n=4)
TNF-α 
exposure: 8 
hours (n=4)
TNF-α 
exposure: 12 
hours (n=4)
TNF-α 
exposure: 24 
hours (n=4)
TNF-α 
exposure: 72 
hours (n=4)
TNF-α 
exposure: 96 
hours (n=4)
1 110.2 24.8 94.9 64.8 90.6 50.6 6.9 452.8 96.6
2 136.4 61.0 49.3 39.1 72.9 98.2 74.7 147.1 195.9
3 114.9 88.3 89.1 50.5 154.5 35.6 86.7 300.6 496.0
4 306.5 20.4 - - 55.6 - 94.5 274.0 386.4
5 233.2 12.1 - - 149.0 - - 292.0 443.5
6 - 10.6 - - - - - 301.2 466.6
7 - - - - - - - - 422.0
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Appendix 44: Relative gene expression of NGAL on podocytes exposed 
to TNF-α for 72 hours 
Experiment - 
Podocyte 
NGAL mRNA
Control 
condition for 72 
hours (n=3)
TNF-α 
exposure: 
1000pg/ml for 
72 hours (n=3)
1 0.004 0.033
2 0.019 0.027
3 0.010 0.028
 
Appendix 45: Protein expression of NGAL on podocytes exposed to TNF-
α for 72 hours 
Experiment - 
Podocyte 
NGAL protein
Control 
condition for 72 
hours (n=3)
TNF-α 
exposure: 
1000pg/ml for 
72 hours (n=6)
1 131.2 452.8
2 152.2 147.1
3 145.4 300.6
4 - 274.0
5 - 292.0
6 - 301.2
 
Appendix 46: Neutralising TNF alpha in macrophage media: MCP1 
protein 
Experiment - 
neutralising TNF in 
macrophage media, 
MCP1 protein ng/ml
Active 
macrophage 
media 
condition 
(n=4)
Active macrophage 
media 
condition+antiTNF 
1ug/ml (n=3)
Active macrophage 
media 
condition+antiTNF 
0.5ug/ml (n=4)
1 90.87 35.50 1.37
2 150.70 96.44 73.37
3 81.09 79.30 77.93
4 157.15 - 20.15
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Appendix 47: Neutralising TNF alpha in macrophage media: NGAL 
protein 
Experiment - 
neutralising TNF in 
macrophage media, 
NGAL protein ng/ml
Active 
macrophage 
media 
condition 
(n=5)
Active macrophage 
media 
condition+antiTNF 
1ug/ml (n=6)
Active macrophage 
media 
condition+antiTNF 
0.5ug/ml (n=6)
1 81.6 121.2 79.3
2 23.6 112.4 1
3 0 0 0
4 0 0 0
5 0 1.2 0
6 - 0 0
 
Appendix 48: Relative gene expression of TNFR1 on podocytes exposed 
to macrophage conditions 
Experiment - 
TNFR1
Control condition 
(n=3)
Active 
macrophage 
media (n=3)
Inactive 
macrophage 
media (n=3)
1 0.76 4.5 3.1
2 0.85 2.1 76.5
3 2.2 7.4 1.8
 
Appendix 49: Relative gene expression of TNFR2 on podocytes exposed 
to macrophage conditions 
Experiment - 
TNFR2
Control condition 
(n=3)
Active macrophage 
media (n=3)
Inactive macrophage 
media (n=3)
1 0.29 0.84 0.076
2 0.13 1 0.31
3 0.25 0.8 0
TNFR2; tumour necrosis factor alpha receptor 2
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Appendix 50: Relative gene expression of TNFR1 on podocytes exposed 
TNF-α concentrations 
Experiment - 
TNFR1
Control condition 
(n=4)
TNF-α exposure: 
10pg/ml (n=6)
TNF-α exposure: 
100pg/ml (n=6)
TNF-α exposure: 
1000pg/ml (n=7)
TNF-α exposure: 
10ng/ml (n=7)
1 2.5 1.9 11.3 4.9 2.3
2 4.3 5.1 2.3 4 7.6
3 2.9 4.1 4.6 3.6 13
4 2.7 2.7 4.2 6.3 0.73
5 - 331.2 372.6 2.7 3
6 - 267.2 169.7 172 114.7
7 - - - 169.7 32
 
Appendix 51: Relative gene expression of TNFR2 on podocytes exposed 
to TNF-α concentrations 
Experiment - 
TNFR2
Control condition 
(n=4)
TNF-α exposure: 
10pg/ml (n=5)
TNF-α exposure: 
100pg/ml (n=8)
TNF-α exposure: 
1000pg/ml (n=6)
TNF-α exposure: 
10ng/ml (n=5)
1 0.074 8.3 15.3 29.1 12.7
2 0.054 16.1 6.8 39 7.5
3 0.042 0.049 16.5 0.97 1.1
4 0.022 0.24 1.3 0.23 16.5
5 - 0.058 0.059 0.25 10.5
6 - - 0.063 0.28 -
7 - - 0.056 - -
8 - - 0.069 - -
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Appendix 52: Relative gene expression of TNFR1 on podocytes exposed TNF-α time-course 
Experiment - 
TNFR1
Control condition 
(n=3)
TNF-α exposure: 
2 hours (n=4)
TNF-α exposure: 
4 hours (n=4)
TNF-α exposure: 
6 hours (n=4)
TNF-α exposure: 
8 hours (n=4)
TNF-α exposure: 
12 hours (n=4)
TNF-α exposure: 
24 hours (n=4)
TNF-α exposure: 
72 hours (n=4)
TNF-α exposure: 
96 hours (n=4)
1 2.5 13.1 18.9 344.1 2.3 6.3 3 17.2 19.7
2 4.3 9.2 12.8 110 1.6 3.1 8.1 20.9 12.3
3 2.9 30.8 8.4 142.7 2.1 1.7 3.1 6.9 35.2
4 2.7 - 99.8 2.3 8.1 5.1 4.1 13.7 3.5
 
Appendix 53: Relative gene expression of TNFR2 on podocytes exposed TNF-α time-course 
Experiment - 
TNFR2
Control condition 
(n=4)
TNF-α exposure: 
2 hours (n=4)
TNF-α exposure: 
4 hours (n=4)
TNF-α exposure: 
6 hours (n=4)
TNF-α exposure: 
8 hours (n=4)
TNF-α exposure: 
12 hours (n=4)
TNF-α exposure: 
24 hours (n=4)
TNF-α exposure: 
72 hours (n=4)
TNF-α exposure: 
96 hours (n=3)
1 0.074 0.3 0.53 1.96 212.5 351.3 269 637.6 637.6
2 0.053 0.19 0.24 1.1 147.2 247.5 272.8 267.2 0
3 0.042 3.3 0.063 1.8 167.9 181.8 134.5 412 0
4 0.022 0.41 0.75 154 276.6 461.9 182.5 0 0
 
 
